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The present study applied a benchmarking strategy to evaluate the outcomes of youth (6 -
15 years) with anxiety disorders treated at 'Systems  ✁ ✂✄☎✆✝ ✞✟✠✡☛☎✆☞✌✍ ✎✆☞✏✄✡ ✟✆✄✡✏✟ ✍✆☎✑✠✞✆✍
(SOC CMHS).  There were three stages of analysis. The first used meta-analytic technique to 
aggregate results of 17 randomised controlled trials of treatments of anxiety in youth. From 
these studies, benchmarks were established for two different outcome criteria: pre-post effect 
✍✠✒✆✍ ✄☞☛ ✏✟✆ ✓☎ ✓ ☎✏✠ ☞  ✁ ✔ ✕✏✟ ✆✑✠☛✆☞✞✠☞✖ ✗✞✡✠☞✠✞✄✡✡✔ ✍✠✖☞✠✁✠✞✄☞✏ ✠✎✓☎ ✑✆✎✆☞✏✌✘ ✙✚ 
subsets from the SOC CMHS data were considered. The first was comprised of youth who 
were selected on the basis of a combination of Child Behavior Checklist profile and DSM 
diagnosis or presenting problem. The second was comprised of youth selected primarily on 
the basis of clinician-generated DSM diagnosis.  Neither subset attained levels of 
improvement commensurate with treatment efficacy benchmarks. Only one subset (selected 
partly on the basis of Child Behavior Checklist profile) achieved results significantly better 
than natural remission and this was only for one natural history benchmark (pre-post effect 
size). The third stage of analysis examined factors associated with reliable improvement and 
treatment response. Results indicated that the relatively poor response of youth from the SOC 
CMHS agencies could not be explained by the socio-psychological characteristics of this 
group. Avenues for future research are suggested, including extension of benchmarking 
✍✏☎✄✏✆✖✠✆✍ ✠☞ ✞✟✠✡☛☎✆☞✌✍ ✎✆☞✏✄✡ ✟✆✄✡✏✟ ✄☞☛ improved understanding of  predictors of treatment 
response. 
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It is estimated that as many as 2.5-5% of youth meet criteria for anxiety disorders 
(Breton et al., 1999; Costello, Mustillo, Erkanli, Keeler, & Angold, 2003; Ford, Goodman, 
& Meltzer, 2003; Lewinsohn, Hops, Roberts, Seeley, & Andrews, 1993; Lewinsohn, 
Zinbarg, Seeley, Lewinsohn, & Sack, 1997), and reviews suggest they are some of the most 
common mental health problems in children and adolescents (Craske, 1997). A large 
proportion of children who are diagnosed with one anxiety disorder can be diagnosed with 
an additional anxiety disorder (40-60%) (Silverman & Ollendick, 2005). Further, anxious 
children are more likely to be diagnosed with depression (Angold, Costello, & Erkanli, 
1999; Brady & Kendall, 1992, Costello et al., 2003; Ford et al., 2003). Youth who suffer 
from anxiety disorders are at risk of a constellation of other difficulties including academic 
and interpersonal problems (Essau, Conradt, & Petermann, 2000; Kubik, Lytle, Birnbaum, 
Murray & Perry, 2003; Strauss, Frame, & Forehand, 1987) with the disorders having a 
moderate to high impact on functioning  (Ezpeleta, Keeler, Alaatin, Costello, & Angold, 
2001). 
Not only do anxiety disorders have concerning implications for the short-term, a 
child who develops these disorders at a young age can struggle with them into adolescence 
(Bittner et al., 2007) and adulthood (Achenbach, Howel, McConaughy, & Stranger, 1995; 
Caspi, Elder, & Bem, 1988; Pine, Cohen, Gurley, Brook, & Ma, 1998; Gregory et al., 
2007)  ✁✂✄☎✆✝✞ ✟✠✡ ☛✆✆✂ ☞✆✡✌✍☎☛✆☞ ✠✡ ✠ ✎✏✠✝✆✑✠✞✒ ☞☎✡✓✍☞✆✍ (Kendall, Seppatini, & 
Cummings, 2012), with symptoms of anxiety in childhood placing the child at increased 
risk for depression (Costello et al., 2003; Pine et al., 1998; Roza, Hofstra, van der Ende, & 
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Verhulst, 2003), substance misuse (Kendall, Safford, Flannery-Schroeder, & Webb, 2004) 
and externalizing disorders (Bittner et al., 2007; Costello et al., 2003) in adulthood. 
Thus, addressing this group of disorders in children is important for at least two 
major reasons. First, as mentioned, they are among the most common mental health 
concerns in youth and thus use of effective interventions may have considerable impact on 
the efficiency and helpfulness of treatment agencies (Hodges & Wotring, 2004).  Second, 
the course of these disorders can be chronic and (as mentioned) place the youth at 
increased risk for poor outcomes in adolescence and adulthood. Intervening when clients 
are children may prevent the development of other problems, including impairment 
secondary to the primary disorder.  
Empirically Supported Treatments and Evidence-Based Practice  
Given the seriousness and pervasiveness of anxiety and other co-morbid mental 
health concerns in children, the question arises as to how these disorders might best be 
treated.  Research suggests that outcomes of youth receiving the treatment usually provided 
 ✁ ✂✄☎☎✆✁ ✝✞ ☎✟✁✝✠✡ ☛✟✠✡✝☛ ☞✟✝✝ ✁✌☞ ✍✎✆☞✆✠✡ ✂✠✏✟✑; UC) are disappointing when compared 
to therapies with established empirical support (Kazdin, Esveldt-Dawson, French, & Unis, 
1987; Mufson et al., 2004; Taylor, Schmidt, Pepler, & Hodgins, 1998; Weiss, Catron, & 
Harris, 2000; Weisz, Weiss, & Donenberg, 1992). Interventions delivered in UC tend to be 
eclectic and reflect preferences of the therapists delivering them rather than interventions 
informed by research.  Some results suggest that, consistent with the adult literature (Addis 
et al., 2004; Linehan, Armstrong, Suarez, Allmon, & Heard, 1991), outcomes for youth 
receiving UC may be no better than natural remission, i.e. the passage of time alone 
(Weersing & Weisz, 2002) or may be quite limited (Ollendick & King, 2004). Outcomes of 
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clients receiving non-specific therapy are generally lower than those found with research 
supported treatments (Beidel, Turner, & Morris, 2000; Hudson et al., 2009; Muris, 
Meesters, & Gobel, 2002) and can improve when therapists change from UC to research 
supported treatments (Cukrowicz et al., 2005). In fact, in contrast to interventions with 
empirical support, meta-analyses (including studies of predominantly externalising 
disorders), show that the average effect size of community treatment is modest and may be 
near to zero (Weiss et al., 1999; Weisz, Jensen-Doss, & Hawley, 2006).  
Research-based interventions, including more recent studies of treatment of anxiety, 
do not always outperform nonspecific therapy or UC, however (Barrington, Prior, 
Richardson, & Allen, 2005; Kendall, Hudson, Gosch, Flannery-Schroeder, & Suveg, 2008; 
Last, Hansen, & Franco, 1998; Silverman et al., 1999b; Southam-Gerow et al., 2010; Weisz 
et al., 2009; Weisz et al., 2012). This lack of difference in outcomes may be because these 
comparisons are typically under-powered (c.f. Kazdin & Bass, 1989). Alternatively, it may 
be because efforts at disseminating research-supported treatments mean that UC is 
increasingly likely to incorporate elements of these research-based treatments and thus be 
more effective (Kendall et al., 2008; Southam-Gerow et al., 2010). Further, while youth 
receiving UC may achieve comparable outcomes to those receiving research-supported 
treatments, they may take significantly longer to reach these outcomes, or make use of 
more resources to do so (Southam-Gerow et al., 2010). 
Interest in identifying and evaluating psychological therapies supported by research 
evidence first crystallised in the 1990s with the seminal work of the Task Force on 
Promotion and Dissemination of Psychological Procedures (1995). The work of the task 
force coincided with, and was complemented by,  ✁✂ ✄☎✆✝✞✂☎ ✟✂✠✡✞✂☛☞✂-✄✝✌✂✞✍ ✎✆✠✂✎✂☛ ✏
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which included interest in identifying and classifying the amount of empirical support for 
particular treatments for youth and other populations. The Task Force developed a system 
for classifying treatments according to the quality and quantity of empirical support for 
their efficacy and this system (among others) remains in use today. Clinical practices (such 
as treatments) were classified within four levels  ✁✂✄☎✆✄☎ ✝✁✞✟ ✠✡☛☞☞ ☛✌✍✂✎☞✆✌✏☛✑✒ ✍✞
✠☛✓✔☛✁✆✟☛✄✍✂☞✒. ✕✞✁ ✆✄✌✍✂✄✖☛  ✠✡☛☞☞ ☛✌✍✂✎☞✆✌✏☛✑✒ ✍✁☛✂✍✟☛✄✍✌ are those interventions evaluated 
using randomised controlled designs, conducted by investigators independent of the 
treatment developers, that yield outcomes superior to placebo or alternative treatments 
(Chambless & Hollon, 1998✗✘ ✠✙✟✔✆✁✆✖✂☞☞✚ ✌✛✔✔✞✁✍☛✑ ✍✁☛✂✍✟☛✄✍✒ (EST) is a term applied to 
describe interventions with empirical support for their efficacy. 
Recent reviews of treatments to address anxiety disorders in youth have identified 
interventions that have a strong evidence base for their use (Chorpita, Daleiden et al., 2011; 
In-Albon & Schneider, 2006; Reynolds, Wilson, Austin & Hooper, 2012; Silverman, Ortiz 
et al., 2008; Silverman, Pina, & Viswesvaran, 2008). Most of these interventions are based 
on cognitive behavioural models of intervention and are delivered in group or individual 
format. Many ✜✝✞✁ ✆✄✌✍✂✄✖☛  ✠✢✞✔✆✄☎ ✣✞✂☞✂✒✤ Barrett, 1995), are based on one of the earliest 
manualised therapies for treatment of anxiety in children ✠Coping Cat✒ ✜✣☛✄✑✂☞☞  ✥✦✦✧✗  ✂
sixteen session individual therapy typically delivered to 7- 13 year olds. 
Within ✍✏☛ ★✂✌✩ ✕✞✁✖☛✒✌ classification system, research findings from studies with 
greatest internal validity ✪ that is, randomised controlled trials (RCTs) - are given the most 
weight. Privileging results of RCTs over other research designs has generated controversy, 
in part related to the degree to which results of these treatment trials can be replicated in 
✠✁☛✂☞ ✡✞✁☞✑✒ ✌☛✍✍✆✄☎✌✘ This is relevant to the present study, which will involve evaluating 
BENCHMARKING TREATMENT OF ANXIETY IN YOUTH   
 
5 
outcomes of community agencies treating youth with anxiety disorders against results of 
published treatment trials. For this comparison to be valid, it should first be established that 
ESTs for youth with anxiety disorders are effective in community settings.  Addressing this 
issue requires an understanding of two of the main types of trials used to evaluate clinical 
interventions. 
Most interventions are initially evaluated in the context of  ✁✂✂✄☎✆☎✝✞ ✟✠✄✆✡☛☞
Prototypically,  efficacy✞ studies use designs where conditions are optimal for success and 
there are tight controls on many aspects of treatment delivery. In practice, this means that 
efficacy trials are conducted in research settings (rather than in agencies where the prime 
task is to deliver healthcare), have rigorous inclusion and exclusion criteria to ensure all 
participants have the disorder of interest, and use samples who are often recruited 
specifically for the study (rather than through clinical referral) (Nathan & Gorman, 2002; 
Weisz, Doss, & Hawley, 2005). Further, the intervention sites often specialise in the 
particular disorder, tend to use research therapists (often graduate students) supervised by 
programme developers, are more likely to train therapists to a prescribed level of 
competency before the treatments begin, and then employ ongoing supervision and 
monitoring of intervention delivery (Hunsley, 2007). The size of clinician caseloads would 
typically be smaller and less diverse than those of clinicians in community agencies 
(Spielmans, Gatlins, & McFall, 2010). This level of client homogeneity (Borkovec & 
Costonguay, 1998; Chambless & Hollon, 1998), therapist training and expertise within the 
organisational context that treatment is delivered is assumed to maximise the likelihood of 
treatment success, and may compromise generalisability of results from efficacy trials. 
✌✍✎ ✏✑✒✓✔✕✔✑✒✖ ✑✗ ✘✎✗✗✔✏✙✏✚✛ ✖✕✜✓✔✎✖ ✙✢✎ ✑✗✕✎✒ ✏✑✒✕✢✙✖✕✎✓ ✣✔✕✍ ✕✍✑✖✎ ✑✗ ✘✎✗✗✎✏✕✔✤✎✒✎✖✖✛
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studies. Prototyp ✁✂✄✄☎✆ ✝✞ffectiveness✟ studies are designed to address whether 
interventions are effective in ✠✡✞ ✝☛✞✂✄ ☞✌☛✄✍✟✎ That is, they are designed to maximize 
external validity while maintaining adequate internal validity (Hunsley & Lee, 2007). 
Effectiveness studies are thus generally conducted in community settings, and typically 
make use of therapists who work in these settings (rather than those having or being 
supervised by those with specialty expertise).  Samples may be more heterogeneous and 
more likely to access the service through referral rather than in response to advertising. The 
degree to which a study is characterised as an ✏efficacy✑ rather than an ✏effectiveness✑ trial 
lays on a continuum that emphasizes internal validity on one end and external on the other 
(Depp & Lebowitz, 2007).  
Hunsley and Lee (2007) conducted a review comparing results of effectiveness trials 
against efficacy for internalizing and externalizing disorders in adults and youth. Results of 
the review were telling. Outcomes and participant retention in effectiveness and efficacy 
trials were comparable. Further, they found that the levels of therapist supervision and 
exclusion criteria in the studies were comparable to conditions in regular community 
agencies. The small number of available studies of treatments for youth meant that they 
included studies where some recruiting was conducted through advertising (rather than 
referral). Nonetheless, the review suggested that implementation of ESTs in the community 
✒✓✔✕✔ ✕✖✖✕✗✘✓✙✕✚✕✛✛ ✘✜✓✢✣✛✤ ✗✢✚ ✢✗✥✓✕✙✕ ✛✓✦✓✣✢✜ ✧★✘✗✧✦✕✛ ✘✧ ✏✓✩✕✢✣✑ ✗✧nditions (i.e. efficacy 
trials). With respect to the treatment of anxiety disorders in youth, they found that most 
effectiveness trials had results comparable or superior to the efficacy benchmark trial. 
Thus, evidence indicates that when community agencies implement empirically 
supported treatments, they obtain similar outcomes to those within treatment efficacy trials. 
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It is possible that differences in conditions at community agencies and those within 
efficacy trials might moderate outcomes in community settings. Research regarding 
potential moderators of outcome in treatment will therefore be appraised. This review will 
commence with consideration of the complexity of cases within efficacy trials as well as 
the potential impact of complexity on outcome. 
Case Complexity  
Case complexity encompasses  ✁✂✄☎✆✝ ✝✞✂✟ ✁✝ ✄✟✠ ✝✠✡✠✆☛✄☞ ☎  ✄✟✠ ☞☎✞✄✟✌✝
psychopathology, comorbidity in clinical presentation, and adversity in socio-demographic 
context (including poverty and parental psychopathology). Westen, Novotny and 
Thompson-Brenner (2004) articulate the common concern that typical exclusion criteria 
mean that efficacy trials often include clients with less complex clinical profiles. The 
implication of this concern is that clients within efficacy trials are easier to treat than 
clients ☛✍ ✄✟✠ ✎✆✠✁✏ ✑☎✆✏✒✌.  This concern is problematic, given the high rates of comorbidity 
found in clinical populations, including youth with anxiety disorders seen at treatment 
facilities (Southam-Gerow, Weisz, & Kendall, 2003). Reviews of efficacy and 
effectiveness studies for a variety of populations and presenting problems suggest beliefs 
regarding selectiveness in recruiting clinical trial populations are not necessarily well 
founded. For instance, some studies suggest that not only are clients in clinical trials 
comparable to community samples in terms of complexity and severity, they may actually 
have more severe symptoms than clients treated in the community (Carroll, Nich, 
McLellan, McKay, & Rounsaville, 1999; Jacobson & Christensen, 1996; Oei & Boschen, 
2009).  
✓✞✍✝✏✠☞ ✁✍✒ ✔✠✠✌✝ (2007) study included an examination of exclusion criteria within 
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efficacy trials in youth and adults. They found most efficacy trials excluded participants (1) 
with conditions that were more urgent or took precedence for treatment (e.g. substance 
abuse) (2) who were participating in concurrent psychotherapy and (3) with mental 
retardation.  They concluded that these common criteria seemed clinically appropriate and 
therefore would not affect the generalizability of results of efficacy trials to community 
settings. Consistent with Hunsley and Lee (2007), authors of a recent meta-analysis of 
treatment of mental health disorders in youth (including anxiety disorders), concluded that 
inclusion and exclusion criteria for RCTs appeared clinically sound; clients were not 
excluded due to comorbidity unless it would impact treatment plans (i.e. unless the 
additional diagnosis would alter treatment priority or be a substantial moderator of outcome 
  for instance, a developmental disability) (Chorpita, Daleiden et al., 2011). Further, these 
conclusions are consistent with Weisz, Hawley and Doss (2004) whose review of treatment 
for youth with anxiety disorders, depressive disorders, Attention Deficit Hyperactivity 
Disorder (ADHD), and Conduct Disorder (CD) revealed that almost half of treatment 
studies had no exclusion criteria related to comorbidity. Stirman, DeRubeis, Crits-
Christoph and Brody (2003), found that 80% of adult clients within their treatment agency 
data-base would be eligible for inclusion in published randomised clinical trials, also 
suggesting that community populations are not substantially different or more difficult to 
treat than samples within efficacy trials. Altogether, these studies suggest that RCTs 
usually do not systematically exclude individuals with more complex clinical presentations. 
It is possible, however, that while complex individuals may not be explicitly excluded, 
those recruited for involvement in clinical trials tend to have a less complex profile than is 
typical of clients in community mental health settings. 
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When examining the characteristics of youth with anxiety disorders in a community 
clinic, Southam-Gerow et al. (2003) found that there was a higher proportion of youth from 
single parent families and with comorbid disruptive disorders than is typical of participants 
of clinical trials.  This finding was consistent with Baker-Ericzen, Hurlburt, Brookman-
Frazee, Jenkins and Hough (2010) who examined the clinical and social profile of parents 
from a large community mental health data-base and compared them to the samples within 
ESTs for parent training. They found that the demographic and symptom profile of youth 
in the community data set and in the RCT samples were similar, although family and child 
contextual characteristics were more complex in the community data set.  
The forgoing review suggests that samples within clinical trials do not systematically 
exclude complex clients and that clients in community settings often have symptoms or 
presentations that are no more severe than those in clinical trials and are sometimes less so. 
There is some evidence that community samples include individuals with more complex 
profiles than samples from efficacy trials - for instance, more comorbid disorders or more 
adverse social contexts.  
Research has also examined whether these and other variables influence treatment 
response. Compton et al. (2004) reviewed treatments for internalising disorders in youth 
and noted that the most frequent finding of studies that look at these socio-demographic 
factors is that they are not related to outcome. This conclusion is consistent with a more 
recent meta-analysis for treatment of anxiety disorders in youth, which also found no 
significant relationship between age, gender, ethnicity and outcomes (Silverman, Pina et 
al., 2008).  With some exceptions (Barrett et al., 1996; Ginsburg et al., 2011; Pina, 
Silverman, Fuentis, Kurtines, & Weems, 2003; Reynolds et al., 2012) numbers of studies 
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of treatments have found that age (Alfano, 2012; Kendall, 1994; Kendall, Brady, & 
Verduin, 2001; Rapee, Schniering, & Hudson, 2006; Treadwell, Flannery-Schroeder, & 
Kendall, 1995), gender (Kendall, 1994; Kendall et al., 2001; Southam-Gerow, Kendall, & 
Weersing, 2001; Rapee, Abbott, & Lyneham, 2006; Treadwell et al., 1995) and ethnicity 
(Kendall, 1994; Kendall et al., 2001; Southam-Gerow et al., 2001; Treadwell et al., 1995) 
are not significantly related to outcome in treatment of children with anxiety disorders.  
Comorbidity appears to have an inconsistent relationship to outcomes. A number of 
studies have found no significant relationship between comorbid conditions and outcomes 
(Flannery-Shroeder & Kendall, 2005; Kendall et al., 2001; Öst, Reuterskiöld & Costa, 
2010; Rapee, 2003; Rapee et al., 2006) whereas others have found youth with depressive 
(Berman, Weems, Silverman, & Kurtines, 2000; Southam-Gerow, et al., 2001, Storch et al., 
2008), externalising (Storch et al., 2008) or non-anxiety comorbidity (Liber, Widenfelt, 
Leeden, Goedhart, Utens, & Treffers, 2010) had worse treatment outcomes than those 
without. Doss and Weisz (2006) found that comorbidity accounted for very little (1%) 
variance in outcome of youth in treatment trials and Ollendick, Jarrett, Grills-Taquechel, 
Hovey, & Wolff (2008) concluded that most studies do not find a significant relationship 
between comorbidity and outcome. Overall, while comorbidity may complicate the 
delivery of ESTs (Southam-Gerow et al., 2003; Southam-Gerow, Chorpita, Miller, & 
Gleacher, 2008), these mixed findings are consistent with Hunsley ✁ (2007) conclusion that 
comorbidity does not have a consistently negative effect on outcomes of therapy.  
The impact of initial symptom severity on outcome has also been examined. Some 
research has found that adults with more severe symptoms at baseline are likely to improve 
more than those with less severe symptoms (Garfield, 1986; Oei & Boschen, 2009; 
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Minami, Wampold, Serlin, Kircher & Brown, 2007), and recent studies of children with 
anxiety have also found that youth with more severe initial symptoms improved more than 
others (Kley, Heinrichs, Bender, & Tuschen-Caffien, 2012; Liber et al., 2008). Consistent 
with Oei and Boschen (2009), Liber, et al. (2008) found that while more severe pre-
treatment symptoms were associated with greater improvement, fewer of these youth 
recovered (i.e. lost their diagnosis) by the end of treatment. Southam-Gerow et al. (2001) 
also found that more severe symptoms at baseline were associated with lower rates of 
 ✁✂✄☎✆✂✁✝✞ ✟✁☎✠ ✡☛☞✌✂✍✝ ✎✌✡✏☛☎✑✌✑✒ Altogether, the most consistent findings appear to be 
that individuals with more severe initial symptoms improve more than those with less 
severe symptoms at pre-treatment baseline. However, they recover (i.e. lose their 
diagnosis) less often. This may be because higher scores are associated with greater 
regression to the mean (and hence greater improvement); but that a larger magnitude of 
✌✠✓✁☎✆✂✠✂☛✍ ✌✑ ✁✂✔✕✌✁✂✎ ✖✂✟☎✁✂ ✁✂✡✄✗✌☛✏  ☛☎✁✠✡✘✞ ✁✡☛✏✂ ☎✟ ✟✕☛✄✍✌☎☛✌☛✏✒ 
Other research has also considered the ability of various indices of social 
disadvantage to predict outcome. Weisz, Donenberg, Han and Weiss (1995) found that 
studies including cases that were rated (by observers) as more complex had lower effect 
sizes than studies with cases that where rated as more straightforward.  Two meta-analyses 
examining predictors of outcome in parenting programmes (Dumas & Wahler, 1983; 
Reyno & McGrath, 2006) found social disadvantage was associated with negative 
treatment outcomes. Gardner et al. (2009) found a limited number of family risk factors 
predicted outcome in a parenting intervention. In their study, contrary to expectations, low 
maternal education predicted greater improvement in child problem behavior, although 
being a single parent predicted less improvement on some outcome measures.   Authors 
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speculated that the counter-intuitive improvements related to extra efforts to engage parents 
from deprived backgrounds. In studies of treatment response for children with anxiety, 
Southam-Gerow et al. (2001) found income and family composition (single versus dual 
parent household) were not significantly related to outcomes. There have been some mixed 
findings regarding the impact of parent psychopathology on outcomes for youth with 
mental health needs (Gardner et al., 2009), although in general, parent pathology 
(particularly maternal depression) seems related to negative outcomes (Berman et al., 2000; 
Crawford and Manassis, 2001; Liber et al., 2010; Southam - Gerow et al., 2001). Legerstee 
et al. (2008) found that maternal anxiety actually predicted better outcomes in adolescents 
(but not children) with anxiety and Liber et al. (2010) found maternal warmth predicted 
worse outcomes. Cobham, Dadds and Spence (1998) found that children whose parents had 
anxiety disorders improved more if the parents participated in anxiety management 
treatment themselves.  
Treatment Implementation, Supervision, Training and Therapist Characteristics. 
Other factors may affect the generalizability of results of clinical trials to the 
community. Efficacy trials make use of interventions that are of a standard length 
(generally 10-16 sessions for cognitive behavioural therapy protocols). This standardisation 
of length compares to the conditions within community agencies (UC) (Hurlbert, Garland, 
Nguyen, & Brookman-Frazee, 2010).  
 RCTs typically include monitoring of adherence to the content of a treatment manual 
within their treatment protocol. In a meta-analysis comparing outcomes from lab and clinic 
based interventions, Weisz et al. (1995) found that monitoring treatment fidelity (i.e. 
adherence to the intervention) was associated with better outcomes in treatment of youth. 
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Research in other populations found weak adherence to procedures was associated with 
worse outcomes (Schoenwald & Hoagwood, 2001). Weisz et al. (2012) found that 
treatments making use of manuals outperformed UC, although this superior performance 
was not clearly related to manual use alone. There is little data regarding the prevalence of 
treatment manual use or adherence monitoring within UC, although the cost or perceived 
compromises to therapist autonomy (among other factors) might mean that they are not 
widely or consistently used (c.f. Zayas, Drake, & Johnson-Reid, 2011).  
Training is another key consideration that influences the generalizability of results of 
ESTs to community agencies (Han & Weiss, 2005; Lochman et al., 2009; Merrill, Tolbert, 
& Wade, 2003). Higher  ✁✂✄☎✄✆ ✂✝ ✞✟✠✡☛✡☛☞ ✌✡☞✍✞ ✎☎ ✠✄✄✂✏✡✠✞☎✁ ✑✡✞✍ ✌✂✟☎ ✏✂✌✒☎✞☎☛✞
delivery of treatments (Lochman et al., 2009). ESTs tend to involve more intense therapist 
training than ✓✔✕✖✗✘✗✘✙ ✖✚ ✛✚✛✖✜✢, which typically includes provision of a treatment manual, 
a one or two day workshop and little or no follow up (Beidas, Barmish, & Kendall, 2009; 
Beidas & Kendall, 2010; Weisz, Doss et al., 2005; Weisz, Sandler, Durlak & Anton, 2005).  
This model of training may be insufficient to impact clinician behaviour and thereby client 
outcome (c.f. Grimshaw et al., 2001; Herschell, 2010; Lochman et al., 2009; Sholomskas, 
et al., 2005). In contrast, Beidas and Kendall (2010) found that training that incorporated 
active learning strategies such as coaching and feedback was associated with improved 
therapist competence and client functioning. 
Supervision can be conceptualised as part of the training process. The nature of 
supervision in clinical trials is likely to be quite different in content and impact than in 
community agencies (Accurso, Taylor, & Garland, 2011). Supervision within UC may 
include a large proportion of time spent in attending to administrative issues with relatively 
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little time or intensity invested in practising or improving therapist competency in core 
components of ESTs (Garland, Plemmons, & Koontz, 2006). In contrast, some studies have 
found that supervision that includes review of video tape and other forms of adherence to 
components of ESTs can enhance therapist competence and ultimately client outcomes 
(Callahan, Almstrom, Swift, Borja, & Heath, 2009; Ng, 2005), including in youth therapy 
(Schoenwald, Sheidow, & Chapman, 2009; Schoenwald, Sheidow, & Letourneau, 2004). 
For instance, the most substantial improvement in competency in medical practice was 
found where supervision consisted of review of actual practice (Kilminster & Jolly, 2000).  
These results suggest optimal training involves both didactic and competency-based 
components. Sufficient quality training and supervision is required to implement ESTs with 
competence, and training and supervision delivered within UC do not usually reflect that 
typically utilised in efficacy trials. Presumably, results of efficacy trials cannot be validly 
generalized to community settings if they require unrealistic demands in terms of training 
or supervision. So, the question remains whether implementing training and supervision to 
this level of competence is feasible within community settings.  
The length of supervision in EST trials and community practices appear comparable 
(approximately one hour every week or two) (Accurso et al., 2011; Schoenwald et al., 
2008), including within RCTs for treatment of youth with anxiety disorders (Bögels  & 
Sigueland, 2006; King, Heyne, & Ollendick, 2005; Muris, Merckelbach, Holdrinet, & 
Sijsenaar, 1998; Nauta, Scholing, Emmelkamp, & Minderaa, 2003; Silverman et al., 1999b; 
Wood, Piancentini, Southam-Gerow, Chu & Sigman, 2006). Hunsley and Lee (2007) 
compared effectiveness and efficacy trials and found that the level of training offered was 
similar across settings. Weisz et al. (2009) considered whether community practitioners 
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could be trained to deliver an EST to adolescents with depression in a time frame realistic 
within community settings. They found minimal training in a specific EST (6 hours and 
additional ongoing supervision) in community practice was sufficient to establish 
reasonable competence in outcomes in therapists with a mean of four   five years training 
in mental health. In a recent treatment review, most interventions for anxiety disorders in 
youth were rated as ✁reasonably trainable✂ (Chorpita, Daleiden et al., 2011). Lastly, models 
for training or supervision have been developed for use within the constraints of 
community resources, including education of clients and cross-agency training (Carroll, 
Martino & Rounsaville, 2010; Southam-Gerow, Rodriguez, Chorpita, & Daleiden, 2012; 
Weisz & Gray, 2008).  
Altogether, these findings suggest that it may be possible to improve the quality and 
impact of supervision provided within UC with available resources, if focus shifts to skill 
development and maintenance rather than remaining on administrative or other tasks. That 
is, whether or not the supervision delivered in UC is similar to RCTs, skill based 
supervision appears to be associated with improved therapist competency and outcomes, 
and could be instituted within the resources available. Any differences between UC and 
ESTs should not compromise generalizability of results of trials evaluating ESTs to 
community settings. 
In sum, although there have been concerns regarding the generalizability of results of 
ESTs in the community because of factors such as the complexity of cases, training and 
supervision requirements, these do not appear well founded.  There are inconsistent 
differences between populations treated within community and RCTs. Further, while the 
content of training, supervision and adherence monitoring are likely to differ between 
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treatment trials and community agencies, comparable results have been achieved within 
resources typically available in community settings. 
Summary 
Overall, it appears that the results of efficacy trials can be generalised to community 
settings (Addis & Waltz, 2002; Persons, Bostrom, & Bertagbolli, 1999; Sanderson, Raue, 
& Wetzler, 1998; Tuschen-Caffier, Pook, & Frank, 2001; Wade, Treat, & Stuart, 1998).  
While there is some inconsistency with recent treatment trials for anxiety disorders, 
reviews generally suggest that ESTs outperform UC.  If effectiveness trials confirm the 
findings of efficacy, and ESTs typically achieve better results than UC, the question 
remains why more agencies do not routinely implement evidence-based practices. Despite 
the existence of ESTs, the type of treatment an individual receives for any mental health 
 ✁✂✄☎ ✆☎ ✝✞✟ ✠✆ ✡✞☛✞☎☞✁ngly arbitrar✌✍ ✎✏✞☎☎✌✑ ✒✄✓✔✑ ✕ ✖✆☎☎✑ ✗✘✘✙✚✛ ✜✟ ✞ ☎✆✢✁✆✣ ✄✤
community practice, Martino, Ball, Nich, Frankfoter and Carroll (2008) found that 
clinicians over-reported the extent to which UC included components of ESTs and that the 
rate of EST use was actually very low. This may account for the inferior results often found 
in UC and is consistent with findings that UC that includes components of ESTs can 
achieve comparable results (Kendall et al., 2008; Southam-Gerow et al., 2001). 
It appears that factors that cannot be changed regarding community practice (e.g. 
demographic and symptom profile of clients) are not consistent moderators of outcome and 
those that are modifiable (training; content of supervision; use of manualised treatments) 
may not be common practice in UC but when systematically altered, are associated with 
improved client outcomes. Further, it appears that results of treatments deemed efficacious 
in research settings are consistently replicated in effectiveness studies in community 
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settings and that these interventions typically achieve superior results to those of UC. Focus 
will now shift to how the results of clinical trials for ESTs can be used to evaluate 
 ✁✂✄ ☎✆✝ ✞✟ ✄ ☎☎✁✟✞✂✞✆✝ ✁✝✞✟✠ ✡☛✆✟✄☞☎✌✍✎✞✟✠✏ as a strategy.  Results of chi✑✒✍✆✟✏✝ ☎✆✟✂✌✑
health agencies utilising the Systems of Care model for mental health practice will be 
considered.  
Benchmarking 
✓☞✆ ✂✆✄☞✟✞✔✁✆  ✕ ✡☛✆✟✄☞☎✌✍✎✞✟✠✏ ✖✌✝  ✍✞✠✞✟✌✑✑✗ ✒✆✘✆✑ ✙✆✒ as a quality assurance 
strategy in the context of the Japanese manufacturing industry (Yoshikawa, Innes, Mitchel, 
& Tanaka, 1993) and has since been introduced into other countries and disciplines, 
including health care in North America and the United Kingdom (Bullivant, 1996; Lorence 
& Jameson, 2002).  Benchmarking is usually conducted within the context of evaluation 
and organisational behaviour management, including attempts to identify and/or implement 
best practices (Francis & Holloway, 2007). Ultimately, the process involves setting 
performance targets that are ambitious yet realistic, and can facilitate the identification of 
effective practices that might then be generalised to other settings or groups (Weersing, 
2005). 
There have been some criticisms of the process of benchmarking. While research 
suggests that differences between research and community settings are not as marked as 
once thought, most RCTs are still conducted within universities under different 
circumstances than are typical in publicly funded mental health settings. Further, small 
changes in pre-treatment means and standard deviations can have relatively large impacts 
on the magnitude of pre- post effect sizes, reducing confidence in a benchmark based on 
effect sizes (Lueger & Barkham, 2010). Lastly, use of a benchmarking strategy is 
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inferential - any differences (or lack of differences) between benchmarks and outcomes of 
comparator groups can only be interpreted with caution, since the reason for these 
differences cannot be established by benchmarking (Weersing, 2005). Despite these 
concerns, benchmarking is one of the more helpful strategies available to bridge the gap 
between research and clinical practice; and can be used to contextualise outcomes achieved 
in community treatment agencies (Minami et al., 2007). 
Within health care, benchmarking processes have been applied to two main kinds of 
service characteristics: the processes associated with client care (e.g. waiting times, 
procedures used) and the outcomes of the services provided (e.g. symptoms, client 
functioning) (Trosa & Williams, 1996). Quality assurance efforts have largely focused on 
processes, which may be more easily influenced by clinicians and administrators than 
outcomes (Sperry, Brill, Howard, & Grissom, 1996). Other work, however, has targeted the 
arguably more challenging and relevant target of improving actual clinical outcomes 
(Hamerlynck, 2005).  
Benchmarking and mental health. Benchmarking allows comparisons against a 
standard without needing an experimental control or comparison group and therefore may 
be an efficient strategy to use when evaluating community treatment centres (Merrill et al., 
2003; Minami et al. 2009). Benchmarking strategies have been used to evaluate outcomes 
of interventions within mental health contexts. The process generally follows four steps; 
 ✁✂ ✄☎✆✝✞✝✞✟ ✠✡☎ ☛☞✌✍✎☎✏✑ ☛✌☛✒✎✓✠✝✌✞ ✓✞✄ ✠☞☎✓✠✏☎✞✠ ✏✌✄☎✎✑  ✔✂ ✕✡✌✌✖✝✞✟ ✌☞ ✕☞☎✓✠✝✞✟ ✓ ✗✟✌✎✄
✖✠✓✞✄✓☞✄✘ ✍☎✞✕✡✏✓☞✙  ✌✆✠☎✞ from the research literature), (3) measuring this outcome in the 
population(s) of interest and (4) comparing performance of these population(s) against the 
gold standard benchmark (Weersing & Weisz, 2002).  
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Studies utilising a benchmarking strategy in mental health have generally made use 
of one of two major approaches. In the first approach, outcomes of efficacy trials are used 
to establish an outcome benchmark and results of effectiveness trials are judged against 
this. Typically, these studies involve evaluating whether a particular empirically supported 
treatment (e.g. cognitive behaviour therapy) achieves results comparable to efficacy trials 
when implemented in the context of a community agency. This type of benchmarking study 
can therefore be considered a kind of effectiveness trial (Weersing, 2005). The second 
approach uses results from published clinical trials to establish two kinds of benchmarks   
treatment efficacy and natural history. ✁✂✄ ☎✆✝✄✞✆✟✄✠✆ ✄✡✡☛☞✞☞✌ ✍✄✠☞✂✟✞✝✎✏ ✝✄✡✑✄☞✆✒ 
outcomes expected following receipt of an empirically supported treatment whereas the 
☎✠✞✆✓✝✞✑ ✂☛✒✆✔✝✌✏ ✍✄✠☞✂✟✞✝✎ ✝✄✡✑✄☞✆✒ outcomes expected following the passage of time 
alone. The impact of treatment from community agencies is then evaluated against these 
benchmark standards (e.g. Weersing & Weisz, 2002). 
There are several examples in the adult mental health literature where the first type of 
efficacy/ effectiveness benchmarking strategy has been used.  For instance, studies have 
examined the generalizability of interventions for different diagnoses including depression  
(Merrill et al., 2003; Persons et al., 1999), Social Phobia (McEvoy, Nathan, Rapee, & 
Campbell, 2012); Panic Disorder (Stuart, Treat, & Wade, 2000; Wade et al., 1998), 
Obsessive  Compulsive Disorder (Franklin, Abramowitz, Kozak, Levitt, & Foa, 2000), and 
with a diagnostically heterogeneous group (McEvoy & Nathan, 2007). Further, the studies 
have taken place in various types of clinics including outpatient clinics (Martinsen, Olsen, 
Tönset, Nyland, & Aarre, 1998), community mental health centres (Wade et al., 1998), 
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public mental health units (Garc✁a-Palacios, Hoffman, Carlin, Furness, & Botella, 2002) 
and private clinics (e.g. Gaston, Abbott, Rapee, & Neary, 2006).  
Some studies found that treatments achieved comparable results in the community to 
what was achieved in efficacy trials (Persons et al., 1999; Warren & Thomas, 2001) while 
others found clients improved, although not as much as within efficacy trials (Oei & 
Boschen, 2009). 
This type of benchmarking strategy has also been applied to evaluating treatments for 
youth. Curtis, Ronan, Heiblum and Crellin (2009) considered the effectiveness of multi-
systemic therapy (MST) in the treatment of juvenile offenders seen in a community mental 
health agency in New Zealand. Benchmark standards for expected outcome were 
established by aggregating results of three efficacy studies of MST for the treatment of 
juvenile offenders. They found that when MST was implemented in the community, results 
were comparable and even superior on some dimensions to the benchmark standard. 
Shirk, Kaplinski and Gudmundsen (2009) compared results of youth with depression 
receiving services in school-based services, to those of youth treated within efficacy trials. 
They found youth achieved similar and sometimes superior results to published trials. 
Dobson, Hopkins, Fata, Scherrer, and Allan (2010) compared results from their youth 
mental health agency to those of a single randomized control trial for the prevention of 
depression in at-risk adolescents (Clarke, Hawkins, Murphy, & Sheeber, 1995). They found 
that their intervention produced greater changes than those of the RCT. While results of 
this study are encouraging, generating a benchmark standard based on a single treatment 
study is somewhat problematic, since it is likely to be less reliable than a benchmark 
standard based on aggregating results of a number of trials (Minami, Serlin, et al., 2008).   
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Farrell, Schlup and Boschen (2010) used a benchmarking approach to evaluate 
treatment for youth with Obsessive - Compulsive Disorder (OCD) in a private clinic. Their 
treatment was based on a standardized manual used in a clinical trial (Barrett, Farrell, 
Dadds, & Boulter, 2005; Barrett, Healy-Farrell, & March, 2004). They used a common 
measure of symptoms in OCD -  ✁✂ ✄✁☎✆✝✞✂✟✠✡ ☛☞✆✂ ✌✞✍✎✟ ✏✑✡✂✡✡☎✒✂ - Compulsive Scale 
(CY-BOCS; Goodman, Price, Rasmussen, & Mazure, 1989) and compared outcomes of the 
private clinic against those from five clinical trials that used the CY-BOCS. They found 
their study group achieved similar or better results than some efficacy trials for youth with 
OCD (de Haan, Hoogduin, Buitelaar, & Keijsers, 1998; Franklin et al., 1998) but were not 
as good as one (Barrett et al., 2004). The study sample was deemed broadly comparable to 
those within the published trials, although the involvement of one of the program 
developers (Farrell) in the effectiveness trial and the fact that the community sample was 
actually conducted within a private clinic meant that results would not necessarily 
generalise to publicly funded community mental health agencies.  The authors did not 
aggregate results of efficacy trials, nor did they use statistical techniques to compare the 
effect size of their study against the benchmark efficacy studies. This was probably because 
visual inspection of results revealed substantial overlap between their results and those of 
the efficacy trials. Relying on visual inspection of effect sizes or confidence intervals, 
however, is problematic since overlap in confidence intervals does not necessarily mean 
that there is no significant difference in terms of pre-post improvement between the groups 
(Wolfe & Hanley, 2002). Further, judgments based on visual inspection of data may be 
prone to bias.  
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Hunsley and Lee (2007) developed an interesting adaptation of the efficacy/ 
effectiveness benchmarking strategy. They reviewed effectiveness RCTs for adult and 
youth interventions, and grouped these within diagnostic categories. They then 
systematically compared outcomes from these effectiveness studies to an efficacy study 
within the same diagnostic category. Comparisons between the effectiveness studies and 
the benchmark efficacy study were made on a variety of dimensions, including pre-post 
effect sizes; clinically significant improvement and processes such as the amount of 
supervision involved.  They found that effectiveness studies achieved comparable results to 
efficacy on most outcome and process dimensions.  
The aforementioned studies used benchmarking to evaluate the impact of particular 
ESTs when delivered in community settings. It is also possible to use benchmarking to 
evaluate UC   that is, the usual service delivered within community agencies against ESTs. 
This may be a particularly helpful and relevant strategy for use in settings that routinely 
collect outcome data pre- and post- treatments. In these situations, information regarding 
client demographics or symptom profile is generally available, although the particulars of 
the intervention that they received usually are not. The evaluation is thus based on the 
premise that it is possible for clients to achieve broadly similar results to those obtained 
within clinical trials for the same problems, if they receive an appropriate treatment (i.e. an 
EST). Establishing and using a standard for improvement might be preferable to simply 
evaluating whether any ✁✂✄☎✆✝✞✂✞✟✠✡ ✁✟ ☛☞✁✞✟✠✡✌ ✡✍✂✄✠✆✂✡ ✎☎✆✂ ✄☎✞- to post-treatment 
occurred in UC. This is because part of the challenge of evaluating UC is that remission of 
symptoms can occur with the passage of time alone. Therefore, even if community 
agencies observe improvements in their client populations between pre- and post-treatment, 
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this is not enough to be confident of the efficacy of the treatment they have delivered. It is 
not clear whether this magnitude of improvement reflects the impact of treatment or simply 
remission that could be expected to occur with the passage of time alone. A benchmarking 
strategy helps address this question, since outcomes for both empirically supported 
treatment and wait list controls can be used as comparators. Thus, community agencies can 
evaluate their services without the need for a comparator group   by generating standards 
for improvement from wait list groups that reflect improvement expected from the passage 
of time alone. Thus, the second type of benchmarking study is exemplified in recent 
innovative research that has examined the impact of UC in community agencies against 
benchmark standards, rather than evaluation of a specific EST in the community.   
Examining results of community agencies against those from clinical trials can act as 
a catalyst for changing practices if results are weaker than expected. Alternatively, if 
results meet or exceed expectations, this can help generate ideas for dissemination and 
implementation of effective practice. In the same way that giving feedback about client 
progress to individual clinicians can reduce the proportion of clients who fail at treatment 
(Harmon et al 2007; Lambert, Hansen, & Finch, 2001; Lambert, 2007; Lambert, Harmon, 
Slade, Whipple, & Hawkins, 2005), providing feedback regarding outcomes of agency 
performance against a pre-determined research-based standard could also shape practice 
and hence potentially improve collective outcomes. 
In a large-scale effectiveness trial, Westbrook and Kirk (2005) found that 1200 adults 
with anxiety, depression and eating disorders treated in the National Health Services in the 
United Kingdom achieved improvements slightly lower than RCTs. This is a remarkable 
outcome, given the scale of the project, the diversity of clients and ESTs and the limited 
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opportunity for checks of adherence to treatment or supervision protocols.  
Blais et al., (2012) made use of benchmark standards to evaluate outcomes of a group 
of adults with depression and anxiety receiving UC in an outpatient clinic, based in an 
academic setting. They used treatment and wait list control benchmarks established by 
aggregating results of ESTs for anxiety and depression (Minami et al. 2007; Norton & 
Price, 2007). They concluded that the university clinic achieved results that were superior 
to a wait list control group, but not as large as the efficacy trials.  They did not use 
statistical analysis to compare the results of their community agency with those of the 
efficacy trials.  Schindler, Hiller and Witthöft (2011) found the pre-post effect size of their 
subsample of clients receiving UC in a community agency was comparable to those of 
treatment groups within published RCTs. This study represented an advance in 
benchmarking methodology since they also included benchmarks for rates of  ✁✂✄☎✆✝✄✂✞
✟✝✠  ✁✂✡☛✄✄☛✆✝✞ (that is, a pre-determined level of improvement in symptoms; and 
movement into  ✝✆✁✡✟☞✞ ✁✟✝✌✂ ✆✍ ✍✎✝✏✑☛✆✝☛✝✌ on a symptom measure). They concluded 
recovery rates were weaker in the community group than in clinical trials. They did not use 
statistical analysis to draw this conclusion, either, however, nor did they combine results of 
RCTs to generate a single aggregate benchmark effect size.  
Minami, Wampold et al. (2008) conducted one of the more methodologically 
sophisticated benchmarking studies to date. They used meta-analyses of randomised 
controlled trials (RCTs) to establish benchmarks for outcomes of treatment for adult 
depression, and compared the effectiveness of UC delivered in a community service 
against these. The benchmark was established using a measure of outcome with a similar 
level of specificity and reactivity as the one used in their community sample (i.e. the 
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Outcome Questionnaire-30.1 (OQ-30); Lambert et al., 2003). The analysis was further 
enhanced by considering the outcomes of the community service against both treatment 
and control group benchmarks. Thus, they were able to consider whether the results of the 
community agency resembled those of treatment groups or wait list control groups within 
clinical trials.  They found that clients in the managed care agencies that they evaluated 
improved as much as participants in RCTs receiving ESTs. 
To date, there has been limited application of benchmarking to treatment for youth in 
community mental health services. One study of treatment of youth with depression 
compared results of youth seen in community services against benchmarks established 
from treatment and control groups of 17 clinical trials (Weersing & Weisz, 2002).  Thus, 
benchmarks generated by this study were based on substantially more treatment trials than 
previous benchmarking studies. They found that results of community services were more 
similar to control groups than treatment groups of clinical trials. That is, the improvement 
 ✁ ✂✄ ☎✁✆✝✞ ✝✟✠✡✆☛✠✝  ✁ ✆☞☎ ✂☛✠✠✌✁ ✆✟ ✝☎✍✎ ✂☎ ✏✑✝ ✁☛ ✒ ✓✓☎✍☎✁✆ ✆☞✑✁ ✏☞✑✆ ✠ ✔☞✆ ☞✑✎☎
happened if the youth had received no service. Weersing and Weisz (2002) used a t- test to 
compare the effect sizes obtained for their treatment and control groups and those obtained 
within the community sample. Minami et al. (2007) point out, however, that this type of 
statistical analysis might be problematic, because the large number of participants in these 
comparisons can sometimes mean that statistically significant but clinically trivial results 
are obtained. That is, while differences between the groups might be statistically reliable, 
the magnitude of this difference can be so small ✆☞✑✆  ✁ ✆☞☎ ✕✍☎✑✄✞ ✏☛✍✄✒✖  ✆ ✏☛✌✄✒ ✁☛✆ ✍☎✓✄☎✂✆
a clinically meaningful difference. Instead, they advocate for the use of ✑ ✕✍✑✁✔☎ ✁✌✄✄✞
hypothesis testing procedure (Serlin, 1985; 1993) whereby the difference between two 
BENCHMARKING TREATMENT OF ANXIETY IN YOUTH   
 
26 
effect sizes must be larger 0.2 (i.e. a  small✁ ✂✄✄✂☎✆ ✝✞✟✂✠ ✡✞✆☛✞☞ ✌✍☛✂☞✁✝ 1998 classification 
system) to be considered clinically significant. 
Benchmarking methodology. The review thus far has focussed on the utility of 
benchmarking as a strategy to evaluate either the transportability of ESTs in the community 
or the services delivered in UC. There are methodological issues that should be carefully 
considered when adopting benchmarking as a way to evaluate results of community 
agencies.  These methodological issues relate to measurement and conceptualisation of 
outcome, as well as the challenges of matching clinical trials with the circumstances within 
community settings. Details regarding these issues will now be addressed. 
 All benchmarking studies of outcome reviewed compare the effect sizes of RCTs 
with those of the community group under consideration. It is important to carefully 
consider the nature of outcome measures used to compare results of community and RCTs 
agencies. For instanc✂✠ ✆☛✂ ✎✏✑☞✞✆✒✓✂ ✍✄ ✂✄✄✂☎✆ ✝✞✟✂✝ ✞✝ ✎✍✓✂✔✏✆✂✓ ✕✖ ✆☛✂  ✝✗✂☎✞✄✞☎✞✆✖✁ ✍✄ ✆☛✂
measure used (Minami, Serlin et al., 2008). That is, measures of specific constructs (e.g., 
anxiety) tend to generate larger effect sizes than measures of general constructs (e.g., 
overall psychopathology), particularly when the specific constructs are targeted within the 
intervention. Measures of specific symptoms such as the Revised ✌☛✞✘✓✔✂☞✁✝ ✙✏☞✞✄✂✝✆
Anxiety Scale (RCMAS; Reynolds & Richmond, 1985✚ ✍✔ ✌☛✞✘✓✔✂☞✁s Depression 
Inventory (CDI; Kovacs, 1992✚ ✡✍✒✘✓ ✕✂ ☎✍☞✝✞✓✂✔✂✓  ☛✞✑☛ ✝✗✂☎✞✄✞☎✞✆✖✁ measures, whereas 
instruments gauging general internalising psychopathology such as the Child Behavior 
Checklist-Internalising broadband scale (CBCL-Int; Achenbach, 1991; Achenbach & 
Rescorla, 2001) could be considered a  ✘✍✡ ✝✗✂☎✞✄✞☎✞✆✖✁ measure. Further, there are 
differences in the magnitude of effect sizes for different constructs (e.g. symptoms versus 
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functioning; Karpenko, Owens, Evangelista, & Dodds, 2009; Rosenblatt & Rosenblatt, 
2002). Thus, when comparing effect sizes in community settings to those of published 
treatment trials, it is important to match the specificity (i.e., global or symptom domains) 
and constructs (e.g., symptoms or functioning) of the measures upon which effect sizes are 
based.  
 ✁✂ ✄☎✂✆✝✞✟✠✟✞✡☛ ☞✌ ✞✁✂ ✍✂✆✎✏☎✂ ✟✎ ✆✑✎☞ ✟✍✒☞☎✞✆✓✞ ✔✁✂✓ ✆✞✞✂✍✒✞✟✓✕ ✞☞ ✕✂✓✂☎✆✞✂
benchmarks that are comparable across settings✖  ✁✂ ✄☎✂✆✝✞✟✠✟✞✡☛ ☞✌ ✆ ✍✂✆✎✏☎✂ ✁✆✎ ✗✂✂✓
operationalised as who rates it - clinician or client (Minami et al., 2007) ✆✓✘ ✟✓ ✝✁✟✑✘☎✂✓☛✎
mental health research, this can be extended to include whether the rating is completed by 
parent or child. Clinician-rated measures tend to generate larger effect sizes than client- 
rated measures (Fava, Evins, Dorer, & Schoenfeld, 2003; Rief et al., 2009). In children 
with anxiety disorders, parent-reported reductions in symptoms are approximately twice as 
large as child-reported reductions in symptoms (Prins & Ollendick, 2003) and in fact, 
child-rated symptoms can resemble effect sizes no larger than wait list controls (Barrett et 
al., 1996; Hudson et al., 2009).  
Concerns regarding the impact of the measure used to establish effect sizes are 
reflected in the fact that most benchmarking studies make use of the same outcome 
measure to establish the benchmark standard or, at least, measures with comparable 
reactivity and specificity (e.g. Dobson et al., 2010; Minami et al., 2009; Schindler et al., 
2011; Weersing et al., 2006; Weersing & Weisz, 2002). Thus far, most studies have used a 
symptom-specific measure of outcome to establish the benchmark and to evaluate outcome 
in their comparator group. However, establishing a treatment efficacy benchmark using a 
symptom-specific measure may be of limited use for community agencies conducting 
BENCHMARKING TREATMENT OF ANXIETY IN YOUTH   
 
28 
large-scale evaluation of the services they deliver. This is because such large scale efforts 
tend to mandate use of measures that are broad based enough to capture the diversity of 
presenting problems typically seen in their clinics. These broad based measures are likely 
to be less sensitive to change in target symptoms and will therefore typically generate 
smaller effect sizes than symptom-specific measures. This suggests the effect sizes 
generated from these broad-based measures are not comparable with those generated from 
specific measures of the target symptom. Therefore, given measures mandated for use 
within community agencies are typically broad-based, establishing benchmark standards of 
outcomes using broad-based measures of psychopathology will likely be extremely helpful. 
For instance, a common broad-based measure of child psychopathology in youth is the 
Child Behavior Checklist (CBCL-/6-18) - a measure commonly used  ✁ ✂✄☎✆ ✝✆ ✞✟✠✡✁☛☞
mental health agencies and within many RCTs for ✝✆ ✞✟✠✡✁☛☞ ✌✡✁☎✍✞ ✆✡✍✞☎✆ ✎✏✝✆✡✁✂✍✝✆
1991; Achenbach & Rescorla, 2001). 
The focus of discussion thus far has been on use of pre-post effect sizes as the metric 
most commonly used to generate benchmarks and evaluate the effectiveness of 
interventions. This information may be of limited utility within clinical settings, however. 
Many clinicians (and agency managers) do not have a strong understanding of the meaning 
of effect sizes and they may therefore not make use of this metric of outcome. Further, 
while effect sizes are relevant to making generalisations about the impact of a treatment on 
the whole group of participants, they do not provide important information regarding 
individual differences in treatment outcome (Hunsley & Lee, 2007; Swanson et al., 2001).  
A potentially important alternative and clinically relevant way of describing outcomes, 
particularly when trying to establish clinician-friendly benchmarks, is the proportion of 
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clients who experience either  clinically significant improvement✁ or complete recovery 
from their presenting disorders.   
Hunsley and Lee (2007) discuss benchmarks for improvement/ recovery for 
particular disorders in children and adolescents. The results of recent meta-analyses were 
used as benchmarks for improvement or recovery rates for each of the target problem areas 
(e.g. anxiety; depression). This was a challenging task, given that improvement/ recovery 
rates are not always reported in clinical trials, and/or are operationalized differently across 
trials.  Clinically significant improvement✁ ✂✄☎ ✆✝✝✞ ✟✠✝✡✄☛☞✟✞✄✌☞✍✝✎ ☞✞ ✄ ✞✏✑✆✝✡ ✟✒ ✓✄✔☎, 
including ☛✂✝ ✠✡✟✠✟✡☛☞✟✞ ✟✒ ✕✌☞✝✞☛☎ ✓✂✟ ✑✟✖✝ ✒✡✟✑  ✠✄☛✂✟✌✟✗☞✕✄✌✁ ☛✟  ✞✟✡✑✄✌✁ ✡✄✞✗✝ ✟✒
functioning on a standardised outcome measure (e.g. Minami et al., 2009).  Some studies 
use a more conservative definition where participants are only considered to have 
demonstrated  clinically significant improvement✁ if they (1) ✑✟✖✝ ✒✡✟✑  ✠✄☛✂✟✌✟✗☞✕✄✌✁ to 
 ✞✟✡✑✄✌✁ ✡✄✞✗✝ ✟✒ ✒✏✞✕☛☞✟✞☞✞✗ ✟✞ ☎☛✄✞✎✄✡✎☞☎✝✎ ✑✝✄☎ures of pathology (such as the CBCL-
/6-18) and (2) demonstrate  reliable✁ change (Farrell et al., 2010).   Reliable ✘✂✄✞✗✝✁ is a 
magnitude of improvement that is beyond what might be expected from measurement error 
alone, and Jacobson and Truax✁☎ ✙1991)  ✚✝✌☞✄✆✌✝ ✘✂✄✞✗✝ ✛✞✎✝✜✁ ✙✚✘✛) can be used to 
quantify the amount of improvement requi✡✝✎ ☛✟ ✆✝ ✕✟✞☎☞✎✝✡✝✎  ✡✝✌☞✄✆✌✝✁✢ 
Clinical trials also report ✡✝☎✏✌☛☎ ✟✒  ✡✝✕✟✖✝✡✔✁ - ✄ ✕✟✞☎☛✡✏✕☛ ☎☞✑☞✌✄✡ ☛✟  clinically 
significant improvement✁. This construct is often operationalized as the proportion of 
participants at post treatment who no longer meet criteria for a DSM diagnosis. However, 
there may be reasons ✓✂✔  ✡✝✕✟✖✝✡✔✁ from a DSM diagnosis might not be a helpful metric 
of outcome to use within community agencies.   First, DSM diagnoses are often established 
with different degrees of rigor and standardisation in clinical practice than in research trials 
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which means change in one might not be comparable to change in the other (Jensen & 
Weisz, 2002; Lewczyk, Garland, Hurlburt, Gearity, & Hough, 2003). The second reason 
relates to the first. It is time consuming and costly to generate a reliable, valid DSM 
diagnosis, and they can only be established by a limited number of highly trained 
professionals (for instance, physicians or psychologists).  Costs mean that sufficiently 
rigorous diagnostic interviews are unlikely to be routinely conducted for all youth at pre- 
and post- treatment in community mental health settings. Therefore benchmark standards 
based on recovery from DSM diagnoses are likely to be of limited usefulness in community 
settings. For this  ✁✂✄☎✆✝ ✞✁✆✟✠✡✂ ☛✄ ✞✂✄✁☞ ☎✆ ✌✟✍✎✆✎✟✂✍✍✏ ✄✎✑✆✎✒✎✟✂✆✓ ✎✡✔ ☎✕✁✡✁✆✓✖✝ 
established from more portable approaches such as from parent-rated measures, may offer 
greater utility in community agencies than rates of diagnostic recovery. 
Discussion, thus far, has focussed on various issues related to measurement when 
conducting benchmarking studies. Another important issue to address when applying a 
benchmarking strategy to evaluate community services is how clinical trials are selected 
when establishing the treatment benchmark standard in the first place. The limited number 
of RCTs evaluating the treatment of anxiety disorders in youth means that there has been 
relatively few effectiveness trials conducted. While it might be ideal to compare outcomes 
of community settings against outcomes of effectiveness studies (rather than efficacy), this 
would drastically reduce the number of studies available with which to establish the 
benchmark, and thus render it less reliable. Further, as noted by Hunsley and Lee (2007), it 
appears that results of effectiveness and efficacy trials are comparable. For these reasons, 
both effectiveness and efficacy trials can be used to generate benchmark standards.  
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Related to consideration of selection of trials to establish benchmarks of outcome are 
strategies to adequately match participants drawn from large-scale community data bases to 
RCT samples. In essence, the challenge of this process relates to how precisely 
characteristics of clients drawn from community databases can be matched to those of 
participants in published trials. Minami, Wampold et al. (2008) outline a process of  ✁✂✄✂
☎✆✁✝✞✄✟✠✡☛ ☞ that is, of identifying a comparable sample of clients from the broader 
participant pool of community mental health agency data bases. There are some challenges 
with this strategy. Diagnoses based on community assessments can be somewhat different 
than those typically used in research studies (Jensen & Weisz, 2002; Lewczyk et al., 2003). 
This may reflect differences in research and community settings with respect to the rigor 
and standardisation of the diagnostic process. As an alternative to diagnosis, information 
regarding clinical presentation can be gleaned from results of dimensional measures of 
psychopathology with population norms (such as the CBCL/6-18; Achenbach, 1991; 
Achenbach & Rescorla, 2001). Profiles from CBCL/6-18 have been used to identify youth 
within broad categori✆✌ ✠✍ ✎✌✏✞✑✠✎✂✄✑✠✒✠✓✏ ✔✌✝✞✑ ✂✌  ✂✡✕✟✆✄✏ ✁✟✌✠☎✁✆☎✌☛✖ ✠☎  ✂✍✍✆✞✄✟✗✆
✁✟✌✠☎✁✆☎✌☛✘ (Krol, DeBruyn, Coolen, & van Aarle, 2006). 
Data reduction is a strategy that can be used to identify subgroups within a broader 
community population, and this approach may be particularly helpful when there is no 
single ideal way for identifying youth with a specific target clinical profile. Considering 
outcomes of subgroups identified in somewhat different ways can assist in interpretation 
and cross validation of results. For instance, this could include examining subgroups of 
clients primarily identified by diagnosis or by profile on measures of psychopathology 
(such as the CBCL). Oei and Boschen (2009) examined outcomes of two subgroups drawn 
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from a larger data set of adults treated for anxiety disorders in a private hospital in 
Australia. They considered the improvement of the full group as well as a group with 
elevated pre-treatment scores on the main outcome measure (the Beck Anxiety Inventory; 
Beck & Steer, 1990). Schindler et al. (2011) examined outcomes of both their full sample 
and a subgroup of adults eligible for inclusion in RCTs. Considering outcomes of different 
subgroups also enriches understanding of factors that might moderate outcome and can 
allow for matching with particular benchmarks. For instance, Minami et al. (2009) 
examined outcomes of students seen at a university counselling centre and extracted 
subpopulations from the larger data set based on characteristics such as treatment 
 ✁✂✄☎✆✝✞✁✟ ✠✡ ✁✂✄☎✆✝✆☛☞ ✌✆☛✍✎✍ ✡✞✟✝✆✟✝ ✝✁ ✝☛✆✏✝☞  ☎✞✆✟✝✍✑ ✏✟✒ ✝✓✆✟  ✁✂✄✏☛✆✒ outcomes of 
these to separate benchmarks (i.e. benchmarks based on RCTs reporting ✡ ✁✂✄☎✆✝✆☛☞ ✏✟✒
✡✞✟✝✆✟✝ ✝✁ ✝☛✆✏✝☞ data).  
Strategies have been suggested to improve the reliability of benchmark standards. 
Weersing and Weisz (2002) suggest it is optimal to establish benchmark standards that are 
based on meta-analyses rather than selected trials. This contrasts with methodology in 
some benchmark research that uses only a single trial for comparison (e.g. Gaston et al., 
2006) or lists results of a handful of trials rather than aggregating them into a summary 
statistic (Oei & Boschen, 2009). The strategy of establishing a benchmark based on the 
aggregation of a number of treatment trials is advantageous because it reflects results 
across a broader range of client and agency characteristics. Related to this issue is the use 
of statistical analysis when examining differences between community groups and 
published trials. It is optimal to use statistical analysis (rather than visual inspection, which 
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can be biased) when comparing outcomes of the community group against benchmark 
standards (Minami, Serlin et al., 2008). 
The process of measurement and benchmarking may have many potential 
contributions to improving outcomes in children's mental health services. Systematic 
measurement and reflection on outcome, as recommended by Bickman (2008), is one of 
the cornerstones of benchmarking and can lead to improvement in practice (Hodges & 
Wotring, 2004). Further, benchmarking may be a useful way to evaluate community 
services in the absence of control groups. 
Thus far, discussion has focused on the importance of treating youth with anxiety 
disorders, the representativeness of conditions in efficacy trials for treating these youth, the 
generalizability of results of efficacy trials to community settings, the use of benchmarking 
as a strategy to evaluate community services, and methodological issues that arise when 
benchmarking. Attention will now turn to gr ✁✂✄  ☎ ✆✝✞✟✠✡✞✄ ✂☛ ☞✡✌✡✟✝ ✠✍✡✎✌☛✞✟✏✄ ✑✞✟✒✆✎
health services including youth with anxiety disorders seen in their care ✓ the 
Comprehensive Community Mental Health Services for Children and their Families (SOC 
CMHS). 
Comprehensive Community Mental Health Services for Children and Their Families 
Program Systems of Care (SOC CMHS) 
✔✟ ✒✍✞ ✕✟✡✒✞✌ ✖✒✆✒✞✄ ✗✕✘✖✘✙✚ ✒✍✞ ✛✄✜✄✒✞✑✄  ☎ ✠✆☛✞✏ ✗✖✢✣✙ ✑ ☞✞✑✞✟✒ ✤✆✄ ✌✞☞✞✎ ✂✞✌ ✒ 
✡✑✂☛ ☞✞ ✒✍✞ ✥✁✆✎✡✒✜ ✆✟✌  ✁✒✠ ✑✞✄  ☎ ✠✍✡✎✌☛✞✟✏✄ ✑✞✟✒✆✎ ✍✞✆✎✒✍ ✄✞☛☞✡✠✞✄✘ ✢☞✞☛ ✒✍✡☛✒✜
communities, serving more than 50 000 children, have been funded through the 
Comprehensive Community Mental Health (CMHS) Services for Children and Their 
✦✆✑✡✎✡✞✄ ✂☛ ✝☛✆✑ ✗✣✍✡✎✌☛✞✟✏✄ ✧✞ntal Health Initiative [CMHI]) to support the adoption of 
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a SOC approach to service delivery (Manteuffel, Stephens, Sondheimer, & Fisher, 2008). 
 ✁✂ ✄☎✆☎✝✂✞ ✟✠ ✡☛☞✂✌ ✍✁✎✏✟☎✟✍✁✆ encourages the implementation of interventions that are 
evidence-based and emphasizes individualized, strengths-based, coordinated, culturally 
competent and community-based services for youth with serious emotional disturbance 
(Holden, de Carolis, & Huff, 2002; Holden, Friedman, & Santiago, 2001).   
Part of the strength of the SOC CMHS model includes its mandated evaluation 
component. This component facilitates (among other things) the examination of outcomes 
of children who receive services within these agencies.  The use of systematic outcome 
measurement enables communities to track their own effectiveness, and enables the 
identification of best practices for particular client groups (Hamerlynck, 2005; Hodges, 
Xui, & Wotring 2004). Mellor-Clark (2006) discusses the helpfulness of consistent 
✠✂✂✑✒☛✡✓ ☞✂✔☛☞✑✎✕✔ ✟✖✝✡✟✞✂☎ ✝✟ ✂✕✡✟✖☞☛✔✂ ☛ ✄✡✖✏✝✖☞✂ ✟✠ ✡✖☞✎✟☎✎✝✆✌✗  ✁☛✝ ✎☎✘ ✠✟☞ ✡✏✎✕✎✡✎☛✕☎ ✝✟
become curious about the outcomes of the services they deliver, factors that might 
contribute to strong or poor results and what might be changed to improve or generalize 
helpful practices.   
The development of a comprehensive data set capturing the longitudinal outcomes of 
clients can fac✎✏✎✝☛✝✂ ✝✁✎☎ ✄✡✖✏✝✖☞✂ ✟✠ ✡✖☞✎✟☎✎✝✆✌ ✙✎✝✁✎✕ SOC CMHS agencies, as they reflect 
on the impact of their services (Hodges, Doucette-Gates, & Kim, 2000; Hodges, Doucettes-
Gates, & Liao, 1999; Walrath, Mandell, & Leaf, 2001).  Current reports of the impact of 
SOC CMHS services provide information regarding changes in symptoms over time. SOC 
CMHS agencies aspire to using EBP, and previous research has found the majority of 
clinicians working in SOC agencies report using EBP (Sheehan, Walrath, & Holden, 2007). 
However, it has not been clearly demonstrated that these communities achieve results 
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comparable to those of efficacious treatments, rather than natural remission in youth with 
anxiety disorders. For instance, it may be that, similar to results of studies of other 
community settings, results of the SOC CMHS community treatments more closely 
resemble UC than ESTs (Weisz et al., 2004).  The ability of SOC CMHS to achieve results 
comparable to those of clinical trials would have substantial implications, since it would 
suggest that it is possible to design and implement large scale system-wide models in 
community settings which deliver services of comparable impact to those in clinical trials, 
as opposed to negligible effect sizes typically seen in UC. 
As mentioned, anxiety disorders are some of the most prevalent problems of children 
 ✁✁✂✄☎✆✄✝ ✞✟✆✠☎✡✂✄☛☞ ✌✂✄✁ ✠ ✟✂ ✠✁✟  ✝✂✄✞✆✂☞✍ ✎✏✁ ✁✟✂✡✂  ✡✂ ✡✂✠ ✁✆✑✂✠✒ ✓✂✔ ☞tudies examining 
the performance of UC in community settings against results of efficacy trials for these 
disorders. As noted, there is reason to believe that treatment delivered in such settings may 
not be optimal, with common barriers to dissemination and uptake of EBP being well 
documented (e.g. Persons, 1997).  
Thus, a benchmarking strategy can be applied to evaluating the effectiveness of SOC 
CMHS agencies, although it is important to exercise caution in particular aspects of the 
methodology. In the present study, the strategy will be applied to evaluate the outcomes of 
the SOC CMHS services for youth with anxiety disorders. This strategy will generate 
benchmarks for improvement in global internalising psychopathology (as measured by the 
CBCL-Internalising/ 6-18 scale), and for ✕clinically significant improvement☛ (as measured 
by improvement on the CBCL-Internalising/6-18 scale). In addition, factors associated with 
treatment response will be explored.   
 




There are several important gaps in the literature regarding benchmarking of 
standards of care in child and youth mental health services.   ✁ ✂✄☎ ✆✝✂✄✁✞✟✠ ✡☛✁☞✌☎✍✎☎✏
treatment and natural history benchmarks have not been established for treatment of 
anxiety disorders in youth using measures of global internalising psychopathology. Further, 
a benchmarking strategy has not been applied to the evaluation of SOC CMHS services in 
the U.S. Applying the strategy will be potentially valuable for several reasons. It will 
enable the establishment of appropriate benchmarks for anxiety disorders for use by other 
youth mental health services (including Canadian). Further, the examination of the impact 
of SOC CMHS services could be used to guide training efforts within those services, 
showcase effective community-based services and may offer evidence of the value of the 
model in generating outcomes comparable to RCTs, even in community settings. 
The present research addressed the following questions;  
(i) What are treatment efficacy and natural history pre-post effect size 
benchmarks for treatment of youth with anxiety disorders?  
(ii) What are treatment and natural history benchmarks for ✑clinically significant 
improvement✟ of youth with anxiety disorders? 
(iii) How do pre-post effect sizes of youth with anxiety disorders treated at SOC 
CMHS agencies compare to treatment efficacy and natural history 
benchmark standards? 
(iv) How does the proportion of youth with anxiety disorders treated in SOC 
✒✓✔✕ ✆✎☎☛✖✗☎✠ ☞✄✁ ☎✘✗✍☎☛✖☎ ✑✖✌✗☛✗✖✆✌✌✙ ✠✗✎☛✗✚✗✖✆☛✂ ✗✛✜✞✁✘☎✛☎☛✂✟ ✖✁✛✜✆✞☎
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to treatment and natural history benchmark standards for  clinically 
significant improvement✁? 
(v) What proportion of youth with anxiety disorders treated at SOC CMHS 
agencies ✂✄☎✆  ✝☎☎✞✁ ☎✟  ✠☎☎✟✁ treatment response? 
(vi) What demographic, family context, child strength and resiliency, child 
functional impairment and child psychopathology variables are associated 
with treatment response of youth with anxiety disorders in SOC CMHS 
agencies? Eleven variables will be considered. 
Hypotheses 
One of the principles of the SOC approach is a commitment to use of EBP in 
community services (Holden et al., 2002), with the majority of clinicians in SOC CMHS 
agencies reporting use of EBP (Sheehan et al., 2007). Further, previous research has noted 
that when community agencies implement evidence-based interventions, they can achieve 
outcomes comparable to those of published clinical trials (e.g. Curtis et al., 2009). Based 
on these findings, it was hypothesised that outcomes of SOC CMHS agencies treating 
youth with anxiety disorders would meet or exceed the treatment benchmarks generated 
from research of ESTs, and would be superior to the passage of time alone. The two kinds 
of treatment benchmarks utilised were (1) those based on both pre-post effect sizes and (2) 
those based on the proportion of youth evidencing  clinically significant improvement✁ 
(CSI).  
There has been some concern that clients seen in community settings are more 
complex than those recruited within efficacy trials and therefore have predictably worse 
outcomes (Westen et al., 2004). Previous reviews, however, have concluded that there is 
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generally no significant relationship between outcomes of treatment for anxiety in youth 
and the presence of comorbid disorders (Ollendick et al., 2008) or adverse social 
circumstances (Southam-Gerow et al., 2001). Nonetheless, it is important to examine 
associations between indices of case complexity (such as comorbidity or adverse social 
circumstances) and treatment response in order to better interpret outcomes of clients of 
community agencies. Based on research reviews, it was hypothesised that indices of case 
complexity (living in poverty or having a comorbid affective or externalising disorder) 
would not be associated with response to treatment of anxious youth served within SOC 
CMHS agencies. Past studies have also generally found that demographic variables 
(including age, sex and ethnicity) are not associated with treatment outcomes in youth with 
anxiety disorders (Silverman, Pina et al., 2008). Nonetheless, these findings have not been 
entirely consistent and it is important to consider these basic variables when attempting to 
understand treatment response in the SOC CMHS youth. Based on the preponderance of 
evidence, it was hypothesised that demographic variables would not be associated with 
response to treatment of anxious youth served within SOC CMHS agencies. Finally, there 
are a number of variables that could be associated with the treatment outcomes of anxious 
children. These include the number of child and family risk factors (such as history of 
abuse, substance abuse, psychiatric hospitalisation), caregiver stress, family functioning, 
child strengths and child functioning at baseline. While these factors have not been 
explicitly evaluated in previous research, studies on related factors (such as parent 
psychopathology) have found significant relationships with treatment outcomes (c.f. 
Berman et al., 2000; Crawford and Manassis, 2001; Liber et al., 2010). Based on these 
related findings and an intuitive understanding of the relationship between family and child 
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liabilities and treatment outcome, it was hypothesised that children and families with fewer 
risk factors, experiencing less caregiver stress, with a greater number of child strengths and 
better functioning would respond to treatment better than those with more risk factors, 
stress, fewer strengths and more impaired functioning at baseline.  
Thus, the study hypotheses were as follows; 
1. Outcomes of youth with anxiety disorders served in the SOC CMHS agencies will 
surpass the natural history benchmark and meet or exceed the treatment efficacy 
benchmark for pre-post effect size. 
2. Outcomes of youth with anxiety disorders served in the SOC CMHS agencies will 
exceed the natural history benchmark for CSI and will meet or exceed treatment 
benchmarks for CSI. 
3. The response to treatment of youth in the SOC CMHS data set will not be 
associated with indices of case complexity (the presence of a comorbid 
externalizing disorder, the presence of a comorbid affective disorder, poverty 
status).  
4.  The treatment response of youth in the SOC CMHS data set will not be associated 
with demographic variables (sex, ethnicity, age).  
5.   ✁✂✂✄☎ treatment response of youth in the SOC CMHS data set will be associated 
with fewer child and family risk factors, less caregiver stress, better family 
functioning, a greater number of child behavioural and emotional strengths and 
better child functioning at baseline. 
 
 




Base Longitudinal SOC CMHS Database 
 The sample for the present study was drawn from the base data set of the national 
evaluation of SOC CMHS agencies. This data set consists of the descriptive and outcome 
data of clients drawn from approximately 30 communities within the United States (US) 
that received initial programme funding grants between 1997 and 2000. Baseline data was 
collected between 1995 and 2006. These communities were within approximately 16 states 
and included rural and urban settings (Manteuffel, Stephens, & Santiago, 2002).  
To be included in the SOC CMHS data set, youth had to meet at least one of the 
following criteria; "(1) a clinical DSM-IV (American Psychiatric Association, 1994) Axis I 
diagnosis, (2) a score in the clinical range on either the Child Behavior Checklist (CBCL) 
(Achenbach, 1991) or the Child and Adolescent Functional Assessment Scale  (Hodges, 
1990), (3) a history of multiple system services (e.g., juvenile justice, child welfare, special 
education), (4) a history of out-of-home placement, or (5) participation in a special 
education programme for students with serious emotional disturbance" (Stephens, Holden, 
& Hernandez  2004, p.182).  Thus, the data set consisted of youth drawn from agencies that 
served youth with complex needs and/or experiencing substantial levels of difficulties. 
The SOC CMHS longitudinal data set contained data for 4563 youth in the age range 
of interest in the present study (6-15 yr olds). Table 1 provides descriptive data from this 
age matched base SOC CMHS longitudinal data set  ✁✂✄☎✆ ✝✞✟✠✡☛☞✌✡✟✄✝ ✍✎✏ ✏✑✒✍✓✔✕ ✖✟
addition, Table 1 provides details of two subsets of youth from the longitudinal SOC 
CMHS who were matched to characteristics of published treatment trials. The two subsets 
of this longitudinal sample were selected on the basis of a number of inclusion and 
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exclusion criteria, in an effort to maximise the match between them and the characteristics 
of youth from published treatment trials. These criteria will be detailed shortly. Selection of 
the two subsets differed on one inclusion criterion. One subset was selected based on a 
combination of Child Behavior Checklist profile and DSM diagnosis or presenting problem 
and (CBCL/6-18; Achenbach, 1991; Achenbach & Rescorla, 2001) (SOCCBCL). The other 
subset was selected on the basis of DSM diagnosis alone (SOCdiag). These two subsets of 
youth form the participant pool for the present study.  
The base longitudinal SOC CMHS data set consisted of youth with a mean age of 
11.6 (SD = 2.6; Table 1). The majority were male 3130 (68.6%), almost half (41.6.8%) 
 ✁✂✄☎ ✁✆ ✝✞✟✂✄✠✡☛☞ ✌✁✍✄✍ ✎✆✆✏✎  ✑✟✏✒✄✑✟ ☎ ✁✆✓✟✔✄  ✄✒✒ ✡✑✎✆ US$15 000) and almost half 
identified themselves as belonging to an ethnic minority (47.5%). The most common 
custody arrangement was houses headed by a lone biological mother (46.6%, n = 2110). 
Families with a biological parent and second biological or step-parent were the next most 
common custody arrangement (23.8%, n = 1076). A sizeable minority of youth in the base 
longitudinal sample were Wards of the State (8.2%, n = 372). 
A sizeable minority of the base longitudinal sample did not have a recorded DSM 
diagnosis (12.3%; n = 559). Examination of the clinical profile of participants with 
recorded DSM diagnoses revealed a small proportion presented with an anxiety disorder 
(5.8%, n = 232), Post Traumatic Stress Disorder (9.8%, n = 392), and there was a larger 
proportion with a mood disorder (34.9%, n = 1396). A substantial proportion of the base 
population had externalising disorders, most commonly Attention Deficit/ Hyperactivity 
Disorder (ADHD) (46.4%, n = 1859) or Oppositional Defiant Disorder (30.0%, n = 1202) 
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with a smaller proportion with Conduct Disorder (7.6%, n = 303). The mean number of 
diagnosed DSM mental health disorders was 1.71 (SD = .77). 
The CBCL/6-18 profile of the base longitudinal SOC CMHS youth is also 
summarised in Table 1. Details regarding the nature of CBCL/6-18 broadband and DSM-
oriented scales will be outlined later. It should be noted briefly, however, that the CBCL-
DSM Anxiety (CBCL-DSM Anx) scale of the CBCL reflects symptoms of anxiety 
disorders and the CBCL-Externalising reflect broad symptoms of externalising 
psychopathology. Around one third of the base longitudinal  ✁✂✄☎✆ ☎✁✝ ✞✟ ✠✡✆ ☛☞☎✞✟✞☞✁☎✌
range on CBCL-DSM Anx DSM-oriented scale  (37.4%, n = 889) (T  >= 70), and around 
three quarters ✍✆☎☎ ✞✟ ✠✡✆ ☛✎✆✏✞✁✟✠✌ range on the CBCL- Externalising broadband scale (T > 
= 64)  (70.2%). Of those with data, around one third of the sample fell within ✠✡✆ ☛☞☎✞✟✞☞✁☎✌
range on the CBCL-DSM Anx ✁✟✎ ☛✎✆✏✞✁✟✠✌ ✑✁✟✒✆ ✓✟ ✠✡✆ CBCL-Externalising (CBCL-
Ext) broadband scale (33.4%; n = 793). That is, around one third of the base sample was 
significantly elevated on scales measuring symptoms of anxiety and externalising 
behaviour.   
Most youth received mental health services (81.5%, n = 3393) with a sizable portion 
receiving services through the child welfare (30.0% n = 1254) or juvenile justice (17.0%, n 
= 709) sectors. The majority of youth received individual therapy (78.9%; n = 3188), and 
around one third received group (34.1%, n = 1367) and/or family therapy (38.9%, n = 
1572).  Well over half indicated that they had received medication as treatment for a 
behavioural or emotional disorder in the six months prior to the initial interview (66.4%; n 
= 2963).  
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Youth in the data set had received a wide range of therapy  ✁✂✄☎✆ ✝✞✟☎✟ ✠✡☛☞☎✌ ✂✍
sessions). In the six months between the initial and second data collection points, the 
median number of sessions for clients in the longitudinal data set was 14 for individual 
therapy (range 1-210), 20 for group therapy (range 1-540) and 8 for family therapy (range: 
1 - 200).  The data set did not contain information regarding the content or focus of 
treatment, but this large number of sessions may reflect receipt of help from multiple 
services. For instance, the vast majority of youth who reported a large number of sessions 
in the six month period (>= 27 sessions) received assistance from three or more services 
(97.9%). This might account for the extremely high number of sessions.  
SOC CMHS Subsets 
For the purposes of the present study, the base longitudinal SOC-CMHS data set was 
systematically reduced ✎✞✏ ✏ ✄☎✑ ✂✍ ✞✠✒✓✡✄✞✂✠ ✏✠✁ ☎✔✒✓✡✄✞✂✠ ✒✌✞✑☎✌✞✏✟ ✕✖✞✄  ✁✏✑✏ ✌☎✁✡✒✑✞✂✠✆
strategy was applied in an attempt to maximise the correspondence between youth in the 
SOC CMHS subsets and participants of published clinical trials. The aim of maximising 
this correspondence was to improve the validity of comparison between outcomes of youth 
in SOC CMHS subsets with treatment efficacy benchmarks (established from the outcomes 
of published clinical trials). Two subsets were used, as a way of cross validating results of 
two alternate strategies for identifying youth with DSM anxiety disorders from the broader 
longitudinal data set. Inclusion and exclusion criteria were identical for both subsets, with 
the exception of the first inclusion criteria, where youth with anxiety disorders were 
identified somewhat differently. Inclusion criteria for the subsets were as follows; 
 
 




  A DSM diagnosis of an anxiety disorder and a score on the CBCL-DSM Anx 
scale in at least the ✁borderline clinical✂ range of functioning (CBCL-DSM 
Anx T >= 65)  
or  
A presenting problem of being ✁✄☎✆✝✞✟✠✂ ✄☎✡ a score on the CBCL-DSM Anx 
scale in the ✁clinical✂ range of functioning (CBCL-DSM Anx T >= 70).  
 
These criteria were used to maximise the likelihood that youth had a 
clinical profile comparable to those in clinical trials, particularly since the 
correspondence between clinic and research-derived diagnoses is not always 
strong (Jensen & Weisz, 2002; Rettew, Lynch, Achenbach, Dumenci, & 
Ivanova, 2009). The CBCL-DSM Anx scale was developed to correspond to 
diagnoses of anxiety disorders (Achenbach & Rescola, 2001), and although 
there has been some mixed results (Ferdinand, 2008), most research suggests 
it is helpful in identifying youth who meet criteria for a DSM anxiety disorder 
(Ebesutani, Bernstein, Nakamra, Chorpita et al., 2010; Krol et al., 2006; 
Nakamura, Ebesutani, Bernstein, & Chorpita, 2009; Seligman, Ollendick, 
Langley, & Baldacci, 2004). As mentioned, details regarding the 
psychometric properties of the CBCL-DSM Anx scale of the CBCL-6/18, 
including discriminant validity, will be discussed in further detail in the 
✁☛☞✄✠✟✌☞☛☞☎✍✂ ✠☞✎✍✝✞☎ ✞✏ ✍✑☞ ✒☞✍✑✞✡✓ 
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Scores  ✁ ✂✄☎ ✆✝✞ ✁ ✝✟✞✠ ✡✟✁☛☎ ☞✁ ✂✄☎ ✌✍✌✎-DSM Anx were 
supplemented ✏ ✂✄ ✟ ✑✡☎✒☎✁✂ ✁☛ ✑✡☞✓✞☎✔ ☞✕ ✆✟✁✖ ☎✂✗✠, because while many 
✗☞✘✂✄  ✁ ✂✄☎ ✒✟✔✑✞☎ ✒✝☞✡☎✙  ✁ ✂✄☎ ✆✝✞ ✁ ✝✟✞✠ ✡✟✁☛☎ ☞✁ ✂✄☎ ✌✍✌✎-DSM Anx, 
not all of these youth would have been seeking treatment for difficulties with 
anxiety. Using presenting problem to supplement CBCL profile increased the 
likelihood that the youth were experiencing symptoms of anxiety severe 
enough to warrant a diagnosis and that they were seeking treatment for this 
issue. The more stringent range of the CBCL-DSM Anx scale (i.e. CBCL-
✚✛✜ ✢✁✖  ✁ ✆✝✞ ✁ ✝✟✞✠ ✡✟✁☛☎✣ was used, because a presenting problem of 
✆✟✁✖ ☎✂✗✠  ✒ ✁☞✂ ✟ ✝☞✁✙✘ ✂ ✕☞✡ ✟ ✚✛✜ ✙ ✟☛✁☞✒ ✒ ☞✕ ✟✁ ✟✁✖ ☎✂✗ ✙ ✒☞✡✙☎✡✤  
 
SOCdiag subset; 
✥ A DSM diagnosis of an anxiety disorder.  
Using a DSM diagnosis of an anxiety disorder, without reference to anxiety 
profile on the CBCL, was used for two reasons: 1) because almost all RCTs 
for treatment of anxiety in youth use diagnosis alone to identify target youth, 
without reference to scores on dimensional measures of psychopathology, 2) 
relying only on a DSM diagnosis meant that the pre-treatment mean and 
standard deviation of scores on the measure used to establish the pre-post 
effect size (i.e. CBCL-Internalising scale) were not artificially influenced by 
aspects of study design and were therefore more likely to mirror those of 
RCTs. This is important, considering the possible impact of elevated pre-
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treatment mean and restricted pre-treatment standard deviation on pre-post 
effect size. 
It should be noted that in the SOC CMHS data set, Post Traumatic Stress Disorder 
(PTSD) was coded separately from other anxiety disorders.  Although PTSD is a DSM IV 
TR anxiety disorder, a diagnosis of PTSD was not used as an inclusion diagnosis in the 
present study. This is because none of the published treatment trials that were used to 
establish outcome benchmarks specifically treated youth with PTSD (see Table 2).  
The remainder of inclusion and exclusion criteria were identical for both subsets, and 
were as follows; 
  Youth were aged 6-15 years, inclusive. This criterion was used because 
examination of clinical trials treating children with mean age 6-12 years 
(which was the target mean age range) revealed most of these included 
children up to 15 years old (see Table 2). Thus, the range of youth in the SOC 
CMHS was extended to be commensurate with the clinical trials used to 
benchmark outcomes.  
  The respondent completing the main outcome measure (the CBCL/6-18) was 
a caregiver. This criterion was applied because all treatment trials used parent 
responders to rate the CBCL/6-18, and paid workers are likely to have 
differing perspectives than parents or guardians (c.f. Achenbach & Rescorla, 
2001). 
  The child was living with the caregiver providing information in the time 
leading up to the baseline assessment. This criterion was applied because 
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thorough knowledge of the child (from having the child live with the 
respondent) was necessary for a valid completion of assessment materials.  
  Youth (or their families) had received individual, group or family therapy. 
This criterion was applied as an attempt to match the type of treatment tested 
within published trials to that received at SOC CMHS agencies. While the 
content of these therapies was not necessarily the same as that within clinical 
trials, the mode of treatment provided was broadly comparable. 
Most exclusion criteria reflected those typically used in clinical trials. Exclusion 
criteria for the sample were defined as follows; 
  Clients with a diagnosis of a pervasive developmental disorder or Mental 
Retardation. While these co-morbidities occur in clinical settings, they are 
typical exclusion criteria for clinical trials because they are likely to represent 
substantial moderators of outcome (e.g. Kendall et al., 2008; Nauta et al., 
2003, Shortt, Barrett, & Fox, 2001).  
  Related to this issue, participants in the SOC CMHS data set were excluded if 
they had a DSM diagnosis of Conduct Disorder, Bipolar Disorder, Psychotic 
Disorder, or a substance related disorder or if their reported presenting 
problems would likely be a higher treatment priority than anxiety (e.g. fire 
setting; sexually assaultive behaviour; substance abuse, suicide attempt, 
homicide threat). Further, they were excluded if their CBCL Externalising 
broadband scale score was more than one standard deviation higher than their 
CBCL Internalising broadband scale score (i.e. a T score 10 or more higher 
than their CBCL-Int T score) (Achenbach & Rescorla, 2001). This criterion 
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was applied to exclude youth with issues likely to be more pressing than the 
anxiety disorder.  In a treatment setting, the problems of participants with a 
profile including these criteria would likely be prioritised over their 
difficulties with anxiety disorders. 
 
Some additional inclusion and exclusion criteria were considered but not used. First, 
youth who received service from juvenile justice agencies (n = 6 in SOCCBCL; n = 4 in 
SOCdiag), or were in therapeutic foster care (n = 2 in SOCCBCL) were not excluded. 
Excluding these youth reduced the sample size but did not affect conclusions. Therefore, 
they were not excluded.  Also, while many treatment trials require children to refrain from 
taking medication or to be on stable doses of medication during the course of treatment 
(e.g. Kendall, 1994); detailed information regarding medication dose was not readily 
accessible for the youth in the SOC CMHS. Uncontrolled medication use has been 
acknowledged as a reality in community research (Weersing, Iyengar, Kolko, Birmaher, & 
Brent, 2006).  Thus, youth were included regardless of the nature of their medication use. 
A final consideration for inclusion and exclusion criteria for the SOC subsamples 
 ✁✂✄☎✁✆ ☎✝ ☎ ✁✄☎✞✁✟☎ ✠✆✝✡✁☛☞ ✌✍✁ ✁ ✍✄✎✁ ✏✁✁✟ ✞✑✒✁✆ ✓✑✟✆✑✟✔✡  ✁✔✄ ✆✑✟✔ ☎✍✁ ✑✞✕✄✖☎ ✝✓ ✠✆✝✡✁☛
of therapy on outcomes in UC (Andrade, Lambert, & Bickman, 2000; Bickman, 1999; 
Bickman, Andrade, & Lambert, 2002; Hansen, Lambert, & Forman, 2002). However, 
because most RCTs included in the present research reported results of treatment 
✠✖✝✞✕✂✁☎✁ ✡☛ ✗ that is, participants who complete treatment and thus receive a reasonable 
✠✆✝✡✁☛ ✝✓ ☎✍✁ ✄✕✘ ✙✡✁✁ ✌✄✏✂✁ ✚✛ ✗ ✄ ✞✑✟✑✞✜✞ ✠✆✝✡✁☛ ✝✓ ☎✍✁ ✄✕✘ was considered as an 
inclusion criteria. Examination of both the SOCCBCL and SOCdiag subsets revealed that 
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 ✁✂✄☎ ✆✄✝✞ ✟✠✡☛✟☞✡✄✟ ✌✍✆☞✎✝✡✟✡✠✁✏ ✠✡✑ ✍✡✑ ✁☛☞✎✝✡ ✁✂✒✡✁ ✍✆✄✁✂✑✡✠☛✓✝✞ ✔n = 63 in SOCCBCL; n 
= 42 in SOCdiag) (see Figure 1), which meant analyses were less reliable and hence the 
critical values for treatment efficacy benchmark were more stringent (Minami et al., 2009). 
However, conclusions of analysis were not altered (details for the ✌✕ ✝✝✏ ☛✄✑ ✌completer✏ 
subsamples are outlined in the Results section). For these reasons, the full SOCCBCL and 
SOCdiag subsets were used in the present study. 
The process of data reduction is illustrated in Figure 1. The final subset samples 
represent a small proportion of the full SOC CMHS longitudinal age matched data set (n = 
101, 2.2%, SOCCBCL; n = 70, 1.7%, SOCdiag). Each step of the data reduction process was 
an attempt to match the present subsets to samples within clinical trials. Reduction of the 
sample was substantial when youth with issues that would take clinical priority (mostly 
externalising problems) were excluded (reduced from n = 2215 to 929). There was also 
substantial reduction when only youth with significant problems related to anxiety were 
included (reduced from n = 622 to n = 101, SOCCBCL or n = 70, SOCdiag). 
The demographic and treatment profiles of youth in SOC CMHS subsets are outlined 
in Table 1.  As can be seen, the demographic profile and treatment of participants in the 
matched subsets are similar to those in the base longitudinal subset. Consistent with the 
inclusion and exclusion criteria of the present study, there was a higher proportion of youth 
with anxiety disorders and scores in the ✌clinical✏ range of the CBCL-DSM Anx in the 
subsets than in the full sample and there was no youth with excluded diagnoses such as 
Psychotic Disorder or a substance related disorder. All youth had either a DSM diagnosis 
of an anxiety disorder, or a presenting problem of anxiety. All youth in the SOCCBCL and 
the majority of youth in the SOCdiag ✁✍✆✠✡✑ ✂✄ ✟✖✡ ✌✓✆✠✑✡✠✝✂✄✡✏ ✆✠ ✌✍✝✂✄✂✍☛✝✏ ✠☛✄☎✡ ✆✕ the 
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CBCL-DSM Anx (100%, n = 101, SOCCBCL; 74.0%, n = 37, SOCdiag), a third in the 
SOCCBCL (36.6%, n = 37) and all of the SOCdiag (100%, n = 70) had a diagnosis of an 
anxiety disorder.  A substantial proportion of both subsets were diagnosed with ADHD 
(49.5%, n = 50 in SOCCBCL; 32.9%, n = 23 in SOCdiag). The pre-treatment CBCL-
Externalising (CBCL-Ext) scores were high in both SOC CMHS subsets (SOCCBCL mean 
(SD) = 70.0 (9.2); SOCdiag mean (SD) = 64.73 (11.0). A substantial proportion of youth in 
the SOCCBCL (77.2%, n = 78) and somewhat fewer in the SOCdiag (50.0%, n = 25) fell 
within the  clinical✁ range of scores for both the CBCL-DSM Anx and CBCL-Ext. That is, 
they had clinically elevated symptoms of both anxiety and externalising psychopathology. 
There was overlap between the two subsets, with 37 youth belonging to both groups. 
 
  




























Figure 1. Data reduction from base longitudinal age matched SOC CMHS to SOC CMHS 
subsets. 
Youth received individual, group or family therapy. 
N = 622  
Living with respondent and caregiver completed CBCL;  
N = 2704 
 
SOCCBCL 
DSM anxiety disorder and CBCL DSM 
Anx T >= 65   
or 
Presenting problem anxiety and clinical 
range CBCL-DSM Anx (>= 70)  
 
N = 101  
Exclude youth with pervasive developmental disorders; Mental Retardation 
N  = 2215  
Exclude youth with problems that would likely take clinical priority (diagnosis 
Conduct Disorder; Bipolar Disorder; Psychotic Disorder; substance-related 
disorders; a suicide attempt, sexually assaultive behaviour, fire setting etc.) 
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Youth n  
Male n (%) 
Age M (SD, Range) 
Ethnic minority n (%) 
Annual household income 
       <US$15 000 n (%) 
 
 
4563   
3130 (68.6) 








11.0 (2.5, 6-15) 
39 (38.6) 
 











Two parents (biological/ step) n 
(%) 
Bio mother only n (%) 
Bio father only n (%) 
Adoptive n (%) 
Grandparents n (%) 
Ward of the State n (%) 


































Family and child risk factors 
None n (%) 
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Two n (%) 

















Sector of services received 
Mental health n (%) 
Education n (%) 
Health n (%) 
Social services/ 
 welfare n (%) 
Juvenile Justice n (%) 
Other n (%) 
 







































Group therapy n (%) 
Individual therapy n (%) 
Family therapy n (%) 
 
Number of sessionsa 
Group therapy median (1st 
quartile, 3rd quartile)  
Individual therapy median (1st 
quartile, 3rd quartile)  
Family therapy median (1st 









20 (7, 35) 
 
14 (6, 24) 
 









10 (10, 24) 
 











12 (5, 19.5) 
 
15 (6, 24) 
 
6 (3, 24) 
 
Medication for behavioural/ 
emotional: Yes n (%) 
 
2963 (66.4) 83 (82.2) 50 (71.4) 
Diagnosisa 
Anxiety disorder n (%) 
PTSD n (%) 
Mood disorder n (%) 
Adjustment Disorder n (%) 
 
Oppositional Defiant n (%)  
ADHD n (%) 
Conduct Disorder n (%) 
Bipolar Disorder n (%) 
Substance related disorder n (%) 
Psychotic Disorder n (%) 
 
PDD/Autism n (%) 
Mental Retardation n (%)  
 
Comorbid anxiety and 
externalising disorder n (%) 
 
Comorbid anxiety and mood 
































































Number of mental health 
diagnoses recorded n (SD) 








Child Behavior Checklist 
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CBCL DSM Anx scale in 
✁✂✄☎✆✝☎✞✟✠✝✡ ✄☎ ✁☛✞✟✠✟☛☞✞✡ ☎☞✠✌✝
at baseline n (%) 
 
In ✁clinical✡ range on both 
CBCL DSM Anx and CBCL-












































Note. Percentages of participants with available data. 
aNot mutually exclusive. 
Measures 
A standard protocol was used for data collection in the SOC CMHS national 
evaluation study. Measures included both standardised instruments and those developed 
specifically for the project. Instruments used in the present study included the Descriptive 
Information Questionnaire (DIQ; Center for Mental Health Service, 2004), the Multi Sector 
Service Contract Questionnaire (MSSC), the Child Behavior Checklist (CBCL/6-18; 
Achenbach, 1991; Achenbach & Rescorla, 2001), the Child and Adolescent Functional 
Assessment Scale (CAFAS; Hodges, 1990; 1996; 2005), the Behavioral Emotional Rating 
Scale (BERS; Epstein & Sharma, 1998), the Caregiver Strain Questionnaire (CGSQ:7; 
Heflinger, & Bickman, 1998) and the Family Assessment Device   General Functioning 
Scale (FAD-GFS; Epstein, Baldwin, & Bishop, 1983). 
Descriptive Information Questionnaire (DIQ; Center for Mental Health Service, 
2004). The DIQ is a semi-structured interview that was designed for the national evaluation 
study (Center for Mental Health Service, 2004). The DIQ gathers descriptive information 
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regarding client demographics, presenting problems, medications and child and family risk 
factors.  ✁✂✄☎✆ ✝✄✞✟ ✠✡☛☞✌✝✞✍ ✄✎☛☎✏✆✑ ✒✝✑✓✄✌✏✞ ✒✞✔☛✂✄✡☞✝✄☛ ✂✌✞✒italisation, a history of being 
physically abused, a history of being sexually abused, a history of having run away, a 
suicide attempt, a history of substance abuse or a history of being sexually abusive toward 
✌☞✂✑✝✞✕  ✖✡✗✄☎✔ ✝✄✞✟ ✠✡☛☞✌✝✞  ✄✎☛☎✏✆✑ ✡ ✂✄✞☞✌✝✔ ✌✠ ✆✌✗✑✞☞✄☛ ✓✄✌☎✑✎☛✑✘ ✞✒✌✏✞✡☎ ✡✙✏✞✑✚ a history 
of mental illness in biological family, whether biological parents have ever been in a 
psychiatric hospital; whether biological parents have ever been convicted of a crime, 
whether there is a history of substance abuse among biological family, and/or whether the 
☛✂✄☎✆✍✞ ✙✄✌☎✌✛✄☛✡☎ ✒✡✝✑✎☞s have received treatment for substance abuse. The DIQ was 
administered by the clinician, using caregivers as respondents.  
Multi Sector Service Contact Questionnaire (MSSC).  The MSSC was developed 
for the national evaluation study. ✜✂✑ ✢✣✣✁ ✡✞✞✑✞✞✑✞ ☞✂✑ ✔✌✏☞✂ ✡✎✆ ✠✡✗✄☎✄✑✞✍ ✏✞✑ ✌✠
services and whether caregivers perceived ✞✑✝✓✄☛✑✞ ☞✌ ✂✡✓✑ ✗✑☞ ☞✂✑ ☛✂✄☎✆✘ ✠✡✗✄☎✔✍✞ ✎✑✑✆✞✕
 Use of services✍ included gathering information regarding the amount of service (i.e. how 
many sessions), type of service (e.g. individual, group or family therapy) and sector of 
services received (e.g. mental health, education, health, social services/welfare, juvenile 
justice). The MSSC does not collect information regarding the content or focus of service. 
Child Behavior Checklist (CBCL/ 6-18; Achenbach 1991; Achenbach & 
Rescorla, 2001).  The CBCL/6-18 is a widely used parent-report measure of child 
psychopathology that gives a standardized measure of symptomatology for children aged 6 
to 18 years (Achenbach, 1991; Achenbach & Rescorla, 2001). There are youth self-report 
(YSR) and teacher-report (TR) versions of the CBCL. The CBCL/6-18 consists of 118 
items rated on a three point scale (0, 1, or 2). Items can be organised into nine empirically-
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derived syndrome scales (Aggressive Behavior; Anxious/Depressed; Attention Problems; 
Rule-Breaking Behavior; Social Problems; Somatic Complaints; Thought Problems; and 
Withdrawn/Depressed).  Of all syndrome scales, the most commonly used as a measure of 
anxiety symptomatology is the CBCL Anxious/Depressed (CBCL-AnxDep), which is 
made up of items reflecting both anxiety and depressive symptoms (which consistently 
covary). The CBCL AnxDep syndrome scale has been used to measure the impact of 
treatments of anxiety disorders in youth (e.g. Rapee et al., 2006). Six CBCL DSM oriented 
scales have also been developed (Affective Problems; Anxiety Problems; Somatic 
Problems; Attention Deficit/ Hyperactivity Problems; Oppositional Defiant Problems; and 
Conduct Problems). In contrast to the syndrome scales, the item pools for the DSM-
oriented scales were rationally derived and based on consensus judgments of expert 
diagnosticians regarding their consistency with DSM diagnoses. The CBCL-DSM oriented 
scale for anxiety disorders (CBCL-DSM Anx) is made up of six items judged to be 
consistent with Generalised Anxiety Disorder; Specific Phobia and/or Separation Anxiety 
Disorder (Achenbach & Rescorla, 2001; Achenbach, Dumenci, & Rescorla, 2003). Lastly, 
scores on the CBCL/6-18 can be organised into two broad-band scales:  CBCL- 
Internalising (CBCL-Int) and CBCL-Externalising (CBCL-Ext).  The CBCL-Int broadband 
scale consists of 32 items reflecting a variety of somatic, depressive, withdrawn or anxious 
behaviours. The six items of the CBCL-DSM Anx scale are all drawn from these 32 items. 
The forgoing scales reflected measures of psychopathology on the CBCL/6-18. There 
are also three social competence scales (Activities; Social; School) that reflect child 
functioning at home, with peers and in school.  Lastly, the Total Problem scale summarises 
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results of the syndrome scales and the Total Competence scale summarises the competence 
scales.  
Raw scores on scales are converted to T scores. On syndrome and DSM-oriented 
scales (including CBCL-DSM Anx) T scores 65-69 fall in the  ✁✂✄☎✆✄✝✞✟✆ ✠✝✞✟✞✠✡✝☛ range 
and those > 69 in the  ✠✝✞✟✞✠✡✝☛ ✄✡✟☞✆ of functioning. The ranges are slightly different for 
broadband scales (i.e. CBCL-Int and CBCL-Ext), where T scores 60-63 fall in the 
 ✁✂✄☎✆✄✝✞✟✆ ✠✝✞✟✞✠✡✝☛ and those >= 64 in the  ✠✝✞✟✞✠✡✝☛ range of functioning.  
Cut off scores were determined by analyses of Receiver Operating Characteristics 
(ROC) (Swets & Pickett, 1982).  The scores of demographically similar clinical and non-
referred populations were compared on these scales; and cut off scores were chosen that 
✌✍✞✟✞✍✞✎✆☎ ✏✑✆ ✒✆✄✠✆✟✏ ✂✓ ✄✆✓✆✄✄✆☎ ✠✑✞✝☎✄✆✟ ✁✆✝✂✔ ✞✏ ✡✟☎ ✟✂✟-✄✆✓✆✄✄✆☎ ✠✑✞✝☎✄✆✟ ✡✁✂✕✆ ✞✏✖
(Achenbach & Rescorla, 2001, p.95). CBCL/6-18 raw scores are preferred for data analysis 
of the syndrome and DSM-oriented scales, because the T scores of syndrome and DSM 
oriented scales are truncated, reducing their variability (Achenbach & Rescorla, 2001). 
Either raw scores or T scores can be used for analysis of broadband scales (i.e. CBCL-Int 
and CBCL-Ext). 
 Although no information regarding the psychometric properties of the CBCL/6-18 
have been established with youth in the SOC CMHS data set, there has been extensive 
research regarding its reliability and validity with other populations. The CBCL/6-18 has 
established reliability (Achenbach, 1991; Achenbach & Rescorla, 2001). Test-retest 
reliability, ✗✄✂✟✁✡✠✑☛✎ ✡✝✒✑✡ ✡✟☎ ✠✂✄✄✆✎✒✂✟☎✆✟✠✆ ✁✆✏✔✆✆✟ ✞✟✏✆✄-parent ratings have been 
examined. Mean ✗✄✂✟✁✡✠✑☛✎ ✡✝✒✑✡ is strong for CBLC-Int (.90), CBCL-Ext (.94) and 
CBCL-Total (.97) broadband scales. Test-retest reliabilities across broadband scales are 
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satisfactory (mean r = .94), as is inter-parent reliability for CBCL-Int (r = .72) and for 
CBCL-Ext (r = .80) broadband scales (Achenbach, & Rescorla, 2001). The mean internal 
consistency of CBCL-DSM Anx is = .72, and mean test-re test reliability is r = .80 
(Achenbach & Rescorla, 2001). 
There has been extensive research regarding the validity of the scales. The CBCL/6-
18 has strong convergent validity with the Conners Parent Questionnaire (Conners, 1973) 
(r = .56 to .86) and the Quay-Peterson Revised Behavior Problem Checklist (Quay & 
Peterson, 1993) (r = .52 to .88) (Achenbach, 1991; Achenbach & Rescorla, 2001), and can 
discriminate between those referred for mental health services and those who are not 
(Achenbach, 1991; Achenbach & Rescorla, 2001).  
Criterion-related and construct validity for the CBCL/6-18 have been examined. 
CBCL/6-18 syndrome scales have been replicated in a number of cultures, and are 
significantly associated with genetic and biochemical markers (Achenbach & Rescorla, 
2001). Of relevance to the present research is the ability of the CBCL- DSM Anx to 
discriminate between youth with and without anxiety disorders. One study found the 
CBCL-DSM Anx scale to be better than the corresponding CBCL-AnxDep syndrome scale 
at discriminating youth with anxiety disorders (Ebesutani et al., 2010) while others have 
found them to be comparable (Achenbach et al., 2003). Some studies have found the 
CBCL-DSM Anx to have only  fair✁ discriminant validity when distinguishing youth with 
anxiety disorders from those without (Ferdinand, 2008); while others have found the scale 
to have  ✂✄✄☎✁ ✆✄✝  ✞✟✝✄✠✂✁) discriminant validity (Ebesutani et al., 2010; Nakamura et al., 
2009) including being able to distinguish youth with anxiety disorders from those with 
externalising disorders. Seligman et al. (2004) found the CBLC-DSM Anx was able to 
BENCHMARKING TREATMENT OF ANXIETY IN YOUTH   
 
59 
distinguish youth with anxiety disorders from those with no anxiety disorders; and from 
those with externalising disorders, but not from those with affective disorders (Seligman et 
al., 2004). Ebesutani et al. (2010), however, found the CBCL-DSM Anx was able to 
distinguish youth with anxiety disorders from those with affective disorders, using 
Receiver Operator Characteristic curves (ROCs).  Krol et al. (2006) compared profiles of 
youth on the CBCL/6-18 against DSM diagnoses generated from an established semi-
structured diagnostic interview (Diagnostic Interview Schedule for Children, DISC IV; 
Shaffer, Fisher, Lucas, Dulcan, & Schwab-Stone, 2000). They found good specificity when 
 ✁✂✄☎ ✆✝✞ ✟✁✆✠✂✡✆☛ cut offs (i.e. ✟clinical☛ range, T >= 70) for CBCL-DSM Anx (specificity = 
.87 - .89) ☞✄✌ ✍✞✆✆✞✠ ✁✞✄✁✂✆✂✎✂✆✏ ✑✝✞✄  ✁✂✄☎ ✆✝✞ ✟✒✞✄✂✞✄✆☛ cut offs (i.e. ✟borderline☛ and 
above, T >= 65) (sensitivity = .27 - .50). Positive predictive power (PPP) (i.e. the chances 
that a youth with an anxiety disorder will be in ✟deviant☛ range on the CBCL-DSM Anx) 
ranged from .29 - .43 when ✟strict☛ scoring rules were used and .21 - .36 when ✟lenient☛ 
rules were used. Negative predictive power (NPP) (i.e. the chances that a youth without an 
anxiety disorder will fall in the ✟normal☛ range on the CBCL-DSM Anx) ranged from .89 - 
.94 for ✟strict☛ scoring and .79 - .97 for ✟lenient☛ scoring. These results are similar to 
Lengua, Sadowski, Friedrich, & Fisher (2001), who found PPP = .50 and NPP = .86. That 
is, the CBCL-DSM Anx might fail to identify some anxious children, but does not identify 
many youth as clinically ✟☞✄✓✂✔ ✁☛✕ ✑✝✔ ☞✠✞ ✂✄ ✖☞✡✆ ✟✄✔✠✗☞✒☛✕ ✘☞✠✆✂✡ ✒☞✠✒✏ ✑✝✞✄ ✟✁✆✠✂✡✆☛
scoring criteria are used. 
Child and Adolescent Functional Assessment Scale (CAFAS; Hodges 1990; 
1996; 2005).  The CAFAS is designed to evaluate impairments in functioning resulting 
from emotional, behavioural, psychological or substance misuse problems in youth aged 
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5.5 - 17.5 years (Hodges, 1990; 2005). It is generally completed by the youth's clinician 
and consists of eight domains measuring functioning in:  School/Work, Home, Community 
(reflecting delinquent behaviour), Behavior Toward Others, Moods/Emotions (primarily 
depression and anxiety), Self-Harmful Behavior, Substance Use and Thinking (reflecting 
thought problems).   Research suggests that following training, raters can achieve good 
rates of reliability (range .63 - .78) (Hodges & Wong, 1996), and inter-rater reliabilities 
tend to be high (Pearson ✁ r correlations above .92) (Rosenblatt & Rosenblatt, 2002). The 
CAFAS has been tested with youth receiving services within systems of care agencies and 
has demonstrated concurrent validity (Hodges et al., 1999; Hodges & Wong, 1996; Hodges 
& Wong, 1997; Manteuffel et al., 2002), convergent validity (Hodges & Wong, 1996) and 
predictive validity (Hodges et al., 1999; Hodges et al., 2000; Hodges & Kim, 2000; Hodges 
& Wong, 1997; Quist & Matshazi, 2000). 
Behavioral Emotional Rating Scale (BERS; Epstein & Sharma, 1998). The BERS 
was designed to ✂✄☎✆✝✂✞✟ ✠ ✟✡☛✝☞ ✁ ✌☎☞✠✍✂✡☛✎✠✏ ✠✆✄ ☎✑✡✝✂✡✆✠✏ ✁✝✎☎✆✒✝☞✁ ✠✆✄ ✎☎✁✂✏✂☎✆✓ies. It 
consists of a 52 item checklist, rated on a 4 point Likert scale. These items are organised 
into five dimensions/ subscales; Interpersonal Strength, Family Involvement, Intrapersonal 
Strength, School Functioning, and Affective Strength and are combined into an overall 
BERS Strengths Quotient. The BERS has demonstrated test-retest reliability, inter-rater 
reliability and internal consistency in other populations of youth (Epstein, Harniss, Pearson 
& Ryser, 1999). Convergent validity has been established with moderate to high 
correlations with questionnaires measuring similar constructs (Harniss, Epstein, Ryser, & 
Pearson, 1999).  
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Caregiver Strain Questionnaire (CGSQ; Brannan et al., 1997). The CGSQ is a 
measure of caregiver strain  ✁✂✄☎✆✝✞✟ ✠ ✡☛ ✆☞✁✝  ✌☞✝☎✍✎✂ ✏✁☞✑✒✝✡✄ ✑☎ ✡  ✁☛✡✆✝✡✞✑☎
difficulties (Brannan et al., 1997). The questionnaire consists of 21 items rated on a 5 point 
Likert scale, with scores combining to form three subscales (Objective Strain, Internalising 
Subjective Strain, Externalising Subjective Strain). The CGSQ has demonstrated reliability, 
internal consistency (Heflinger, Northrup, Sonnichsen, & Brannan, 1998), construct 
validity (Brannan et al., 1997) and predictive validity (Foster, Saunders, & Summerfelt, 
1996) with other populations of youth. 
Family Assessment Device-General Functioning Scale (FAD-GFS; Epstein et al., 
1983; Byles, Byrne, Boyle, & Offord, 1988). The FAD-GFS is a 12 item measure of 
family functioning, including items related to how families interact, communicate and 
work together (Epstein et al., 1983; Byles et al., 1988). Items are rated on a 4 point Likert 
scale. The test has demonstrated test-retest reliability (Kabacoff, Miller, Bishop, Epstein, & 
Keitner, 1990; Miller, Epstein, Bishop, & Keitner, 1985), construct validity (Byles et al., 
1988; Epstein et al., 1983; Fristad, 1989; Heflinger et al., 1998; Miller et al., 1985) and 
predictive validity (Epstein et al., 1983; Fristad, 1989) in other populations of youth.  
Data Collection 
Participants were recruited for the national evaluation study when they entered 
services at SOC CMHS agencies. Researchers (employed by the SOC CMHS agencies) 
explained the study and obtained informed consent (or assent) and then guided them 
through data collection (Holden et al., 2001). Data collection involved face-to-face 
interviews and completion of questionnaire outcome measures (Stephens et al., 2004). 
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Data for the national evaluation project were collected at intake to clinical services, 
then six months and twelve months later. The baseline and six month data were used for 
the present study. Standardised time periods were used rather than standardising data 
collection to post treatment (or follow up after treatment), because in clinical settings, the 
length of treatment is not fixed.  Thus, intervals spacing the timing of data collection were 
standardised instead.  
The standardised protocol that was administered included interview and 
questionnaires. The DIQ, CBCL/6-18, CAFAS, BERS, CGSQ and FAD-GFS, were 
administered at intake to the SOC CMHS agencies and six months afterward by agency 
staff.  DSM diagnoses were obtained from management information systems, case records 
or clinician assessments.  Outcome data were entered into a data file by community 
evaluation staff and sent to the national evaluation office. Results were aggregated across 
settings.  
For the purposes of the present study, access to the national evaluation data set was 
obtained following a formal application to Macro International Inc.- the company 
contracted to collect and manage the SOC CMHS national evaluation information.   
Ethics Clearance 
Ethical clearance for the national evaluation project was obtained from the local 
Institutional Review Boards of the agencies involved in the project. Guardians of children 
under 10 years old gave informed consent and their children assented to participate in the 
SOC CMHS national evaluation study. Both guardians and children over 10 years old gave 
informed consent for participation in the SOC CMHS national evaluation study.  
Participant data were submitted to the CMHS without identifying information. 
BENCHMARKING TREATMENT OF ANXIETY IN YOUTH   
 
63 
The Research Ethics Board at Lakehead University waived ethical clearance for the 
present study (see Appendix 1). 
Selection of Clinical Trials for Treating Anxiety Disorders 
The present study  ✁ ✂✄☎✁ ✆✝✞ ✟✝✠ ✡☎☛☞✝✞✌✍ ☎✄  ☞✎ ✏✑✒✒✓✔ ✍✄☛ ✄☎✕✖ ✗✘☛ benchmarking 
the impact of community treatments against published trials. After the ✙✄ ☛✕☎✄✌ ✂✘✂✚☞ ✄✝✘✞ 
was identified (i.e. children with anxiety disorders, mean age 6-12 years) appropriate 
clinical trial research studies to establish treatment and natural history benchmarks for 
clinical practice were identified. Interventions aimed at addressing anxiety disorders were 
targeted. 
Inclusion criteria. Studies were screened, based on the following inclusion criteria:  
Age. Mean age of participants in the study was between 6 and 12 years, inclusive. As 
mentioned, it was noted that many RCTs with mean age in this range included youth up to 
15 years old (see Table 2). For this reason, the range of youth included in the SOC subsets 
was 6-15 years. 
Clinically significant anxiety disorders. Participants had clinically significant 
symptoms of an anxiety disorder as evidenced by a DSM diagnosis (e.g., DSM✛IV TR; 
American Psychiatric Association, 2000), established with a formal diagnostic interview 
using ✝✞✍✄☛✚✟☎✞✄✍ ✍✚✜✢  ✍ ✄✢☎ ✙Anxiety Disorders Interview Schedule✌ (ADIS P-C; 
Silverman, 1987; Silverman & Albano, 1996; Silverman & Nelles, 1988) or a score falling 
in the ✙clinical✌ range of impairment in symptoms as measured by a standardised measure 
of anxious psychopathology.  
Comorbid conditions. The intervention was not targeted at youth with developmental 
disabilities or pervasive developmental disabilities. Further, the major focus of the trial was 
addressing anxiety disorders, not a comorbid condition (e.g. a personality disorder or 
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medical condition). Studies of treatments for youths with comorbid conditions were 
included if the primary defining presenting problem was an anxiety disorder. 
Study design. The study had to include the following features; participants were 
randomly allocated to treatment condition, and parent-rated CBCL-Int pre and post T 
scores were reported. Criteria related to inclusion of the CBCL/6-18 were applied for at 
least two major reasons. First, the SOC CMHS national evaluation study used the CBCL/6-
18, and the measure is commonly used within clinical trials for the treatment of anxiety 
disorders in youth. As noted, it is preferable to use the same measure to establish the 
benchmark and to measure outcome in the comparator community group (Minami, Serlin 
et al., 2008), as is common practice within previous benchmarking studies (e.g. McEvoy & 
Nathan, 2007; Minami, Serlin et al., 2008; Weersing et al., 2006; Weersing & Weisz, 
2002).  This is important, considering, as mentioned, the magnitude of an effect size can be 
impacted by the nature of the measure used to calculate it (Minami, Serlin, et al., 2008). 
Second, other community agencies are more likely to have aggregate information on a 
generic measure such as the CBCL/6-18 than the plethora of target - specific measures used 
within studies of anxiety disorders (such as the Multidimensional Anxiety Scale for 
Children (MASC; March, Parker, Sullivan, & Stallings, 1997). A treatment efficacy 
benchmark based on this broad-based measure of psychopathology is therefore more useful 
for those agencies than a target-specific measure. 
Clinic-referred. At least some participants were referred or self-referred for treatment 
(i.e., not all participants were recruited to the study through advertising). This criterion was 
applied because advertising-recruited participants may have better outcomes than those 
referred to community agencies (Brent et al., 1998; Lincoln & Rief, 2004).  
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Bona-fide psychosocial treatment. The treatment delivered within the RCT was a 
psychosocial treatment that had been identified as  ✁ ✂✄ ☎✁ ✆✝✞✟✠ ✠✂✡☛ efficacious within a 
recent review (Davis III & Whiting, 2011 or Silverman, Pina, et al., 2008). This criterion 
was applied so that only interventions with empirical support were used when generating 
benchmark standards. Further, the treatment delivered was manualised (Minami et al., 
2007). Manualised treatments facilitated tests of treatment fidelity within the trials and 
replication of the intervention in the community. 
Identification of Clinical Trials for Inclusion 
Consistent with previous benchmarking studies (e.g., Minami, Wampold et al., 2008), 
several methods were used to identify appropriate clinical trials for treatment of youth with 
anxiety disorders. First, meta-analyses and reviews of youth psychotherapy were 
considered as a means of identifying potentially appropriate trials (c.f. Cartwright-Hatton, 
Roberts, Chitsabesan, Fothergill, & Harrington, 2004; Chorpita, Daleiden et al., 2011; 
Compton, Burns, Egger, & Robertson, 2002; Compton et al., 2004; David-Ferdon & 
Kaslow, 2008; Davis III & Whiting, 2011; Hunsley & Lee, 2007; Silverman, Ortiz et al., 
2008; Silverman, Pina, et al., 2008; Verdeli, Mufson, Lee, & Keith, 2006; Weisz et al., 
2004; Weisz, Jensen-Doss et al., 2006). Second, PsychInfo and Dissertation data-bases 
were searched for appropriate clinical trials published between January 1990 and 
September 2011. Date of earliest publication was limited to when the Child Behavior 
Checklist was first published (Achenbach, 1991) and to contain the number of volumes that 
had to be searched manually.  Searches were conducted using terms i☞✌✂✍✎✏☞✑ ✒✁✞✄ ✁✓✄☞✁✔✕
✒✁✞✏ ✂☎✕✔ ✒✝☎✡✌✖✟✁✖✄✞ ✝✡✔✕ ✗✏☞✁✄✞✘✄☞✁✏✟☞✗  ☞✎ ✗ ☞✙✏✄✁✡✗✔ ✒✁✞ ✍✓ ✕✔ ✒✚✠☎✄☎☎✏✘✄ ✛✟✓✝✍✂☎✏✘✄
Disorde✞✕✔ ✒✏☞✁✄✞☞ ✂✏☎✏☞✑✕✔ ✒✝✖✟✠✏ ✕✔ and "emotional disorders", to generate a selection of 
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potentially appropriate studies. Also, the reference lists of treatment trials were 
searched.   Lastly, data-bases where ongoing RCTs are registered   ✁✂✄☎☎✆✝✞ ✂✟✝✞☎✟✠✠✆✡
☛☎☞✌✠✍✎ ✌✝✡ ✁✂✠☞✝☞✏✌✠☛☎☞✌✠✍✑✒✟✓✎- were searched to identify randomized control trials that 
were underway but not published. While both published and unpublished research studies 
generated from the above search strategies were considered, no unpublished research 
studies were identified that met all inclusion and exclusion criteria. 
Five studies which otherwise met criteria for inclusion in the present research only 
reported data generated from CBCL-Int raw scores (Bodden, et al., 2008; Cohen, 
Deblinger, Mannarino, & Steer, 2004; Deblinger, Mannarino, Cohen, Runyon, & Steer, 
2011; Levy, Hunt, & Heriot, 2007; Liber et al., 2008). Preliminary analysis revealed 
studies using CBCL-Int raw scores generated effect sizes that were consistently smaller 
than the CBCL-Int T scores, possibly due to differences in scaling. Thus, it appeared that 
effect sizes generated from the CBCL-Int raw scores were not commensurate with those 
from CBCL-Int T. Therefore, only studies reporting CBCL/6-18 T scores were included. 
No studies treating youth with PTSD met all inclusion and exclusion criteria. Therefore, 
youth in the SOC CMHS data set identified with PTSD (but not another anxiety disorder) 
were not specifically included in the present study.  
Using these criteria, 18 clinical trials were identified to establish the clinical 
benchmarks (Barrett et al., 1996; Barrett, 1998; Beidel et al., 2000; Cartwright-Hatton et 
al., 2011; Cobham et al., 1998; Flannery-Schroeder & Kendall, 2000; Heyne et al., 2002; 
Kendall, 1994; Kendall et al., 1997; Kendall, Hudson, Gosch, Flannery-Schroeder, & 
Suveg, 2008; Lyneham & Rappee, 2006; Nauta et al., 2003; Rapee et al., 2006; Shortt et 
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al., 2001; Silverman et al., 1999a; Silverman et al., 1999b; Southam-Gerow et al., 2008; 
Spence, Holmes, March & Lipp, 2006) (see Table 2).  
 ✁✂✄ ☎✆✝✞ ✟✄✠✁✟✡ ✟✄✞☛☞✡✞ ✁✌ ✡✟✄✍✡✂✄✎✡ ✏✑✁✂✠☞✄✡✄✟✞✒ ✓✔✄✟✄✍✞ ✁✡✔✄✟✞ ✟✄✠✁✟✡ ✟✄✞☛☞✡✞ ✁✌
✡✔✄ ✓✔✁☞✄ ✞✍✂✠☞✄ ✕✎✑☞☛✖✕✎✗ ✡✔✁✞✄ ✓✔✁ ✖✕✖ ✎✁✡ ✟✄✑✄✕✘✄ ✍ ✌☛☞☞ ✏✖✁✞✄✒ ✁✌ ✡✔✄✟✍✠✙ ✚✄✑ause they 
✖✟✁✠✠✄✖ ✁☛✡ ✚✄✌✁✟✄ ✑✁✂✠☞✄✡✕✁✎ ✁✌ ✡✔✄ ✡✔✄✟✍✠✙ ✠✟✁✡✁✑✁☞ ✛✕✜✄✜ ✏✢✝✝✒ samples). This distinction 
is relevant, because clients sometimes leave treatment early because they are not 
benefitting - meaning their sub-optimal results are not included ✓✔✄✎ ✁✎☞✙ ✏✑✁✂✠☞✄✡✄✟✒
results are reported. Therefore, completer samples may overestimate treatment 
effectiveness. Some research suggests that the effect sizes of ✏intent to treat✒ (ITT) samples 
are around 10% lowe✟ ✡✔✍✎ ✏✑✁✂✠☞✄✡✄✟✒ ✞✍✂✠☞✄✞ (Eddy, Dutra, Bradley, & Westen, 2004; 
Westen & Morrison, 2001). Some previous benchmarking studies have only included used 
ITT results (i.e. including both treatment completers and non-completers) from RCTs to 
generate benchmarks (Minami, Serlin et al., 2008). This is because these are considered 
more appropriate for comparison with results from community data-sets which include 
both treatment completers and non-completers.  However, excluding studies that report 
only results of treatment completers meant that 13/18 studies would be excluded from 
analysis. Therefore, ✞✡☛✖✕✄✞ ✟✄✠✁✟✡✕✎✗ ✄✕✡✔✄✟ ✏✑✁✂✠☞✄✡✄✟✒ ✁✟ ✏✢✝✝✒ ✖✍✡✍ ✓✄✟✄ ✕✎✑☞☛✖✄✖ ✓✔✄✎
establishing treatment efficacy and natural history benchmarks. In studies where both were 
reported, the ITT results were included in the present analysis, thus generating a more 
conservative estimate of treatment efficacy benchmark effect size. It should also be noted 
that some studies conducted analyses with ITT data but only reported pre- and post-CBCL 
Int means for treatment completers. ✝✔✄✞✄ ✓✄✟✄ ✑☞✍✞✞✕✌✕✄✖ ✍✞ ✏✑✁✂✠☞✄✡✄✟✒ ✞✍✂✠☞✄✞ since it 
was the ✏completer✒ means that were used for analyses in the present study. As mentioned, 
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conclusions reached using the results of SOC CMHS treatment completers (SOCCBCL n = 
63; SOCdiag n = 42) were not different from those using the SOC CMHS who started but 
did not  ✁✂✁✄☎✁ ✆ ✝✞✟✟ ✠✡☛☞✁✌ ☛✝ therapy (SOCCBCL n = 101; SOCdiag n = 70) (see Results 
section). Thus the full samples of the SOC CMHS subsets were used in the present study.  
Clinical Trial Characteristics  
Characteristics of the 18 clinical trials (including client demographics; treatment 
length and format; treatment setting) are detailed in Table 2. As can be seen, the mean age 
for treatment participants fell within six to 12 years, and most included youth up to 15 
years (and some included youth up to 18 years). The proportion of boys and girls in each 
study was fairly even. Of the 11 studies reporting minority status of participants, only one 
sample comprised more than 50% of youth from ethnic minorities (53.6%), whereas most 
samples had relatively few youth from minority groups (0 - 39.0%) (k = 10).  Table 2 also 
provides details of the key characteristics of therapy length and format, therapy settings, 
therapists and recruitment strategies. Overall, treatment consisted of 8-18 sessions (median 
= 12 sessions). While RCTs evaluating treatment for any type of anxiety disorders were 
eligible for inclusion, only trials addressing either anxiety disorders in general, or 
specifically Generalised Anxiety Disorder, Separation Anxiety Disorder and phobic 
disorders (including Social Phobia Disorder) met inclusion and exclusion criterion.  RCTs 
for treatment of Obsessive Compulsive Disorder (OCD) or Post Traumatic Stress Disorder 
(PTSD) did not. The majority of studies were conducted in university or research-based 
clinics with graduate students and university-based practitioners (usually programme 
developers) (15 out of 18), although a substantial minority (4 out of 18) were based in 
community or hospital settings with community practitioners (one study included both 
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university and community sites). The studies that provided information regarding 
supervision usually reported incorporating two-hour weekly group supervision sessions. 
Treatment fidelity was monitored in the majority of studies, using checklists and video or 
audio-recording of a random selection of sessions. These checks were usually conducted by 
independent observers. Most trials used therapists with a Masters degree in a mental health 
discipline. Some of these were doctoral students. Most studies reported only using referral 
or self-referral for recruitment to receive services, although seven studies used a mixture of 
advertising and referral to recruit participants. Thus, a number of studies had at least some 
of the characteristics of effectiveness trials and made use of levels of supervision and 
training comparable to many community settings.  
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43.8 - Mean 14.0 sessions 
























58.3 - Combined 10 individual 
child CBT; 6 parent 
CBT group in clinic  
(+ 2 booster sessions) 
Combined 5 individual 
child sessions CBT via 
internet + 5 in clinic; 3 
parent group CBT 
sessions via internet + 3 











Note. A dash indicates that the information was not reported. N = total number of participants at randomisation; Suprvn= supervision; 
Trtmnt Fidelity = treatment fidelity; Recrt = recruitment; OAD = Overanxious Disorder; SOP = Social Phobia; SAD = Separation 
Anxiety Disorder; GAD = Generalised Anxiety Disorder; Spec Ph = Specific Phobia; Panic D = Panic Disorder; Sim Ph = Simple 
Phobia; Agoraph = Agoraphobia; CBCL Int = score in  clinical✁ range on Child Behavior Checklist ✂ Internalising; PBCI = score in 
 clinical✁ range of Preschool Behavior Checklist Internalising; CBT = cognitive behavioural therapy; CPT = parent training; Clinical 
psychts = clinical psychologists; Grad stdnts = graduate students; Doctoral stdnts = doctoral students; MA psychts = Masters qualified 
psychologists; Psychts = psychologists; MA thrpsts = Masters qualified therapists; post doc = post doctoral fellow; Fidelity checkd ✂ 
fidelity of session content checked using checklists and audio or video-tapes of sessions; Advrtng = advertising.




The first major focus of data analysis was to establish pre-post effect size treatment 
efficacy and natural history benchmarks. This was achieved by aggregating results of 
treatment trials using random effects meta-analytic methods described by Hedges and 
colleagues (Borenstein, Hedges, Higgins, & Rothstein, 2009; Hedges & Vevea, 1998). A 
fully random effects model was used because there were likely to be a range of true effect 
sizes both within and between studies (Borenstein et al., 2009) and random effects 
models generate results that are more generalizable than fixed effects models (Hedges & 
Vevea, 1998).  When aggregating results, studies with more precise effect size estimates 
were given more weight (Borenstein et al., 2009). Some meta-analyses also attempt to 
weight the contribution of studies according to their quality (c.f. Moher et al., 1998).  
This practice is considered problematic, however, for statistical and methodological 
reasons (Emerson, Burdick, Hoaglin, Mosteller, & Chalmbers, 1990; Greenland & 
 ✁✂✄☎✆✝✞✟ ✠✡✡☛☞ Higgens, Altman & Stern 2011; Juni, Witschi, Bloch, & Egger, 1999; 
Lipsey & Wilson, 2001).  Using quality ratings to weight studies generates a compound 
weight for each study (consisting of weight according to precision and quality). An 
adaptation of the statistical theory upon which the data analysis is based would be 
required, to take these quality ratings into account (Lipsey & Wilson, 2001).  Further, 
quality ratings themselves are problematic, because scoring of particular items is 
somewhat arbitrary and the scales consistent of items reflecting different constructs (such 
as the quality of reporting practices of studies and the quality of study design per se) 
(Greenland, 1994). This may explain (in part) why quality scales are not consistently 
associated with systematic differences in study outcomes (Emerson et al., 1990; Juni et 
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al., 1999).  As part of the Cochrane Collaboration Handbook Review, Higgens & Green 
(2006) conclude that weighting according to quality within meta-analyses is time 
consuming, not empirically validated and can lead to misleading results. Thus, in the 
present research, studies were not weighted according to quality ratings. Rather, 
characteristics of study design that might systematically influence internal validity and 
outcome (e.g. randomization of participants; participant recruitment strategy; use of 
treatment manual) were incorporated in selection criteria for studies and/or were 
considered in moderator analysis ( ✁✂✁ ✄completer☎ versus ✄intention to treat☎ analysis). 
It is important to recognize that treatment efficacy benchmarks can be affected by 
publication bias. Publication bias can include the tendency for studies with significant 
results to be published, while studies with null findings are not (Sackett, 1979). Studies 
with large samples sizes are likely to have significant results due to increased power. 
Smaller studies with null findings might not be submitted for publication; or might be 
less likely to be published if submitted. Thus, publication bias is assessed by considering 
the distribution of effect sizes relative to the precision of effect sizes (which is related to 
sample size). Three strategies were used to examine publication bias in the studies 
selected for the present research. First, a funnel plot charting study effect sizes against 
their standard errors was generated (Light & Pillemer, 1984). In the absence of bias, the 
distribution of study effect sizes should be symmetrical around the mean effect size. It is 
expected that large studies (at the top of the graph) will congregate around the summary 
mean effect size, and the distribution of effect size estimates for smaller studies (at the 
base of the graph) will also be symmetrical around the mean but will be more spread out. 
✆ ✝✞ ✟ ✠ ✄✡☛✝✝ ☞☎ ✌✍✠✎  ✏✑☞☞ ✒  ✡✓✔✕ ✖✁ ✗✓✝✘ ✔✌ ☞✙✟ ✎☛✒☞✑✞✠✚✑✓✝ ✒✑✠✌ ✑✌ ✞✓✝✌✑✌✚ ✝✚ ✏✑✚✍
BENCHMARKING TREATMENT OF ANXIETY IN YOUTH   
 
77 
(although not proven by) an asymmetrical distribution of effect size estimates around the 
mean, typically featuring a higher concentration of studies exhibiting large standard 
errors (i.e. less precise outcomes) and large effect sizes, without corresponding studies 
with small effect sizes and large standard errors (Borenstein, 2009). Du ✁✂ ✁✄☎ ✆✝✞✞☎✟✞✠✡
☛☞✌✟✍ ✁✄☎ ✎✟✂✂✠ ✁✄✁✂✏✡✟✡ ✝✁✡ ✑✡✞☎ ☞✒ ✓✑✁✄☞✟✎✏ ✁✡✏✍✍✞☞✌✏ ✟✄ ☞✔✞ ☎✟✡☞✌✟✕✑☞✟✒✄ ✒✎ ✞✎✎✞✖☞ ✡✟✗✞✡
(relative to their standard errors) (Duval & Tweedie 2000a; 2000b). The test generates a 
mean effect size estimate that is adjusted to compensate for the hypothesized publication 
✕✟✁✡ ✕✏ ✟✍✘✑☞✟✄✙  ✁✂✑✞✡ ✒✎ ✡☞✑☎✟✞✡ ✁✡✡✑✍✞☎ ☞✒ ✕✞ ☛✍✟✡✡✟✄✙✠✚ Lastly, Begg & Mazumdar✠✡
rank order correlation test was used to assess evidence of publication bias. This test is 
based on the assumption that studies with larger effect size estimates are more likely to 
be published than those with similar sample sizes but smaller effect sizes. Thus, 
publication bias is consistent with a significant correlation between effect size estimates 
and the standard errors of the effects (Begg & Mazumdar, 1994). Calculations for 
synthesizing results of studies and for examining publication bias were performed using 
Comprehensive Meta-Analysis v.2 (CMA: Biostat, 2006) software. 
The second major focus of data analysis involved comparing results of SOC CMHS 
subsets against these benchmarks, using a strategy adapted from Minami, Serlin et al. 
(2008). Results from the SOC CMHS subsets were compared to these benchmark 
standards to establish whether levels of improvement (1) were clinically equivalent to the 
treatment efficacy benchmark (2) were better than the natural history benchmark but 
inferior to the treatment efficacy benchmark, or (3) were clinically equivalent to the 
natural history benchmark (Minami, Serlin et al., 2008). Thus, two comparisons were 
made for each SOC CMHS subset, the first between the SOC CMHS subset and the 
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treatment efficacy benchmark, and the second between the SOC CMHS subset and the 
natural history benchmark.  
A 'range null' hypothesis testing procedure was used in this benchmarking 
analysis. This approach was developed by Serlin and Lapsey (1983; 1985) as way of 
identifying differences between effect sizes that were both statistically and clinically 
meaningful.  ✁✂✄☎✄✆✝✂✆ ✞☎✆✟ ✠✡✝☛☎✁☞✄ ✡✝✄✝✌✡✍✟✎ ✏✑✒ ✓✌ ✔✄✕✌✖✖✗ ✝✘✘✝✍✆ ✄☎✙✝✚  ✁✟✝✂✎ ✛✜✜✢✣
was nominated as a clinically meaningful magnitude of difference between effect sizes 
(Curtis et al., 2009; Minami, Serlin et al., 2008; Minami et al., 2009). In practice, this 
meant that differences between the true effect sizes of SOC CMHS subsets and the true 
benchmark effect sizes that were less than 0.2 standard deviations were considered 
clinically equivalent.  ✤✟✝ ✔✡✌✂✥✝ ✂☞✖✖✗ ✟✦✠✁✆✟✝✄☎✄ ✆✝✄✆☎✂✥ ✠✡✁✍✝✧☞✡✝ ✌✖✖✁✞✄ ✘✁✡ ✌
comparison between the effect size of the comparator group and a range of effect sizes, 
✡✌✆✟✝✡ ✆✟✌✂ ✆✟✝ ✕✁✡✝ ✆✡✌✧☎✆☎✁✂✌✖ ✔✠✁☎✂✆ ✂☞✖✖✗ ✆✝✄✆✑ ✤✟✝ ✔✡✌✂✥✝ ✂☞✖✖✗ ✠✡✁✍✝✧☞✡✝ ☞✆☎✖☎✄✝✄ ✌ ✂✁✂-
central t statistic when making these statistical comparisons (Serlin & Lapsley, 1985; 
1993), and generates critical values that identify the effect size the community group 
must exceed to be considered either clinically equivalent to (or better than) the treatment 
benchmark or significantly better than the natural history benchmark.  The R statistics 
program was used to perform calculations for the ✔range null✗ hypothesis testing 
procedure, including identification of critical values. 
A third set of analyses were conducted to establish treatment and natural history 
benchmarks ✘✁✡ ✔✍✖☎✂☎✍✌✖✖✦ ✄☎✥✂☎✘☎✍✌✂✆ ☎✕✠✡✁☛✝✕✝✂✆✗ (CSI) and to compare results of 
youth in the SOC CMHS subsets to these CSI benchmarks. Two-sample z tests for 
proportions were used for these comparisons. Consistent with the definition used in 
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published clinical trials,  c✁✂✄✂☎✆✁✁✝ ✞✂✟✄✂✠✂☎✆✄✡ ✂☛☞✌✍✎✏☛✏✄✡✑ ✒✆✞ operationalized as 
falling ✠✌✍☛  ☎✁✂✄✂☎✆✁✑ ✡✍  ✞✓✔☎✁✂✄✂☎✆✁✑ functioning on the CBCL-Int scale (Achenbach, 
1991; Achenbach & Rescorla, 2001) ✕ that is from CBCL-Int T >= 65 to CBCL-Int T < 
65 (e.g. Cartwright-Hatton et al., 2011).  ✖✗✂✞ ✍☞✏✌✆✡✂✍✄✆✁✂✘✆✡✂✍✄ ✍✠  ☎✁✂✄✂☎✆✁✁✝ ✞✂✟✄✂✠✂☎✆✄✡
✂☛☞✌✍✎✏☛✏✄✡✑ ✙✍✏✞ ✄✍✡ include a requirement for statistically reliable improvement, 
which has been used as part of the definition of  treatment response✑ by other scholars 
(c.f. Jacobsen, Roberts, Berns, & McGlinchey, 1999). Further, CBCL-Int T = 65 is not 
identified as a cut off point for the CBLC-Int ✔✝ ✡✗✏ ✞☎✆✁✏✞✑ ✙✏✎✏✁✍☞✏✌✞ (Achenbach & 
Rescorla, 2001). Nonetheless, this ✙✏✠✂✄✂✡✂✍✄ ✍✠  ☎✁✂✄✂☎✆✁✁✝ ✞✂✟✄✂✠✂☎✆✄✡ ✂☛☞✌✍✎✏☛✏✄✡✑ was 
used in the present research. This is because it mirrored definitions used within published 
studies and hence allowed for direct comparison of results of the SOC subsets with those 
of clinical research trials. The StarStat: Significance Testing Calculator (DataStat Inc., 
1995-2011) was used to conduct the two-sample z tests for proportions. 
A fourth set of analyses was conducted to identify  ✟✍✍✙✑ ✆✄✙  ☞✍✍✌✑ treatment 
responders.  Only the SOCCBCL subset was used for this analysis, because of the small n 
in the SOCdiag subset. ✚✍✓✡✗ ✒✏✌✏ ☎✁✆✞✞✂✠✂✏✙ ✆✞  ✟✍✍✙✑ ✡✌✏✆✡☛✏✄✡ ✌✏✞☞✍✄✙✏✌✞ if they 
satisfied two conditions. First, youth whose pre-treatment scores fell from the  ✙✏✎✂✆✄✡✑ 
(CBCL-DSM Anx T >= 65) to  ✄✍✌☛✆✁✑ (CBCL-DSM Anx T < 65) range of functioning 
on the CBCL-DSM Anx scale AND who demonstrated  reliable change✑ on the CBCL-
DSM Anx were considered  ✟✍✍✙✑ treatment responders. Youth whose initial CBCL-
✛✜✢ ✣✄✤ ✞☎✍✌✏ ✒✆✞ ✂✄ ✡✗✏  ✙✏✎✂✆✄✡✑ ✌✆✄✟✏ pre-treatment, and who did not meet these two 
criteria, were classified as  ☞✍✍✌✑ treatment responders. Use of the CBCL-DSM Anx T = 
65 as a cut off was consistent with recommendations in Achenbach and Rescorla (2001) 
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for dichotomising samples into groups  ✁ ✂✄☎✆✝✞✟✠✡  ☛ ✂✟ ☛☞✞✌✡ ✁✍✟✎✠✝ ✟✝✟✏. Youth whose 
CBCL- DSM Anx scores improved by a statistically reliable amount were classified as 
✂☛☎✌✝✞✑✌☎ improvers✡. Those whose scores did not, ✒☎☛☎ ✎✌✞✓✓✝✁✝☎✄ ✞✓ ✂✟ ✟-✝☞✔☛ ✆☎☛✓✡. 
✂Reliable change✡ was established using the ✂Reliable Change Index✡ (RCI; Jacobson et 
al., 1999; Jacobson & Truax, 1991). Essentially, the RCI establishes a threshold for 
improvement that is beyond the measurement error of the instrument used - in this case, 
the CBCL-DSM Anx.  Since Jacobsen and colleagues introduced ✠✕☎ ✎ ✟✎☎✔✠  ✁ ✂☛☎✌✝✞✑✌☎
✎✕✞✟✏☎✡, a number of methods for establishing the RCI have been developed (Wise, 
2004).  Wise (2004) reported that the five major methods he reviewed generated 
comparable results. This led him to conclude that the method recommended by Jacobson 
et al. (1999) should be the default approach because it is easier to understand than the 
other methods. This makes it a better choice for use in community agencies, where a 
straightforward calculation of the RCI is preferable✖ ✗✕✍✓✘ ✙✞✎ ✑✓ ✟✡✓ ☎✠ ✞✌✖ ✚✛✜✜✜✢
method for calculation of the RCI was used in the present study, and was based on the 
following formula; 
 
✣✤✥✦✧✦★ ✩✪✫ ✬✭✮ = 






✣✤✥✦✧✦★ ✩✪✫ ✬✭✮ = Reliable Change Index for the CBCL-DSM Anx DSM oriented 
scale 
✰✱✲✦✧✦★✳✩✪✫ ✬✭✮ = Pre-treatment CBCL-DSM Anx raw score 
✰✵✶✷✦✧✦★✳✩✪✫ ✬✭✮ = 6month CBCL-DSM Anx raw score 
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SD = Pre-test standard deviation of CBCL-DSM Anx raw scores for SOCCBCL         
 ✁✂✄☎ ✆✝ ✄☎✞ ✟✠✡✆✝✆✠☛✡☞ ✌☛✝✍✞ ✁✎ ✏✑✏✒-DSM Anx at pre-test = 1.77. 
rxx = test-retest reliability of the CBCL-DSM Anx (test-retest reliability = 0.80;                                                 
Achenbach & Rescorla, 2001) 
 
Participants whose scores improved beyond a RCI of 1.96 (i.e. p < .05) were 
considered to have demonstrated reliable change. In practice, this meant youth whose 
CBCL-DSM Anx raw score decreased by 1.55 or more during the six months after 
treatment initiation were considered to have demonstrated ✟reliable☞ change.  
The fifth major focus of data analysis was an examination of factors associated with 
treatment response. First, a logistic regression to examine prediction of ✟treatment 
response☞ was planned. Logistic regression assesses the combined prediction of a 
dependent variable from a set of variables, as well as the unique prediction of each 
variable relative to the others. Thus, the unique predictive value of each variable is 
influenced, in part, by which other variables are included within the analysis (Tabachnik 
& Fidell, 2013). Various methods have been suggested for deciding the appropriate ratio 
of cases to predictor variables within logistic regression (e.g. Tabachnick & Fidell, 2013). 
Research by Peduzzi, Concato, Kemper, Holford & Feinstein (1996) indicated that the 
number of predictors should be limited by the size of the smallest of the two outcome 
groups, with a recommended ratio of approximately 1 predictor for every 15 participants 
✆✝ ✄☎✞ ✓✔☛✡✡✞✌ ✁✎ ✄☎✞ ✍✌✁✂✕✓ ✖✟✞✗✞✝✄ ✄✁ ✕✌✞✘✆✠✄✁✌✙☞ ✌☛✄✆✁✙ ✚✞✘✂✛✛✆✜ et al., 1996). The sample 
size (n = 101) meant that the maximum number of youth in the smaller of the groups 
(✟good☞ versus ✟poor☞ treatment responders) would be 50, and hence a maximum of three 
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variables could be used to predict treatment response. Poverty status, externalizing 
comorbidity and affective comorbidity were chosen as predictor variables, since they 
represent possible confounds impacting outcome of the SOC CMHS group (c.f. Westen 
et al., 2004 ✁ ✂✄☎✆✝✞✟✠ ✡✟☛✟☞✡✌ was operationalized using household income, as recorded in 
the DIQ, consistent with the definition used by the national evaluation study.  Youth were 
✍✎☛✡✡✏✑✏✝✒ ☛✡ ✝✏✟✓✝✞ ✂living ✏✔ ✕☎✆✝✞✟✠✌ ✖when household income was less than $15 000) or 
✂✔☎✟ living ✏✔ ✕☎✆✝✞✟✠✌ ✖when household income was $15 000 or more). Externalising 
comorbidity was operationalized using DSM diagnosis, as recorded in the DIQ. Youth 
✗✝✞✝ ✍✎☛✡✡✏✑✏✝✒ ☛✡ ✝✏✟✓✝✞ ✂✍☎✘☎✞✙✏✒ ✝✚✟✝✞✔☛✎✏✡✏✔✛ disorder✌ (having a DSM diagnosis of 
either ADHD or ODD at baseline  ☎✞ ✂✔☎ ✍☎✘☎✞✙✏✒ externalising disorder✌ (not having a 
DSM diagnosis of ADHD or ODD at baseline).  Affective comorbidity was 
operationalized using DSM diagnosis, as recorded in the DIQ. Youth were classified as 
✝✏✟✓✝✞ ✂✍☎✘☎✞✙✏✒ ☛✑✑✝✍✟✏✆✝ disorder✌ ✖having a DSM diagnosis of a mood disorder at 
baseline  ☎✞ ✂✔☎ comorbid affective disorder✌ ✖✔☎✟ ✓☛✆✏✔✛ ☛ ✜✢✣ ✒✏☛✛✔☎✡✏✡ ☎✑ ☛ ✘☎☎✒
disorder at baseline). The three variables were entered into the logistic regression 
concurrently, since there was no a priori reason to enter them in separate steps. 
Univariate analyses were also used to examine factors associated with treatment 
response. Unlike multivariate analysis, the relationship between factors in prediction of 
outcome is not taken into account in univariate analysis. However, it does allow for 
examination of a larger number of factors than does multivariate analysis (with correction 
for Type 1 error). These features of univariate analysis are particularly helpful in the 
present study, given that the investigation of factors associated with response to anxiety 
treatment in children is currently largely exploratory. For instance, some variables being 
BENCHMARKING TREATMENT OF ANXIETY IN YOUTH   
 
83 
considered in the present research (e.g. child strengths; child functional impairment) have 
not been examined at all in previous studies (t  ✁✂✄ ☎✆✁✂ ✝✞✟ ✠✡ ☛☞✄✌✍✄✎✏ ✑✒  ✌✟ ☎✡✌
✑✓  ✝✟ ✁✝✄☎✁✔✄✡✁ ✝✄✞✓ ✡✌✄✝✞ ☛✄✝✄ ✕ ✔✓☎✝✄✌  ✡ ✖✖ ✗☎✝✘☎✙☞✄✞ ✝✄☞☎✁✄✌ ✁  demographics, 
family context, child strengths, child functional impairment and child psychopathology.  
Independent samples t-tests were used for comparisons of continuous variables and Chi 
squared tests were used for comparisons of categorical variables. Demographic variables 
were drawn from the DIQ questionnaire, and included age, gender, and ethnicity. Family 
context variables included the total number of family and child risk factors at baseline 
(from the DIQ), caregiver stress (total raw score on CSQG), general family functioning 
(total FAD-caregiver score) and poverty status (from the DIQ). Child strengths were 
measured using the BERS strength quotient. Child functional impairment across settings 
was measured using CAFAS total score. Child psychopathlogy was assessed using DSM 
diagnoses recorded in the DIQ. These were examined using univariate analyses to 
ascertain their relationship with treatment response, independent of other variables. 
Limited research on factors associated with treatment response in children with anxiety 
disorders meant a relatively large number of factors were examined. Because of the large 
number of analyses conducted, results were vulnerable to Type 1 errors. To reduce Type I 
error, a Bonferroni correction was applied to alpha, which was set at .005.  
Lastly, a secondary analysis of moderators of effect sizes for the treatment trials 
was conducted using a Q test, which is comparable to an analysis of variance in primary 
research (Borenstein et al., 2009). A fully random effects model was used in the 
moderator analysis. The analysis examined seven possible moderators of effect size 
outcomes: treatment completion status (✑completer✟  ✝ ✑✘✡✁✄✡✁ ✁  ✁✝✄☎✁✟); research setting 
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(community clinic or research); recruitment (referral only or both advertising and 
referral); method of intervention (in-person or via bibliotherapy, phone, internet, or 
email); method of delivery (group or individual), persons involved (parent, child, or both) 
and age of youth (7 or older or 6 or younger). Due to the number of analyses being 
conducted, a Bonferroni correction to the alpha was applied. The alpha was set at .007. 
Calculations for this analysis were performed using the CMA software (Biostat, 2006). 
Pre-Analysis Preparations 
Calculation of treatment efficacy benchmark. Results of clinical trials were 
aggregated to establish a pre-post effect size treatment efficacy benchmark.   A single 
summary effect size from each study was used to contribute to the overall benchmark, so 
that studies with multiple subgroups did not have a disproportionate influence on the 
generation of the benchmark (Minami, Serlin, et al., 2008). The process of generating a 
single effect size per study progressed through a series of stages, depending on features 
of study design, such as the number of raters and treatment subgroups. In essence, the 
process involved aggregating effect sizes across parents within each subgroup, then 
across subgroups within each study, then effect sizes across studies, to generate the pre-
post effect size treatment efficacy benchmark (Borenstein et al., 2009). Details of this 
process follow. 
Calculation of pre-post effect size estimates. Consistent with previous studies 
(Minami, Serlin et al., 2008; Oei & Boschen, 2009; Westbrook & Kirk, 2005), effect size 
estimates were calculated by standardising change scores with the standard deviation 
(SD) of the pre-test group. The pre-treatment SD was used to standardise treatment gain, 
rather than the more commonly used pooled SD, because it meant that the estimated 
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effect size reflected the magnitude of change against the distribution of untreated youth. 
This made greater conceptual sense for the purposes of the present study than use of 
standardised gain scores (Lipsey & Wilson, 2001). Also, the true effect size of a 
treatment might be better estimated using the standard deviation of the pre-test score, 
rather than a pooled standard deviation, because it is not influenced by repeated measures 
and the impact of treatment (Morris, 2000).  
Because small sample sizes can result in inflated effect size estimates, a correction 
for small sample size was utilised. Consistent with Minami, Serlin et al. (2008) and 
Curtis et al. (2009), each estimated effect size was multiplied by the correction for small 
 ✁✂✄☎✆  ✝✞✆ ✟✆✠✆☎✡✄✆✟ ☛☞ ✌✆✟✍✆  ✎✏✑✒✏✓✔ ✕c✖✗ ✘✙✚ ✔ ✛✙✆ ✍✆✜✆✢✁☎ ✣✡✢✂✚☎✁ ✣✡✢ ✤✁☎✤✚☎✁✛✝✜✍
the corrected pre-post effect sizes estimate was as follows; 
✥ ✦ ✧★✩✪✫✬ ✭ ✩✪✮✯✰✱ ✲✳✪✫✬✴ ✵  * (c) 
(2) 
where; 
✥  = the corrected pre-post effect size estimate. 
✩✪✫✬ = the mean CBCL-Int T score at pre-treatment. 
✩✪✮✯✰ = the mean CBCL-Int T score at post treatment. 
✲✳✪✫✬= the standard deviation of the pre-treatment CBCL-Int scores. 
c = adjustment for small sample size = 1 - ✶✷✸✹✺ 
n = sample size 
 
The variance of this estimated effect size is as follows (Lipsey & Wilson, 2001); 












✑= variance of effect size estimate 
r = correlation between pre- and post- CBCL-Int scores = 0.45 (based on 
Bodden et al., 2008). 
✓  = corrected pre-post effect size estimate  
n = sample size.  
Aggregating effect size estimates across raters. ✔✕ ✖✗✘✙✚✛✖ ✜✢✛✣✛ ✤✥✗✢ ✦✥✗✢✛✣✧✖ ★✕✙
✩★✗✢✛✣✧✖ ✣★✗✚✕✪✖ ✜✛✣✛ ✣✛✫✥✣✗✛✙✬ ✗✢✛ ✩✚✣✖✗ ✖✗✛✫ ✚✕ ✪✛✕✛✣★✗✚✕✪ ★ ✖✚✕✪✭✛ ✛✩✩✛✮✗ ✖✚✯✛ ✫✛✣ ✖✗✘✙✰
✜★✖ ✗✥ ★✪✪✣✛✪★✗✛ ✗✢✛ ✛✩✩✛✮✗ ✖✚✯✛✖ ★✮✣✥✖✖ ✫★✣✛✕✗✖✧ ✣★✗✚✕✪✖✱ ✲✢✛✖✛ ✥✘✗✮✥✦✛✖ ✜✛✣✛ ✕✥✗
independent (since they reflected the behaviour of the same child) and the aggregation 
process had to take the dependency into account so that the error in the estimate was not 
underestimated and the precision of the summary effect size was not overestimated 
(Borenstein et al., 2009).  The composite parent effect size estimate (✓✳) is the mean of 
✦✥✗✢✛✣✧✖ ★✕✙ ✩★✗✢✛✣✧✖ effect sizes and the variance of this composite, was calculated as 
follows (Borenstein et al., 2009);   
✴✏✵  ✶ ✷
✸





✴✏✵ ✶ ❃❄❅❆❄❇❈❉ ❊❋ ●❍❉ ❈❊■❏❊❑❆●❉ ❉❋❋❉❈● ❑❆▲❉▼ ✓✳ 
✴✼ ✶ ❃❄❅❆❄❇❈❉ ❊❋ ❅❄●❉❅ ◆  
✴✾ ✶ ❃❄❅❆❄❇❈❉ ❊❋ ❅❄●❉❅ ❖  
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✞☛  ✁ ✂✄☎☎✆✝✟✠✡✄☞ ✌✆✠✍✆✆☞ ✎✄✠✏✆☎✑✒ ✟☞✓ ✔✟✠✏✆☎✑✒ ✆✔✔✆✂✠ ✒✡✕✆ ✆✒✠✡✎✟✠✆✒✖ ✆✒✠✡✎✟✠✆✓ ✟✒ r 
= 0.7, based on aggregation of results of studies measuring both. 
 
Where the number of mothers and/or fathers in each (sub) group was not reported 
in the study or could not be established from contact with the authors, numbers were 
estimated using information within the trial (such as the number of mothers and fathers in 
the entire study or the degrees of freedom within analyses).   
Aggregating effect sizes across subgroups within studies. The second step in 
generating a single effect size for each treatment study was to aggregate effect sizes 
across subgroups in studies t✏✟✠ ✡☞✂✝✗✓✆ ✎✗✝✠✡✘✝✆ ✙✌✄☞✟ ✔✡✓✆✑ ✠☎✆✟✠✎✆☞✠✒✚ ✛☞ ✒✠✗✓✡✆✒
☎✆✘✄☎✠✡☞✜ ✙✌✄☞✟ ✔✡✓✆✑ ✟☞✓ ✆✢✘✆☎✡✎✆☞✠✟✝ ✒✗✌✜☎✄✗✘✒✖ ✄☞✝✣ ☎✆✒✗✝✠✒ ✄✔ ✙✌✄☞✟ ✔✡✓✆✑ ✒✗✌✜☎✄✗✘✒
were used. Results of all ✙bona fide✑ treatments were aggregated (rather than being 
examined separately) because the focus of the present study was on generating a 
benchmark of any efficacious treatment, not on comparing the relative efficacy of 
different treatments. Composite effect sizes estimates (Ys) were generated for each 
clinical trial, and are outlined in Table 3. 
Aggregating effect size estimates across studies.  Third, having combined effect 
sizes across raters and th✆☞ ✟✂☎✄✒✒ ✙✌✄☞✟ ✔✡✓✆✑ ✠☎✆✟✠✎✆☞✠ subgroups within studies, the 
next step was to aggregate ✆✟✂✏ ✒✠✗✓✡✆✒✑ ✒✗✎✎✟☎✣ ✆✔✔✆✂✠ ✒✡✕✆ ✆✒✠✡✎✟✠✆ ✤Ys) to generate the 
treatment efficacy benchmark YTE. The summary effect size estimates for each study (Ys) 
and the treatment efficacy benchmark (YTE) are outlined in Table 3.  
 
  





Study Treatment Effect Size Estimates, Treatment Efficacy Benchmark and Effect Size 
Estimates for SOC CMHS Subsets 
 





Barrett et al. (1996) 
 
53 - - 1.14 (0.2) 
Barrett (1998) 
 
56 - - 3.02 (0.4) 
1.75b (0.4) 
 
Beidel et al. (2000) 30 68.4 (7.2) 60.2 (8.1) 1.11 (0.2) 
 
Cartwright-Hatton et al. 
(2011) 
 
34 66.6 (7.6) 59.4 (6.6) 0.92a (0.2) 
Cobham et al. (1998) 
 




Kendall (2000)  
 
25 - - 1.68 (0.3) 
Heyne et al. (2002) 
 
57 - - 1.28 (0.2) 
Kendall (1994) 
 
27 70.7 (7.0) 58.1 (10.3) 1.75 (0.3) 
Kendall et al. (1997) 
 
60 - - 1.32 (0.2) 
Kendall et al. (2008) 
 
111 - - 0.73a (0.1) 
Lyneham and Rapee 
(2006) 
 
78 - - 1.07a (0.2) 
Nauta et al. (2003) 
 
76 71.5 (9.5) 61.7 (9.5) 0.90 (0.1) 
Rapee et al. (2006) 
 
180 - - 0.65a  (0.1) 
Shortt et al. (2001) 
 
48 - - 6.91 (0.9) 
 
Silverman et al. (1999a) 25 72.9 (7.6) 61.6 (8.4) 1.45 (0.3) 
Silverman et al. (1999b) 
 
65 - - 0.74 (0.2) 
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Southam-Gerow et al. 
(2010) 
 
15 66.5 (9.2) 58.9 (9.0) 0.79 (0.3) 
Spence et al. (2006) 45 - - 0.91 (0.2) 
 
     
     
SOCCBCL 
 
101 73. 3 (6.6) 68.0 (11.2) 0.79 (0.11) 
 
SOCdiag 70 68.4 (9.0) 63.7 (12.1) 0.52 (0.14) 
     
 
Treatment efficacy benchmarkc: YTE = 1.05 (SE = .08) 
 
Note. Dashes indicate single mean (SD) not available because of multiple informants or 
subgroups; n = Number of youth on which mean CBCL-Int is based, established from 
number of CBCL-Int questionnaires completed (where available) or number of youth 
whose data was reported; CBCL-Int Mpre = Mean pre-treatment CBCL-Int T score; SD = 
standard deviation of mean pre-treatment CBCL-Int T score; CBCL-Int Mpost = Mean 
post-treatment CBCL-Int T score; YS = Study effect size estimate for each study; SES = 
standard error of effect size estimate. 
aEffect size based on intent to treat data. bWinsorized effect size estimate  cTreatment 
efficacy benchmark with results of Shortt et al. (2001) excluded from analysis and results 
of Barrett (1998) winsorized.  
 
Within meta-analyses, studies with extreme outlying values can distort findings, 
leading to spurious or misleading conclusions (Lipsey & Wilson, 2001). There is some 
variability in practice, but outliers are commonly identified as those effect size estimates 
that are 2 or 3 standard deviations from the mean summary effect size (Lipsey & Wilson, 
2001).  Examination of the results listed in Table 3 revealed that Shortt et al. (2001) 
generated an effect size estimate that was substantially larger than any other study (Ys = 
6.9, SE = 0.9). Results of this study were so disparate from the others that it did not 
appear to fall within the same population of effect sizes and it was eliminated from 
further analysis (Lipsey & Wilson, 2001). The magnitude of the effect size estimate of 
the Barrett (1998) study (Ys = 3.02) was almost 2 standard deviations higher than the 
BENCHMARKING TREATMENT OF ANXIETY IN YOUTH   
 
90 
summary effect size that was generated after Shortt et al. (2001) was eliminated (YTE Barrett 
incl. = 1.12). The next highest effect size was 1.75 (see Figure 2). Including such an 
unusually large effect size appeared inconsistent with the goal of generating realistic and 
representative treatment efficacy benchmarks for use in community agencies, but 
eliminating the study would lead to a loss of data. In order to limit the impact of outliers 
but minimise data loss, previous meta- ✁ ✂✄☎✆☎ ✝ ✞✆ ✟✠✡✁☎☛☞✡✌✆✍✎ outcomes of studies 
with extreme results (e.g. Cook, Williams, Guerra, Kim, & Sadek, 2010; Crepaz et al., 
2009; Derzon 2001; Durlak, Weissberg, & Pachan, 2010; Kobayashi, 2005; Malouff, 
Thorsteinsson, Rooke, Bhullar, & Schutte 2008; Shadish & Baldwin, 2005). 
✟Winsorizing✎ involves replacing the extreme values of outliers with more moderate ones. 
The next highest value in the distribution can be used as the replacement value (Lipsey & 
Wilson, 2001).  Following this rationale, results of the Barrett (1998) study were 
✟winsoriz✆✍✎ ✏ and the study was assigned the same effect size estimate as the study with 
the next largest effect size (i.e. 1.75) (Lipsey & Wilson, 2001).  With these changes 
made, synthesising results of the remaining treatment studies revealed an overall 
summary estimate effect size for all studies of YTE = 1.05 (SETE = 0.08). This value 
became the pre- post effect size treatment efficacy benchmark (see Table 3).  
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Study name Subgroup within study Outcome Statistics for each study Point estimate and 95% CI
Point Standard Upper Lower 
estimate error limit limit
Barrett et al., 1996 Combined Combined 1.14 0.18 1.48 0.79
Barrett, 1998 Combined Combined 3.02 0.35 3.70 2.33
Beidel et al., 2000 Child CBT Mother 1.11 0.24 1.58 0.64
Cartwright-Hatton et al.,  2011 Parent CBT Parent 0.92 0.21 1.34 0.51
Cobham et al., 1998 Combined Mother 0.96 0.15 1.26 0.66
Flannery-Shroeder et al.,  2000 Combined Combined 1.68 0.33 2.32 1.04
Heyne et al., 2002 Combined Combined 1.28 0.18 1.64 0.92
Kendall  et al., 1997 Child CBT Combined 1.32 0.18 1.67 0.97
Kendall et al., 2008 Combined Combined 0.73 0.11 0.94 0.52
Kendall, 1994 Child CBT Mother 1.75 0.31 2.36 1.13
Lyneham and Rapee, 2006 Combined Combined 1.07 0.15 1.36 0.77
Nauta et al., 2003 Combined Parent 0.90 0.14 1.17 0.62
Rapee et al.,  2006 Combined Parent 0.65 0.09 0.81 0.48
Silverman et al., 1999a Child + Prnt Group Parent 1.45 0.29 2.02 0.87
Silverman et al., 1999b Combined Parent 0.74 0.15 1.03 0.45
Southam-Gerow et al.,  2010 Child CBT Parent 0.79 0.31 1.39 0.19
Spence  et al., 2006 Combined Parent 0.91 0.19 1.28 0.55
1.12 0.10 1.31 0.94
-4.00 -2.00 0.00 2.00 4.00
Deterioration Improvement
Figure 2. Study and summary effect size estimate(s) for treatment groups of clinical trials with Shortt et al. (2001) removed
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Publications bias. Visual inspection of the pattern of distribution of effect size estimates 
illustrated on the funnel plot is consistent with publication bias (see Figure 3). As can be seen, 
there are four studies with large standard errors and relatively large effect sizes but no 
corresponding studies with similar standard errors but small effect size estimates.  Duval and 
 ✁✂✂✄☎✂✆✝ ✞trim and f☎✟✟✆ was used to impute values for these studies (see dark spots, Figure 3). 
Using this analysis, an estimated unbiased adjusted effect size of YTEadj = .95 was generated. 
Begg and Mazum✄✠✡✆✝ ✡ank correlation test also yielded a significant result, indicating that the 
relationship between the magnitude of effect size estimates and standard errors of the effect sizes 
was significant, ☛✂☞✄✠✟✟✆✝ ✌ = .54; p = .001. Hence, results of the three tests were consistent with 
publication bias.




Figure 3. Funnel plot of standard error by effect size estimates for treatment groups of clinical trials, with effect size estimates of 



















Funnel Plot of Standard Error by Point estimate
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Calculation of natural history benchmark. Consistent with Minami, Serlin et 
al. (2008), a  natural history✁ effect size benchmark was established based on results of 
wait list control groups of the clinical trials. The 10 studies that used wait list control 
groups (i.e. Barrett et al., 1996; Barrett, 1998; Cartwright-Hatton et al., 2011; Flannery-
Shroeder & Kendall, 2000; Kendall, 1994; Kendall et al., 1997; Rapee et al., 2006; 
Silverman et al. 1999a; Spence et al., 2006) were aggregated to establish this benchmark, 
which reflects the magnitude of improvement that might be expected with the passage of 
time a✂✄☎✆✝ ✞✄✟✠✆✡✁☛ ☞☎✌ ✍☞✟✠✆✡✁☛ ✡☞✟✎☎✏☛ ✑✆✡✆ ☛✒☎✟✠✆☛✎☛✆✌ ✓☛✎☎✏ ✟✆✔✠☎✎✕✓✆☛ ✎✌✆☎✟✎✔☞✂ ✟✄
those within treatment groups (Borenstein et al., 2009). As can be seen in Table 4, most 
effect size estimates for wait list control groups fell between 0.2 ✖ 0.5. Only one study 
showed deterioration in scores (Silverman et al.,1999a), and results of this study appeared 
somewhat disparate from the others (Figure 4). However, the difference between the 
effect size estimate of this study and the overall mean, did not approach 2 standard 
deviations, thus winsorizing was not considered (Lipsey & Wilson, 2007). The natural 
history effect size benchmark was calculated as YNH = 0.30; SENH  =.07. 
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Table 4  
 
Study Wait List Control Effect Size Estimates, Natural History Benchmark and Effect Size 
Estimates for SOC CMHS Subsets 
 






Barrett et al. (1996) 23 - - 0.38 (0.21) 
Barrett (1998) 16 - - 0.38 (0.25) 
Cartwright-Hatton et al. 
(2011) 























Kendall et al. (1997) 34 - - 0.18 (0.18) 
Lyneham and Rapee 
2006 
22 - - 0.10 (0.22) 
 










Silverman et al. (1999a) 16 67.5 (9.1) 71.3 (6.8) -0.40(0.27) 
Spence et al. (2006) 23 68.7 (5.6) 66.8 (8.6) 0.33 (0.22) 
     
SOCCBCL 
 




70 68.4 (9.0) 63.7(12.1) 0.52 (0.14) 
 
Natural History effect size benchmark YNH = 0.30 (SENH = .07) 
 
Note. Dashes indicate single mean not available because of multiple informants;  
N = Number of questionnaires used to establish mean (where available) or number of 
youth in group; CBCL-Int Mpre = Mean pre-waitlist CBCL-Int T score; SDpre = standard 
deviation of pre wait-list mean CBCL-Int T score; CBCL-Int Mpost  = Mean post wait list 
CBCL-Int T score; SDpost = standard deviation of post wait-list mean; YWLC = study 
effect size estimate for wait list control groups for each study; SEWLC standard error of 
study wait list control estimated effect size.
BENCHMARKING TREATMENT OF ANXIETY IN YOUTH   
 
96 
Study name Subgroup within study Outcome Statistics for each study Point estimate and 95% CI
Point Standard Upper Lower 
estimate error limit limit
Barrett et al., 1996 WLC Combined 0.38 0.21 0.80 -0.04
Barrett, 1998 WLC Combined 0.38 0.25 0.88 -0.12
Cartwright-Hatton et al.,  2011 WLC Parent 0.51 0.18 0.87 0.15
Flannery-Shroeder et al.,  2000 WLC Combined 0.38 0.32 1.01 -0.25
Kendall  et al., 1997 WLC Combined 0.17 0.18 0.53 -0.18
Kendall, 1994 WLC Mother 0.28 0.25 0.78 -0.21
Lyneham and Rapee, 2006 WLC Combined 0.10 0.22 0.53 -0.34
Rapee et al.,  2006 WLC Parent 0.42 0.12 0.65 0.20
Silverman et al., 1999a WLC Parent -0.40 0.27 0.13 -0.93
Spence  et al., 2006 WLC Parent 0.33 0.22 0.77 -0.11
0.30 0.07 0.44 0.16
-2.00 -1.00 0.00 1.00 2.00
Deterioration Improvement
Figure 4. Study and summary effect size estimate(s)  for wait list control groups of clinical trials
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Calculation of SOC CMHS subset effect size estimates. The effect size estimates 
for each of the SOC CMHS subsets was calculated, using the same basic formula that 
was used to estimate the effect sizes within the clinical trials. Specifically, the effect size 
estimates were calculated as follows;  
✞☛ ✁ ✌ ✒✂✄✁☎✁✆ ✝✟✠ ✡☞✍ ✎ ✄✁☎✁✆ ✝✟✠ ✏✑✟✠✓ ✔ ✕✖✁☎✁✆ ✝✟✠ ✡☞✍✗ ✘ ✙ ✚✛✜ 
(5) 
where; 
✞☛ ✁ = effect size estimate for SOC CMHS subset (adjusted for sample size) 
✄✁☎✁✆ ✝✟✠ ✡☞✍  = the mean CBCL-Int T score at pre-treatment. 
✄✁☎✁✆ ✝✟✠ ✏✑✟✠✓ = the mean CBCL-Int Tscore six months post treatment-initiation. 
✕✖✁☎✁✆ ✝✟✠ ✡☞✍  = the pre-treatment standard deviation of the CBCL-Int T scores. 
c = adjustment for small sample size (see formula 2). 
 
Note that the second outcome measurement is taken six months post treatment-
initiation, rather than directly post-treatment. As mentioned, this is because in community 
settings, the duration of treatment is inconsistent. Thus, the timing of the second outcome 
measurement is standardised by amount of time following treatment initiation, rather than 
by length of treatment. The six month time period encompasses the duration of all 
clinical trials included within the present study. The pre-treatment CBCL-Int T mean 
(SD) of youth in the SOCCBCL matched subset was 73.3 (6.6) at pre-treatment and 68.0 
(11.2) at six months post treatment initiation. Hence, when adjusted for sample size, the 
SOCCBCL subset generated a pre-post estimated effect size of YSOCCBCL = 0.79.  The mean 
(SD) CBCL-Int T of the youth in SOCdiag subset was 68.4 (9.0) and 63.7 (12.1) at six 
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months. Hence, with adjustment for small sample size, the effect size estimate for the 
SOCdiag subset was Ysocdiag = 0.52.  
The variance of the effect size estimate was calculated as follows (Lipsey & 
Wilson, 2001); 
✞☛ ✁ = 
✒✄ ✂☎ ✌ ✆☛ ✁✝ ✟ ✠☛ ✁✡ ☞
✍✎☛ ✁
✏  (6) 
where; 
✞☛ ✁ = variance of the effect size estimate of the SOC subset 
✆☛ ✁ = the pre-post correlation of CBCL-Int T scores for the SOC subset 
✂✆☛ ✁ ✁✑✁✓ ✔ 0.49; ✆☛ ✁ ✕✖✗✘ ✔ 0.47) 
✠☛ ✁ = the pre-post estimated effect size for the SOC subset (YSOCCBCL = .79; YSOCdiag 
= .52). 
✎☛ ✁ = the sample size of the SOC subset (SOCCBCL = 101; SOCdiag = 70) 
 
Using this formula, the variance of the SOCCBCL subset effect size estimate was 
VSOC CBCL = 0.01 and the variance for the SOCdiag subset was VSOC diag = 0.02.   
Summary information regarding treatment efficacy benchmark, natural history 
benchmark and SOC subset effect sizes are summarised in Table 5 and their relative 
distributions are illustrated in Figure 5. 
 
  




Benchmark and SOC CMHS Subset Effect Size Estimates  
 
Group N K Y VY  CI .025  CI .975  
Treatment efficacy benchmark 
(YTE) 
1004 17 1.05 .006 0.90 1.20 
 
Natural history benchmark 
(YNH) 
287 10 0.30 .005 0.16 0.44 
 














SOC CMHS YSOC diag  70 - 0.52 .02 0.26 0.77 
 
Note. N = number of youth whose data were used to generate effect size estimate; K = 
Total number of studies; Y =Pre-post effect size estimate; VY  = Variance of effect size 
estimate; CI .025  = Lower confidence interval at 95 percent; CI .975  = Upper confidence 
interval at 95 percentile
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Study name Statistics for each study Point estimate and 95% CI
Point Standard Lower Upper 
estimate error limit limit
Treatment efficacy benchmark 1.05 0.08 0.89 1.21
Natural history benchmark 0.30 0.07 0.16 0.44
SOC CMHS_CBCL 0.79 0.11 0.57 1.01
SOC_CMHS_diag 0.52 0.14 0.25 0.79
-2.00 -1.00 0.00 1.00 2.00
Deterioration Improvement
Figure 5. Treatment efficacy benchmark, natural history benchmark and effect size estimates for SOCcbcl and SOCdiag subsets
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 ✁✂✄☎✂✁✆✝✞✟ ✞✠ ✡☛✟✄☞✌✁✍✎ ✠✞✍ ✏clinically significant improvement✑. The 
✒✓✔✒✔✓✕✖✔✗ ✔✘ ✒✙✓✕✖✚✖✒✙✗✕✛ ✘✙✜✜✖✗✢ ✘✓✔✣ ✤✚✜✖✗✖✚✙✜✥ ✓✙✗✢✦ ✔✗ ✕✧✦ ★✩★✪-Int to ✤✛✫✬✚✜✖✗✖✚✙✜✥ 
range has been reported in a minority of studies, with some using cut off scores of 
CBCL-Int T = 65 (Flannery-Schroeder & Kendall, 2000; Kendall et al., 2008) and others 
CBCL-Int T = 70 (Kendall, 1994; Kendall et al., 1997; Heyne et al., 2002; Silverman et 
al., 1999a; Silverman et al., 1999b; Spence et al., 2006) to differentiate ✤✚✜✖✗✖✚✙✜✥ ✙✗✭
✤✗✔✗✚✜✖✗✖✚✙✜✥ ✓✙✗✢✦✛. A cut off of CBCL Int T = 65 was chosen for the present study, 
since this was closer to the cut off of CBCL Int T score = 64 recommended by 
Achenbach and Rescorla (2001) for classification of clinical status (CBCL Int T = 60-63 
✤✬✔✓✭✦✓✜✖✗✦✥ ✚✜✖✗✖✚✙✜ ✓✙✗✢✦; CBCL-Int T ✮✯ ✰✱ ✤✚✜✖✗✖✚✙✜✥ range). Results of studies are 
reported in Table 6 based on information obtained from published results (k = 3) or from 
the authors (k = 5) for treatment groups (total: k = 8 studies). Results were aggregated 
across groups where studies reported results for multiple groups or raters (e.g. Flannery-
Schroeder & Kendall, 2000; Heyne et al., 2002; Kendall et al., 2008; Spence et al., 2006). 
 
  





 ✁✂✄☎✄✆✝✂✂✞ ✟✄✠☎✄✡✄✆✝☎☛ ☞✌✍✎✏✑✒✌✒☎☛✓ (CSI) across Treatment Groups of Clinical Trials 
and  ✁✂✄☎✄✆✝✂✂✞ ✟✄✠☎✄✡✄✆✝☎☛ ☞✌✍✎✏✑✒✌✒☎☛✓ Treatment Benchmark 
 
 % CSI  N in ✔clinical✕ 
range pre-treatment 
 
Beidel et al. (2000) 66.7a  30 
Cartwright-Hatton et al. (2011) 70.3a  34 
Flannery-Schroeder and Kendall (2000) 77.8  19b 
Heyne et al. (2002) 63.0a  46 
Kendall et al. (1997) 55.3a  34 
Kendall et al. (2008) 57.9c 38 
Rapee et al. (2006) 44.2a 102 
Spence et al. (2006) 60.7  28 
 
✔Clinically significant improvement✕ treatment benchmark CSITE  = 57.5 (SD = 10.0) 
 
Note. CSI =  Clinically significant improvement✕ i.e. proportion of youth who were in 
✔clinical✕ range of CBCL-Int pre-treatment (CBCL-Int T score >= 65) who fell to 
✔✖✗✘✙✚✛✜✛✙✢✚✕ ✣✢✜✤✥ ✦✧✖★-treatment (CBCL-Int T score < 65); N = number of youth in 
✔✙✚✛✜✛✙✢✚ ✣✢✜✤✥✕ ✧✩ ✪✫✪✬-Int pre-treatment (CBCL-Int T score >=65); SD = standard 
deviation of ✔clinically significant improvement✕ benchmark. 
 aBased on data from author bEstimate based on information reported in publication 
cWeighte✭ ✮✥✢✜ ✢✙✣✧✖✖ ✮✧★✯✥✣✕✖ ✢✜✭ ✩✢★✯✥✣✕✖ ✣✢★✛✜✤✖✰ 
 
Table 6 shows that only a minority of studies reported ✔clinically significant 
improvement✕, and a weighted mean of CSITE = 57.5% (range: 44.2 - 77.8%) of youth 
moved from the ✔clinical✕ range on the CBCL-Int at pre-★✣✥✢★✮✥✜★ ★✧ ✔sub-clinical✕ ✣✢✜✤✥
post-treatment. This weighted mean will act as the ✔✙✚✛✜✛✙✢✚✚✱ ✖✛✤✜✛✩✛✙✢✜★ ✛✮✦✣✧✲✥✮✥✜★✕
treatment benchmark (CSITE  = 57.5%, SD = 10.0). 
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Table 7  
 
 ✁✂✄☎✄✆✝✂✂✞ ✟✄✠☎✄✡✄✆✝☎☛ ☞✌✍✎✏✑✒✌✒☎☛✓ ✔✁✟☞✕ for Wait List Control Groups of Clinical 
Trials and  Clinically Significant Improvement✓ Natural History Benchmark 
 




Cartwright-Hatton et al. (2011) 38.9a 36 
Flannery-Schroeder and Kendall (2000) 20.5 9b 
Kendall et al. (1997) 43.5a 23 
Rapee et al. (2009) 32.3a 52 
Spence et al. (2006) 10.0 20 
 
✖Clinically significant improvement✜ natural history benchmark CSINH = 31.9 (SD = 10.6) 
 
Note.  CSI ✢ ✖✗✘✙✚✙✗✛✘✘✣ ✤✙✥✚✙✦✙✗✛✚✧ ✙★✩✪✫✬✭★✭✚✧✜ ✙✮✭✮ ✩roportion of youth in wait list 
control group who were in ✖clinical✜ range on the CBCL-Int pre-wait list (CBCL-Int T 
score >= 65) who fell to ✖✤✯✰ ✗✘✙✚✙✗✛✘✜ range post-wait list (CBCL-Int T score < 65). 
aInformation supplied by author bEstimated from information in publication. 
 
Table 7 illustrates that almost one third of youth in wait list control groups who 
were in the ✖clinical✜ range on the CBCL-Int pre-waitlist fell ✧✫ ✖✤✯✰✗✘✙✚✙✗✛✘✜ range of 
functioning post wait-list.  This weighted mean will be used as the ✖✗✘✙✚✙✗✛✘✘✣ ✤✙✥✚✙✦✙✗✛✚✧
✙★✩✪✫✬✭★✭✚✧✜ natural history benchmark (CSINH = 31.9%; SD = 10.6). 
Calculati✱✲ ✱✳ ✴✵linically significant improvement✶ in SOC CMHS subsets. At 
pre-treatment, 89.1% (i.e. n = 90) of youth in the SOCCBCL subset and 70.0% (i.e. n = 49) 
in the SOCdiag subset were in the ✖✗✘✙✚✙✗✛✘✜ ✪✛✚✥✭ of the CBCL-Int (CBCL-Int T >= 65). 
Of these, CSISOC CBCL = 23.3% (n = 21) and CSISOCdiag = 30.6% (n = 15) fell ✧✫ ✖sub 
✗✘✙✚✙✗✛✘✜ range six months after the start of services at SOC CMHS agencies. 





 Clinically Significant Improvement✁ in Benchmarks and SOC CMHS Subsets 
 
Group N K CSI SD 
Treatment CSITE 331 8 57.5% 10.0 
Natural history CSINH  140 5 31.9% 10.6 
     
SOCCBCL  90 - 23.3% - 
SOCdiag  49 - 30.6% - 
Note. A dash indicates information not applicable. N = total number of youth at pre-
✂✄☎✆✂✝☎✞✂ ✟✞ ✠✡☛✟✞✟✡✆☛☞ ✄✆✞✌☎ ✍✞ ✎✏✎✑-Int; K = total number of studies; CSI = ✠clinically 
significant improvement☞ i.e. p✄✍✒✍✄✂✟✍✞ ✍✓ ✔✆✝✒☛☎ ✟✞ ✠✡☛✟✞✟✡✆☛☞ ✄✆✞✌☎ ✍✓ ✓✕✞✡✂✟✍✞✟✞✌ on 
CBCL-Int who fell ✂✍ ✠sub-✡☛✟✞✟✡✆☛☞ range post- treatment or post-wait time; SD = 
standard deviation of CSI; CSITE= ✂✄☎✆✂✝☎✞✂ ✖☎✞✡✗✝✆✄✘ ✓✍✄ ✠✡☛✟✞✟✡✆☛☛✙ ✔✟✌✞✟✓✟✡✆✞✂




Testing the SOC CMHS subsets against the treatment efficacy benchmark.  
First, the true effect size estimate of each SOC CMHS subset was tested against the true 
treatment efficacy effect size benchmark. The null hypothesis (H0) was that the difference 
between the true treatment efficacy benchmark and the true effect size of the SOC subset 
was equal to or greater than the maximum margin allowed (i.e. ✣ ✤ 0.2) to be considered 
clinically equivalent. The alternative hypothesis (✥✦) was that the difference between the 
true SOC subset and the true treatment efficacy benchmark was less than the maximum 
allowed margin (i.e. ✣ ✤ 0.2) (Serlin & Lapsey, 1985; 1993; Minami et al., 2009); 
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✞☛ :  ✁ ✒✂✄☎ ✌  ✆ ✒✝✟✠☎ ✡ ☞ (7) 
 
✞✍ :  ✁ ✒✂✄☎ ✌  ✆ ✒✝✟✠☎ ✎ ☞ (8) 
where; 
  ✁ ✒✂✄☎= true treatment efficacy benchmark 
 ✆✒✝✟✠☎ = true effect size of SOC CMHS subset. 
☞ =  0.2 (i.e. maximum difference between true effect size of SOC CMHS subset 
and true treatment efficacy benchmark allowed, for them to be considered clinically 
equivalent). 
 
That is, to be considered clinically equivalent to the true treatment efficacy 
benchmark, the true SOC CMHS subset effect size ✏✑✓✔✕✖✗✘ fall more than 0.2 of a 
standard deviation below this benchmark (Serlin & Lapsley, 1985; 1993). The test 
statistic t (TE) for the hypothesis test follows a non-central t distribution, with degrees of 
freedom (✙)  = N ✚ 1, where N = sample size of the SOC subset. The formula for the non-
centrality parameter ✛✜✒✂✄☎) for the treatment efficacy benchmark is as follows (Minami, 
Serlin, et al., 2008); 
✜✒✂✄☎ = ✢✣ ✛ ✁ ✒✂✄☎ ✌ ☞) (9) 
where; 
✣ =  sample size of the SOC subset (SOCCBCl = 101;  SOCdiag = 70)  
  ✁ ✒✂✄☎= true treatment efficacy benchmark 
 
☞ = 0.2  
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Using the  range null✁ hypothesis testing procedure, a critical value (YCV [TE]) can be 
identified, which is the value the observed effect size for the community samples (YSOC) 
has to exceed to be considered clinically equivalent to the treatment efficacy benchmark 
(with an alpha of 0.05). If the observed effect size of the SOC subset (YSOC) exceeds this 
critical value, then the null hypothesis is rejected and the impact of the community 
treatment can be considered clinically equivalent (or better) than the treatment efficacy 
benchmark. If it does not exceed the critical value, this would indicate that there is no 
evidence that the effectiveness of treatment at SOC agencies is clinically equivalent to 
that delivered in clinical trials. The critical value is identified using the sample size (N) 
and non-centrality parameter ✒✞☛✂✄.  The formula for the critical value (YCV [TE]) is as 
follows; 




✆✝☛✂✟☞✠✡✌✍✎✏ = the 95
th percentile of the non-central t distribution  
N = size of the SOC subset (SOCCBCL; = 101, SOCdiag = 70) 
 
It should be noted that the smaller sample of the SOCdiag subset means the observed 
effect size is less reliable, hence the critical values are slightly more stringent for this 
subset. 
Testing the SOC CMHS subsets against the natural history benchmark. The 
 range null✁ hypothesis test was also used to compare the effect size estimates of each 
SOC CMHS subset with the natural history effect size benchmark. The strategy was the 
same as that used for testing against the treatment efficacy benchmark, except the signs in 
the null and alternative hypotheses were reversed. That is, the true effect size of the SOC 
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subset had to exceed the true natural history benchmark by more than 0.2 standard 
deviations to be considered significantly different and hence more clinically impactful 
than the passage of time alone. The null and alternative hypotheses can be stated as 
follows (Minami, Serlin et al., 2008; Minami et al., 2009); 
✞☛ :  ✁ ✒✂✄☎✆ ✌  ✝ ✒✟✠✆ ✡ ☞ (11) 
 
✞✍ :  ✁ ✒✂✄☎✆ ✌  ✝ ✒✟✠✆ ✎ ☞ (12) 
where; 
 ✁ ✒✂✄☎✆= true effect size of the SOC CMHS subset. 
 ✝ ✒✟✠✆= true natural history benchmark 
☞ = 0.2 (minimum difference required to be considered significantly different). 
 
The test statistic for this hypothesis also follows a non-central t distribution, with 
degrees of freedom (✏✑ = N -1. The formula for the natural history non-centrality 
parameter ✓✔✟✠) is as follows (Serlin & Lapsley, 1985; 1993); 
✔✟✠ = ✕✖ ✓ ✝ ✒✟✠✆ ✗ ☞) (13) 
where; 
✖ = size of the SOC subset (SOCCBCl = 101; SOCdiag  = 70),  
 ✝ ✒✟✠✆= true natural history benchmark 
☞ = 0.2  
The formula for the critical value (✘☎✙ ✒✟✠✆) is as follows (Serlin & Lapsley, 1985; 
1993; Minami, Serlin et al., 2008); 








✞✒☛ ✁☞✂✄☎✆✝✟ = the 95
th percentile of the non central t distribution 
N = size of the SOC CMHS subset (SOCCBCL = 101; SOCdiag = 70),  
✠☛  = non-centrality parameter for the natural history benchmark. 
 
If the observed pre-post effect size of the SOC subsets (Ysoc) exceeds this critical 
value ✡✌✍✎ ✒☛ ✁✏, then the null hypothesis is rejected and it can be concluded that 
treatment effectiveness in SOC CMHS agencies is both clinically and statistically 
superior to the passage of time alone. If it does not exceed this critical value, this would 
indicate that there was no evidence that improvement in the SOC CMHS subset is more 
substantial than the passage of time alone. That is, there is no evidence that the impact of 
services received at SOC CMHS agencies is any greater than the natural history of 
symptom remission.  
Results 
Overview of Results Section 
The results section reports findings of five sets of analyses. First, both SOC CMHS 
subsets were evaluated against the treatment efficacy effect size benchmark and the 
natural history effect size benchmark. These analyses were conducted to establish 
whether the magnitude of improvement of youth receiving treatment at SOC CMHS 
agencies was comparable to those of youth in treatment trials, or mirrored a magnitude of 
improvement commensurate with the passage of time alone. The pre-post effect size 
estimates for the SOC CMHS subsets were compared to the treatment efficacy and 
natural history benchmarks by establishing whether the difference b✑✓✔✑✑✕ ✓✖✑✗✑ ✘✙✚✛✜✗✢
BENCHMARKING TREATMENT OF ANXIETY IN YOUTH   
 
109 
effect sizes was larger than = 0.2  - that is, a difference considered clinically significant.  
This comparison was made using the  range null✁ hypothesis testing procedure, 
developed by Serlin and Lapsley (1985; 1993). Second, the evaluation of each SOC 
CMHS subset against treatment and natural history ✂✄☎✆✝✞✟✠✡☛ ☞✌✠  clinically significant 
improvement✁ was considered. A two-sample z test for proportions was used to compare 
the proportion of youth in SOC CMHS subsets who evidenced  clinically significant 
✍✞✎✠✌✏✄✞✄☎✑✁ to those in treatment and wait list groups of treatment trials.  Third, details 
✌☞ ✟☎✟✒✓☛✍☛ ✌☞ ✑✝✄  ✆✌✞✎✒✄✑✄✠✁ ☛✔✂☛✟✞✎✒✄☛ ✟✠✄ ✌✔✑✒✍☎✄✕✖ ✗✌✔✠✑✝, a logistic regression was 
conducted, examining the ability of 3 variables to predict reliable treatment improvement. 
Also, pre-treatment differences between  ✘✌✌✕✁ ✌✠  ✎✌✌✠✁ ✑✠✄✟✑✞✄☎✑ ✠✄☛✎✌☎✕✄✠☛ on 11 
variables were examined.  Lastly, a secondary analysis used a Q test to examine seven 
moderators of outcome within the clinical trials was conducted. 
Hypothesis 1: Evaluating the SOC CMHS Data Against Pre-Post Effect Size 
Benchmarks 
Evaluating SOCCBCL data against the treatment efficacy benchmark. First, the 
SOCCBCL subset effect size was tested against the treatment efficacy benchmark.  The 
treatment efficacy benchmark was YTE =1.05. Taking reliability into account, the critical 
value for the treatment efficacy benchmark for the SOCCBCL subset was identified as 
✙✚✛ ✜✢✣ ✤✥✚ ✚✦✚✧★ = 1.06 (see Table 9). Because the observed SOCCBCL subset effect size 
(YSOC CBCL = .79) did not exceed this critical value ✩✙✚✛✜✢✣ ✤✥✚ ✚✦✚✧★ = 1.06), it was 
concluded that there was no evidence that youth in the SOCCBCL subset improved as much 
as youth in clinical trials who received ESTs, t (100) = 10.6, ✪✢✣ ✫ ✬✭✮✯ p > .05. That is, 
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there was no evidence the effectiveness of treatment at SOC CMHS agencies could be 
considered clinically equivalent to that of ESTs. 
Evaluating SOCCBCL data against the natural history benchmark.  The 
SOCCBCL subset pre-post effect size was tested against the natural history effect size 
benchmark (YNH). The natural history benchmark was YNH = 0.30. Taking reliability into 
account, the critical value for the natural history effect size benchmark for the SOCCBCL 
subset was identified as ✞☛  ✒✁✂ ✄☎☛ ☛✆☛✝✟ = .68. Because the observed SOCCBCL subset 
effect size (YSOC CBCL = .79) exceeded the critical value for the natural history 
benchmark ✠✞☛  ✒✁✂ ✄☎☛ ☛✆☛✝✟ = .68), it was concluded that youth in the SOCCBCL subset 
improved significantly more than youth in wait list control groups of published clinical 
trials, t (100) = 6.9, ✡✁✂ ✌ ☞✍✎, p < .05 (see Table 9). That is, the magnitude of 
improvement in the SOCCBCL subset was greater than would be expected from the 
passage of time alone. 
Evaluating SOCdiag data against the treatment efficacy benchmark. Next, the 
SOCdiag subset effect size was tested against the treatment efficacy benchmark (YTE). As 
mentioned, the treatment efficacy benchmark was YTE =1.05. Taking reliability into 
account, the critical value for the treatment efficacy benchmark for the SOCdiag subset 
was identified as ✞☛ ✒✏✑ ✄☎☛ ✓✔✕✖✟ = 1.10 (see Table 9). Because the observed SOCdiag 
subset effect size (YSOC diag = .52) did not exceed the critical value of the treatment 
efficacy benchmark ✠✞☛ ✒✏✑ ✄☎☛ ✓✔✕✖✟ = 1.10), it was concluded that there was no evidence 
that the improvement of youth in the SOCdiag subset was clinically equivalent to that of 
youth in clinical trials receiving ESTs, t (69) = 9.2, ✡✏✑ ✌ ✗✍✘✙ p > .05.  
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Evaluating SOCdiag data against the natural history benchmark.  The SOCdiag 
subset effect size was tested against the natural history benchmark (YNH). As mentioned, 
the natural history benchmark was YNH = 0.30. Taking reliability into account, the critical 
value for the natural history effect size benchmark for the SOCdiag subset was identified 
as ✞☛ ✒✁✂ ✄☎☛ ✆✝✟✠✡ = .72 (see Table 9). Because the SOCdiag subset effect size estimate 
(YSOC diag  = .52) did not exceed this critical value ☞✞☛ ✒✁✂ ✄☎☛ ✆✝✟✠✡ = .72), it was 
concluded that there was no evidence improvement of youth in the SOCdiag subset was 
any greater than that of youth in wait list control groups, t (69) = 6.0✌ ✍✁✂ ✎ ✏✑✓, p >. 05 
(see Table 9). That is, improvement of youth in the SOCdiag subset could be considered 




Effect Size Estimates of SOC CMHS Subsets Tested Against Critical Values of Treatment 
Efficacy and Natural History Benchmarks. 
 
 Treatment Efficacy Natural History 
Subset N YSOC (SE) ✔✕✖✗✘✙✚ t ✛ ✍✜✢ ✔✕✖✗✣✤✚ t ✛ ✍✁✂ 
SOCCBCL 101 0.79 (0.11) 1.06 10.6 100 8.5 0.68 6.9 100 5.0 
SOCdiag 
 
70 0.52 (0.14) 1.10 9.2  69 7.1 0.72 6.0 69 4.2 
Note. N = number of youth in subset; YSOC = observed effect size estimate for subset; SE 
= standard error of effect size estimate; ✞☛ ✥✜✢✦ = critical value for treatment efficacy 
benchmark; t = non-central t test statistic; ✧ ✎ degrees of freedom; ✍✜✢ = noncentrality 
parameter for treatment efficacy benchmark; ✞☛ ✥✁✂✦ = critical value for natural history 
effect size benchmark; ✍✁✂ = non-centrality parameter for natural history effect size 
benchmark. 
 
Evaluating SOC CMHS subsets against unbiased adjusted effect size estimate. 
If the adjusted unbiased effect size estimate (YTEadj = .95) was used as the treatment 
efficacy benchmark, both the SOCCBCL subset, t (100), 9.54, ★ = 7.54, p >.05 and the 
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SOCdiag, t (69) = 8.31, ✂ = 6.27, p > .05 would still fail to exceed the critical value for the 
treatment efficacy benchmark. Thus, use of this adjusted unbiased effect size estimate 
would not alter conclusions of the study and was not used as the treatment efficacy 
benchmark.  
Hypothesis 2:  ✁✄☎✆✄✝✞✟✠ ✡☛☞ ☞✌✍✡ ✎✄✝✄ ✄✠✄✞✟✏✝ ✑clinically significant 
improvement✒ ✓✔✟✕✖✗✄✘✙✏✚  
The proportion of youth in the SOCCBCL and SOCdiag subsets who fell from the 
✛✜✢✣✤✣✜✥✢✦ ✧★ ✧✩✪ ✛✫✬✭✜✢✣✤✣✜✥✢✦ range on the CBCL-Int was compared to both treatment and 
natural history CSI benchmarks (CSITE  and CSINH, respectively) (see Table 8). Results 
revealed that compared to youth in the treatment groups of clinical trials, there were 
significantly fewer youth in the SOCCBCL subset, z = 6.47, p < 0.001 and in the SOCdiag 
subset, z = 3.7, p < .001 who ✪✮✣✯✪✤✜✪✯ ✛✜✢✣✤✣✜✥✢✢✰ ✫✣✱✤✣✲✣✜✥✤✧ ✣✳✴✵★✮✪✳✪✤✧✦.  Further, 
there was no significant difference between the natural history CSI benchmark and the 
proportion of youth who ✫✩★✶✪✯ ✛✜✢✣✤✣✜✥✢✢✰ ✫✣✱✤✣✲✣✜✥✤✧ ✣✳✴✵★✮✪✳✪✤✧✦ in the SOCCBCL 
subset, z = 1.36, p = 0.07 nor in the SOCdiag subset, z = .17, p = 0.43. That is, the 
✴✵★✴★✵✧✣★✤ ★✲ ✰★✬✧✩ ✪✮✣✯✪✤✜✣✤✱ ✛✜✢✣✤✣✜✥✢✢✰ ✫✣✱✤✣✲✣✜✥✤✧ ✣✳✴✵★✮✪✳✪✤✧✦ in both the SOCCBCL 
and SOCdiag subsets was significantly lower than treatment groups and not significantly 
different from wait list control groups in clinical trials. 
Hypotheses 1 and 2: Evaluating SOC CMHS ✑completer✒ data against benchmarks.   
As noted in the method, the full SOC CBCL and SOCdiag subsets were used in the 
present study, since conclusions from these full subsets did not differ from those of the 
✛completer✦ subsamples. For the SOCCBCL completer subset, pre-post effect size was 0.83 
(compared to 0.79 for the full SOCCBCL subset). Because of smaller sample size and 
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hence reduced reliability, the critical value for the treatment efficacy benchmark for the 
SOCCBCL completer subset was CV TE SOC CBCL  cmpltr = 1.12 and the critical value for the 
natural history benchmark for the SOCCBCL completer subset was CV NH SOC CBCL  cmpltr = .74. 
Hence, the SOCCBCL completer subset, like the full SOCCBCL subset, was significantly greater 
than the natural history benchmark, t  ✁✂✄ ☎ ✆✝✞✟✠ ✡ ☎ ☛✝✂☞✠ p < .05, but not the treatment 
efficacy benchmark, t  ✁✂✄ ☎ ☞✝☞✟✠ ✡ ☎ ✁✝✌✍✠ p >.05. Further, the proportion of youth 
✎✏✑✒✎✓✔✑✓✕ ✖✔✗✑✓✑✔✘✗✗✙ ✚✑✕✓✑✛✑✔✘✓✜ ✑✢✣✤✥✏✎✢✎✓✜✦  CSI) in the SOCCBCL completer subset was 
17.5% (compared to 23.3% for the full SOCCBCL subset). Hence, like the full SOCCBCL 
subset, the SOCCBCL completer subset was not greater than the CSI natural history benchmark 
(CSI natural history benchmark = 31.9%) and significantly lower than the treatment CSI 
benchmark (CSI treatment benchmark = 57.5%), z = 7.22, p < .001. Thus, conclusions of 
analysis of the SOCCBCL completer subset did not differ from those of the full SOCCBCL 
subset. Hence, the full SOC CMHS subsets were used in the present study. 
For the SOCdiag completer  subset, pre-post effect size was 0.57 (compared to 0.52 for 
the full SOCdiag  subset). The treatment efficacy critical value was CV TE SOC diag cmpltr = 
1.19 and the natural history critical value was CV NH SOC diag cmpltr = 0.80. Thus, like the 
full SOC diag subset, there was no evidence that the SOCdiag completer subset surpassed the 
natural history benchmark critical value, t (41) = 5.15, ncp = 3.24, p >.05. Further, for 
this subset, the proportion of youth evidencing CSI was 33.3% (compared to 30.6% for 
full SOCdiag subset). There was no significant difference between this value and the CSI 
natural history benchmark, z = 0.14; p = 0.44.  Thus, conclusion of analysis of the SOC 
diag completer subset did not differ from those of the full SOCdiag subset.  
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Hypotheses 3, 4 and 5: Factors Associated with Treatment Response 
Of the 101 youth in the SOCCBCL  ✁✂ ✄☎ ✆✝ ☎✞✄ ✟✠✄✡✆☛✝☎☞ ✌☛✝✍✄ ✎✏ ✏✁✝✑☎✆✎✝✆✝✍ ✎✝ ☎✞✄
CBCL-DSM Anx at baseline (i.e. CBCL-DSM Anx T >= 65), 21 (20.8%) were classified 
☛  ✟✍✎✎✠☞ ☎✌✄☛☎✒✄✝☎ ✌✄ ✓✎✝✠✄✌ ✔ ✕✞✆✖✄ ☎✞✄ ✒☛✗✎✌✆☎✘ ✙✚9.2%, n = 79) were classified as 
✟✓✎✎✌☞ ☎✌✄☛☎✒✄✝☎ ✌✄ ✓✎✝✠✄✌  (n = 1, not classified due to missing data). That is, only a 
✒✆✝✎✌✆☎✘ ✎✏ ☎✞✄ ✛✜✢ ✢✣✤✛ ✘✎✁☎✞ ✏✄✖✖ ✏✌✎✒ ✟✠✄✡✆☛✝☎☞ ☎✎ ✟✝✎✌✒☛✖☞ ✌☛✝✍✄ ✎✏ ✏✁✝✑☎✆✎✝✆✝✍ ✎✝
the CBCL-DSM Anx AND improved by a statistically reliable amount (i.e. CBCL DSM 
✥✝✦ ✌☛✕  ✑✎✌✄ ✌✄✠✁✑✄✠ ✂✘ ✧ ✎✌ ✒✎✌✄★✩ ✤✎✕✄✡✄✌✔ ✎✏ ☎✞✄ ✪✫✪ ✘✎✁☎✞ ✆✝ ☎✞✄ ✟✠✄✡✆☛✝☎☞ ✌☛✝✍✄
pre-treatment, 48.5% (n ✬ ✭✮★ ✠✄✒✎✝ ☎✌☛☎✄✠ ✟✌✄✖✆☛✂✖✄☞ ✆✒✓✌✎✡✄✒✄✝☎ ☛✝✠ ✧✪✩✯✰ ✙n = 22) 
✕✄✌✄ ✆✝ ✟✝✎✌✒☛✖☞ ✌☛✝✍✄ ✎✏ ✏✁✝✑☎✆✎✝✆✝✍ ✎✝ ☎✞✄ ✢✱✢✲-DSM Anx post-treatment (i.e. 
CBCL-DSM Anx T < 65). 
✳✆☎✞  ✎ ✏✄✕ ✘✎✁☎✞ ✑✖☛  ✆✏✆✄✠ ☛  ✟✍✎✎✠☞ ☎✌✄☛☎✒✄✝☎ ✌✄ ✓✎✝✠✄✌ ✔ ✆☎ ✕☛  ✝✎☎ ✓✎  ✆✂✖✄ ☎✎
conduct a logistic regression, since a sample of this size would only allow for one 
predictor of outcome (c.f. Pelluzzi et al., 1996). For this reason, a logistic regression was 
conducted using ✟✌✄✖✆☛✂✖✄ ✆✒✓✌✎✡✄✒✄✝☎ status☞ ☛  ☛✝ alternative dependent variable  
✙ ✆✝✑✄ ☎✞✄✌✄ ✕✄✌✄ ✭✮ ✟✌✄ ✓✎✝✠✄✌ ☞ ✆✠✄✝☎✆✏✆✄✠★✩ ✟✴✄✖✆☛✂✖✄ ✆✒✓✌✎✡✄✒✄✝☎ status☞ was not the 
first choice as a dependent variable, since it did not incorporate the clinically relevant 
component of ✟✏☛✖✖✆✝✍ ☎✎ ✝✎✌✒☛✖ ✌☛✝✍✄☞ of internalising symptomatology within its 
operationalization. However, using this less conservative operationalisation of response 
to treatment allowed a multivariate analysis of factors associated with a positive 
treatment outcome,  
Before the logistic regression was conducted, data were screened for accuracy of 
data entry, missing values and multivariate outliers. Frequency plots were used to 
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examine data entry accuracy; no apparent errors were detected. Data for co-morbid 
externalizing diagnosis and comorbid affective diagnosis status were available for all 
youth. A small proportion of participants were missing information regarding poverty 
status (3.0%, n = 3) and reliable improvement status (1.0%, n = 1). No significant 
patterns in the variables used within the logistic regression were identified using Missing 
Values Analysis in SPSS (Tabachnick & Fidell, 2013).  Because there were relatively 
few cases with missing data, and no apparent pattern to their missingness, these were 
deleted from the logistic regression analysis. Multivariate outliers were examined using 
 ✁✁✂✄☎ ✆✝☎✞✟✠✡☛ ☞✌) (Tachnick & Fiddell, 2013).   ✁✁✂✄☎ ✌ is a measure of the influence 
of particular cases on an analysis, and values greater than 1 may be cause for concern 
(Cook & Weisberg, 1982). None were detected.  
Thus, following deletion of cases with missing information, the logistic regression 
was conducted using data from 97 youth ☞✍✎ ✏✑☛✒✝✟✓✒☛ ✝✔✕✑✁✖☛✑☎✄ ✟✠✆ ✗✘ ✏✠✁✠
✝✔✕✑✁✖☛✑☎✄✙✚ Results of the logistic regression indicated that the model was not 
significant, Chi square = 0.40 (3), p = .94 and accounted for almost no variance in 
outcome, Nagelkerke R squared = 0.6%. None of the variables were significant unique 
predictors of reliable improvement status in the context of the others. With the full model, 
53.6% of cases were correctly classified using these variables, which only improved base 
rate classification (51.5%) by a marginal amount. 
Assumptions underlying logistic regression were tested. There was no evidence of 
multi-collinearity among predictor variables, based on Tolerance values and results of 
collinearity diagnostic tests (range of Tolerance values .97-.99; variance proportions for 
dimension with smallest eigenvalue = .01, .08; 94) (Field, 2009; Tabachnick & Fiddell, 
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2013). Standardised residuals (z) were used to examine evidence for outliers in the 
logistic regression solution, with scores larger than 3 indicative of a cause for concern 
(c.f. Field, 2009; Tabachnick & Fiddell, 2012). None were detected.  Lastly, examination 
of independence of errors using methods outlined by Field (2009) revealed no evidence 
of over dispersion, since the dispersion parameter  ✁✂ was less than one.  
Results of univariate analyses ✄☎✆✝✞✟✠✡☛ ☞☛☎☎✌✍ ✞✡✌ ☞✝☎☎✟✍ ✎✟✏✞✎✆✏✡✎ responders 
revealed there were no significant differences on any of the 11 variables examined in, t 
(98) = -1.94 to 1.55, ns; range of Chi square (1) = -1.00 to 0.62, ns. Further, even without 
✞ ✑☎✡✒✏✟✟☎✡✠ ✄☎✟✟✏✄✎✠☎✡ ✎☎ ✞✓✝✔✞✕ ✎✔✏✟✏ ✖✏✟✏ ✡☎ ✗✠☛✡✠✒✠✄✞✡✎ ✌✠✒✒✏✟✏✡✄✏✗ ✘✏✎✖✏✏✡ ☞☛☎☎✌✍
✞✡✌ ✍✝☎☎✟✍ ✟✏✗✝☎✡✌✏✟✗ ☎✡ ✞✡✙ ☎✒ ✎✔✏ ✚✚ ✛✞✟✠✞✘✓✏✗ ✏✜✞✆✠✡✏✌✢  
Moderators of Effect Size Within Clinical Trials 
There was significant heterogeneity ✖✠✎✔✠✡ ✗✎✣✌✠✏✗✍ summary effect size estimates, 
Q (16) = 48.2, p < .001. Secondary analysis was conducted to examine sources of 
heterogeneity using a Q test. When a Bonferroni correction was applied (alpha set at 
.006), no significant moderators of outcome were identified. One moderating effect 
approached significance. There was a non-significant trend for outcomes of studies 
reporting ☞ITT✍ data to differ from those reporting ☞completer✍ data, Q (1bet) = 7.0, p = 
0.008. The six treatment trials ✟✏✝☎✟✎✠✡☛ ☞✠✡✎✏✡✎ ✎☎ ✎✟✏✞✎✍ ✌✞✎✞ ☛✏✡✏✟✞✎✏✌ marginally lower 
effect size estimates than the 11 trials ✟✏✝☎✟✎✠✡☛ ✌✞✎✞ ✒✟☎✆ ☞✄☎✆✝✓✏✎✏✟✍ ✗✞✆✝✓✏✗ ✆✏✞✡
(mean YITT = .85, SE= .09; mean Ycompleter = 1.20, SE = .09 for ITT and completer trials 
respectively).  There were no significant differences in effect size estimates in treatment 
trials based on research setting, Q (1 bet) = .05, p = .83; recruitment, Q (1 bet) = 0.0, p = 
.88; mode of delivery, Q (1 bet) = 1.10, p = .30; persons involved, Q (2 bet) = 2.2, p = .34; 
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method of delivery, Q (1 bet) = 1.71, p = .43; or minimum age of youth, Q (1bet) = 22, p = 
.64. That is, there was no evidence that studies conducted in research settings (as opposed 
to the community), where recruitment included advertising (rather than referral alone), 
where therapy was conducted in person (rather than via technology) had better outcomes. 
Further, there was no clear advantage for treatment to be delivered in a particular format 
(individual or group), with particular people involved (parent, child or both) or with 
children in a certain age range (6 years or less; 7 years or more). 
Discussion 
The aim of the present research was threefold. Firstly, to generate benchmark 
standards for pre-post effect sizes and rates of  clinically significant improvement✁ that 
can be used to evaluate outcomes of treatment of anxiety disorders in youth. These 
benchmarks were established from results of clinical trials and based on a common 
broadband measure of psychopathology (the CBCL-Int/6-18). Given the increasing 
emphasis on implementation of EBP in applied settings, the present study was an attempt 
to bridge the gap between research and clinical practice by establishing standards for 
treatment effectiveness that are accessible and useful for treatment agencies in the 
community. 
The second objective of the present study was to examine outcomes of youth with 
anxiety disorders treated at SOC CMHS agencies against these benchmarks. It is 
important to evaluate the impact of UC within SOC CMHS services, particularly given 
previous findings that UC is sometimes no more effective than natural remission in 
treating psychopathology, and that ESTs can be implemented in community agencies 
with success that is comparable to that of published efficacy trials.  
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The  ✁✂✄☎ ✆✝✞✟✠ ✂✡✟ ☛☞✌  ✆ ✂☎✟✍ ✂✎✏ ✑✒✆✆☎✓ ☞✍☎ ✑✔✆✆✄✓  ✄✟☞ ✕✟✍  ✄✟✌✔✆✍☎✟✄✌ ☛✂ ✁✂✍
youth treated at the SOC CMHS agencies, and to attempt to identify factors associated 
with improvement or treatment response in these youth. Having an empirically based 
understanding of what factors are associated with outcome can inform understanding for 
particular populations, including youth seen at SOC CMHS agencies. For instance, 
understanding factors associated with treatment response or reliable improvement can 
help tailor case management (by attempting to influence variables associated with 
treatment response), prevent treatment failure, and ultimately enhance treatment success. 
Further, it can provide information regarding what variables, though intuitively 
appealing, are not associated with treatment response, and may be less valuable to focus 
intervention upon. Lastly, it can inform understanding of mechanisms influential in the 
development and maintenance of anxiety disorders (Kendall, Settipani, & Cummings, 
2012).  
The first part of the discussion will address each of these objectives and will then 
explore issues secondary to the main findings that emerged during the course of the 
research. 
Treatment Efficacy and Natural History Benchmarks for Pre-Post Effect Sizes 
Attempts were made to be appropriately conservative when generating effect size 
estimates for each study, including adjusting for small sample size and making 
allowances for dependency between outcomes. Further, including both ✎☞ ✁✟✄✓✌ and 
✕✆ ✁✟✄✌✓ outcome ratings, while increasing the statistical complexity of analysis, meant 
both perspectives were taken into account when generating estimates of effect sizes. 
Lastly, eliminating one study (Shortt et al., 2011) and ✑☛✂✍s✆✄✂✖✂✍✒✓  ✁✟ ✄✟✌✗✘ ✌ ✆✎ another 
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(Barrett, 1998) also contributed to a more conservative treatment efficacy benchmark. 
Consistent with recommendations (Higgens et al., 2011; Lipsey & Wilson, 2001), quality 
ratings were not used to weigh the contribution of studies to the summary mean effect 
size. However, inclusion/ exclusion criteria were adopted that meant a minimum standard 
of rigor in design was required for studies to be included in the analysis. Further, the 
influence of features of research design that might exert a systematic influence on results 
(e.g. ITT versus completer analysis) were examined. 
There was significant heterogeneity within  ✁✂✄☎✆ ✝ ✆✞✞✆✟✁  ☎✠✆ ✆ ✁☎✡☛✁✆  although 
most were larger than 0.8. Secondary analysis was conducted to examine sources of 
heterogeneity within the treatment efficacy studies ☞ that is, possible moderators of 
outcome in the clinical trials. After a Bonferroni correction was applied, no significant 
moderators of outcome were identified. However, treatment ✌✟✍✡✎✏✆✁✆✑✝  ✁☛✁✂ 
approached significance. T✑☎☛✏  ✑✆✎✍✑✁☎✒✓ ✌☎✒✁✆✒✁ ✁✍ ✁✑✆☛✁✝ data generated marginally lower 
effect size estimates than those reporting data from ✌✟✍✡✎✏✆✁✆✑✝  ☛✡✎✏✆  (p < .008). This 
trend is consistent with previous research which has found effect sizes generated from 
studies reporting ✌☎✒✁✆✒✁ ✁✍ ✁✑✆☛✁✝ data are lower than those from studies reporting results 
of ✌✟✍✡✎✏✆✁✆✑✝  ☛✡✎✏✆  ✔Eddy et al., 2004; Westen & Morrison, 2001). The finding could 
reflect the impact of common research methodology, where the baseline symptom scores 
of treatment drop-outs are carried forward and used as an estimate of their post-treatment 
symptoms. Hence (by definition) these participants do not improve and the treatment 
effect sizes from these studies are therefore likely to be lower than those reporting 
✌✟✍✡✎✏✆✁✆✑✝  ☛✡✎✏✆ ✕ ✖☎✗✆✒ ✁✘☛✁ in the present study, even youth in wait list control 
groups improved by a moderate amount over time, adopting this strategy might yield an 
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excessively conservative result for drop-outs from anxiety treatments. It does reflect the 
importance, however, of considering attrition when evaluating the outcomes of 
community samples and of considering the nature of data reported (ITT or completer) 
when aggregating studies to form benchmarks.  
Treatment setting (research versus community), minimum age of participant (7 
years or older versus 6 years or younger), delivery format (group versus individual), 
parent involvement (parent versus child versus both), delivery mode (in person versus via 
technology), recruitment method (referral only versus both referral and advertising) were 
not significant moderators of the outcome. Further, none of these moderators would have 
been significant, even without a Bonferroni correction to alpha. These findings are 
consistent with previous research, which found effectiveness studies achieved 
comparable results to efficacy (Hunsley & Lee, 2007), and that parent involvement and 
treatment delivery format were not significant moderators of outcome (Liber et al., 2010; 
Reynolds et al., 2012; Silverman, Pina et al., 2008). Results were inconsistent with some 
previous findings. For instance, previous research has found that effect sizes from 
samples recruited via advertising were larger than for those recruited from referral (Brent 
et al., 1998). This might be because studies that recruited exclusively through advertising 
were excluded from the present research and, as a result, the potential impact of 
recruitment method may have been diluted.  
Heterogeneity of effect size estimates in the treatment trials highlights the 
importance of using a larger number of studies to generate benchmarks, since any single 
study is unlikely to represent the range of possible outcomes. Compared to previous 
benchmarking research (e.g. Curtis et al., 2009; Farrell et al., 2010) the present study 
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used far more studies to generate the benchmark (k =17), improving confidence in the 
reliability of the result. 
The treatment effect size benchmark generated from the present research, while 
using a broadband measure of psychopathology, is comparable in magnitude to the 
summary mean effect size of a recent meta analysis of treatments of anxiety disorders in 
youth (In Albon & Shneider, 2006), even though this meta-analysis reported pre-post 
effect sizes generated from a symptom-specific measure of anxiety. Analysis of findings 
of clinical trials indicated there was some evidence of asymmetry in the distribution of 
effect sizes (in relation to standard errors). There were a disproportionate number of 
studies with small samples, but relatively large effect sizes, without a commensurate 
number of studies with small samples and small effect sizes. It is possible that this 
asymmetry was caused by publication bias. That is, it is possible that studies with small 
samples were less likely to be published if they had small effect sizes than if they had 
large ones. If the asymmetry was due to publication bias, analyses suggest that the best 
estimate of the unbiased treatment efficacy effect size composite was YadjRCT = 0.95. 
Using the adjusted effect size would not alter conclusions of the present study (since the 
effect size estimates of the SOC subsets still would not surpass this benchmark), but does 
demonstrate the importance of taking the possibility of publication bias into account 
when generating benchmarks. When attempting to interpret results of tests of publication 
bias, alternative reasons to account for findings (including heterogeneity) can be 
investigated. This includes considering systematic methodological differences between 
smaller and larger studies that might account for sources of heterogeneity in the 
distribution of effect size estimates (Sterne, Gavaghan & Egger, 2000). While only one 
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marginally significant moderator was established to account for heterogeneity of effect 
size estimates in the present study (i.e. completer versus ITT status), future research 
could continue to examine possible sources of heterogeneity in study outcomes. A greater 
number of studies will allow examination of factors that interact to systematically 
influence outcome and hence heterogeneity. Several strategies have been suggested to 
attempt to minimise publication bias in research. These include requiring that clinical 
trials are registered before they commence, in order to adequately track the proportion of 
studies that are published and to decrease the possibility that only studies with significant 
findings are published (Ioannidis, 2005). Further strategies to decrease publication bias 
include becoming more open to publishing null or non significant findings and having 
minimum sample size requirements (Ioannidis, 2005).  Using minimum sample size 
requirements would reduce the likelihood of studies with null findings being withheld 
from publication due to inadequate power.  
It was notable that even youth who were in wait list control groups (on average) 
improved by a moderate amount (summary effect size = 0.30). This finding highlights 
two issues. First, when evaluating outcomes of community agencies, it is important to be 
aware that youth with anxiety disorders are likely to experience moderate improvement 
with the passage of time alone. Results show that even a reasonable amount of 
improvement might be considered clinically equivalent to natural remission. The second 
issue relates to the first.  The results show that when evaluating treatment of youth with 
anxiety disorders in community agencies, improvement per se is not enough to 
demonstrate adequate impact. A fairly substantial magnitude of improvement is required 
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to show improvement superior to wait list control groups and an even more substantial 
one is required to be considered clinically equivalent to EST treatments. 
The second major benchmark standard considered in the present study was 
 ✁✂✄☎✄✁✆✂✂✝ ✞✄✟☎✄✠✄✁✆☎✡ ✄☛☞✌✍✎✏☛✏☎✡✑ (CSI) ✒ operationalized as the proportion of the 
✞✆☛☞✂✏ ✄☎ ✡✓✏  ✁✂✄☎✄✁✆✂✑ ✌✆☎✟✏ on the CBCL-Int at pre-treatment who moved to 
 ✞✔✕✁✂✄☎✄✁✆✂✑ range at post-treatment. While this improvement does not take measurement 
error into account, generating a benchmark based on this information was helpful because 
this was the way CSI was reported in published trials and this could therefore be 
compared directly to results of treatment trials. Further, this operationalization of CSI is 
an easily understood and calculated measure of improvement, making it potentially more 
helpful in community settings. Fewer trials contributed to these benchmarks than the pre-
post effect size benchmarks, meaning they may be less reliable. Ultimately, aggregating 
results of eight studies showed that a mean of 57.5% of youth in treatment groups within 
✖✗✘✞ ✠✏✂✂ ✠✌✍☛  ✁✂✄☎✄✁✆✂✑ ✡✍  sub-✁✂✄☎✄✁✆✂✑ functioning post treatment. Thus, even when 
youth receive ESTs, only a little over half of the group can be expected to fall to the  ✞✔✕-
✁✂✄☎✄✁✆✂✑ range of functioning on the CBCL-Int post-treatment. The relatively modest 
proportion of youth evidencing  clinically significant improvement✑, even after receiving 
efficacious treatments, suggests that CSI may be a less sensitive measure of change than 
pre-post effect sizes.  Nonetheless, this metric of outcome may be more accessible and 
clinically relevant to community services than effect sizes, and should be considered 
when evaluating ✆✟✏☎✁✄✏✞✑ ✌✏✞✔✂✡s.  
 
 




As can be seen in Figure1, the ultimate samples of SOCCBCL n  = 101 or SOCdiag n = 
70 were considerably reduced from the 4500 or so youth in the full age matched SOC 
CMHS longitudinal data set. Further, these (relatively) small subsets could have been 
reduced even more, by using additional inclusion criteria (such as treatment completion; 
or including only youth treated within the mental health treatment sector). The ultimate 
size of the subsets was similar to previous benchmarking studies of youth (e.g. Weersing 
et al., 2006) and the reduction partly reflects the fairly stringent inclusion and exclusion 
criteria that were used to identify the subsets. While using these criteria reduced the size 
of the subsets, it also increases confidence in the validity of comparison between results 
of SOC CMHS youth and those of participants in clinical trials. Another reason for the 
substantial reduction in sample size may be because of the nature of the agencies 
contributing information to the national evaluation SOC CMHS data set. A substantial 
portion of youth in the SOC CMHS national evaluation study were served within 
agencies in the special education, child welfare and youth justice sectors. Youth served in 
these sectors would be disproportionately affected by the exclusion criteria of the present 
study - such as excluding youth with a diagnosis of a developmental disability or with 
severe externalising behaviour. This could account for the large reduction in the 
proportion of the sample eligible for participation in the present study and is not 
necessarily a reflection of the generalizability of treatment conditions within clinical 
trials compared to community mental health outpatient settings.  
A third possible reason for the large reduction in sample size relates to the 
challenge of matching SOC CMHS clients to youth treated within clinical trials, 
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particularly with respect to clinical profile.  Only some of the youth with  borderline✁ or 
even  clinical✁ range scores on the CBCL-DSM Anx had a clinician-designated DSM 
diagnosis of an anxiety disorder (see Table 1). The low prevalence of youth with 
identified anxiety diagnoses in the SOCCBCL subset (even amongst those with 
substantially elevated symptoms of anxiety and/or a presenting problem of anxiety) may 
reflect a tendency for clinicians to under-diagnose anxiety and other internalising 
disorders in youth (Richardson, Russo, Lozano, McCauley, & Katon, 2010). Previous 
research has found that youth are less likely to be diagnosed with an anxiety disorder by 
community clinicians than when they are assessed by researchers using standardised 
diagnostic tools (Jensen & Weisz, 2002; Rettew et al., 2009). This may be because the 
externalising problems are more obvious or disruptive and hence more likely to be 
identified by community clinicians. Alternatively, there may be other factors that 
influence community-generated diagnoses such as insurance or availability of resources 
for particular disorders but not others. For instance, there may be practitioners available 
to prescribe medication for ADHD but not to deliver CBT for anxiety disorders.  
Selection of participants with significant problems related to anxiety was a 
challenging process. Selection by anxiety diagnosis (i.e. the SOCdiag subset) yielded a 
smaller sample and was likely less psychometrically reliable (c.f. Jensen & Weisz, 2002) 
than selection by CBCL profile. However, pre-treatment mean and SD of CBCL-Int 
scores in this subset were more comparable with those of clinical trials (see Table 2), 
making interpretation of results somewhat easier.  Selection based on a combination of 
diagnosis, presenting problem and CBCL-DSM Anx profile (i.e. SOCCBCL) was (likely) 
more psychometrically sound, but confounded interpretation of results due to a higher 
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pre-treatment mean CBCL-Int and a smaller pre-treatment standard deviation than those 
seen in clinical trials (see Table 2). The implications of these issues will be discussed in 
the sections to follow, in the context of results of the benchmarking process. 
Hypothesis 1: Comparison of SOC CMHS Subsets with Treatment Efficacy and 
Natural History Benchmarks.   
 ✁✂ ✄☎✂✆✂✝✞ ✆✞✟✠✡ ☛☞✠✂ ✟✆✂ ✌✍ ✞✁✂ ✎☎☞✝✏✂ ✝✟✑✑✒ ✁✡✄✌✞✁✂✆✓✆ ✞✂✆✞✓✝✏ ✄☎✌✔✂✠✟☎✂ ✞✌
compare the SOC subsets to effect size benchmarks (Serlin, 1975; 1983). This meant that 
evaluation of results from the SOC agencies could incorporate consideration of both 
statistically and clinically meaningful outcomes, which is of particular relevance to 
community agencies. 
Comparison of each SOC subset with pre-post benchmarks yielded somewhat 
different results. The SOCCBCL subset evidence moderate gains that surpassed the critical 
value of the natural history benchmark but not the treatment efficacy benchmark. That is, 
there was no evidence that gains in this subset were as substantial as might be expected 
after receiving ESTs, although treatment gains were significantly better than natural 
remission. Similar to the SOCCBCL subset, improvement in youth in the SOCdiag subset 
also failed to exceed the critical value for the treatment efficacy benchmark. However, 
the magnitude of improvement of youth in the SOCdiag subset did not even surpass the 
critical value of the natural history benchmark (Table 9).  Hence, there was no evidence 
that the impact of SOC services for this subset was clinically any different from what 
might be expected from natural remission of anxiety symptoms (Minami, Serlin et al., 
2008). The magnitude of improvement in the SOCdiag youth was comparable to that seen 
in large-scale evaluations of UC (Trask & Garland, 2012). Further, it is consistent with 
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previous research that has found UC in community settings is associated with a similar 
degree of improvement as that seen within wait list control groups (Weersing & Weisz, 
2002). 
Thus, inconsistent with hypothesis 1, neither subset achieved improvement as 
substantial as that evidenced in youth who received ESTs for anxiety disorders in RCTs. 
Improvement in SOCCBCL youth was superior to wait list control groups, whereas there 
was no evidence the SOCdiag subset was more impactful than natural remission. These 
 ✁✂ ✄☎✆✝✁✂✆ ✞✟✠✟ ✡✄✆✁ ☛✠☎✟ ☞✁✠ ☛✌✟ ✍ ✁✎✏✄✟☛✟✠✑ ✆☎✒✆✡✎✏✄✟✆ ✁☞ ☛✌✟ ✓✔✕ ✕✖✗✓ ✆☎✒✆✟☛✆✘ 
There are several reasons why results of the two subsets, which were identified 
using similar inclusion and exclusion criteria, differed from each other (where one 
surpassed the natural history benchmark and the other did not). First, it could be that the 
SOCCBCL subset had more obvious signs of anxiety than the SOCdiag subset and hence 
were more likely to receive appropriate treatment and this was why they improved more 
than the other subset.  Youth presenting with severe internalising symptoms might be 
more likely to receive treatment specifically to address anxiety, rather than competing 
externalising diagnoses. Alternatively, differences in the observed effect sizes of the two 
subsets may relate to their pre-treatment CBCL-Int mean and SD scores. Examination of 
the mean and standard deviation of the SOCCBCL subset (mean = 73.3, SD = 6.6) revealed 
that the mean of this group was higher than the pre-treatment mean of any of the clinical 
trials, and the standard deviation was lower (see Table 3). The pre-treatment mean and 
standard deviation of the SOCdiag subset (mean = 68.4, SD = 9.0), however, were more 
commensurate with those of clinical trials. Hence, while attempts were made to match 
these two subsets to clinical trials, the SOCCBCL was not as comparable on pre-treatment 
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mean and standard deviation of the dependent variable from which effect size estimates 
were generated. As mentioned, more severe symptoms at pre-treatment have been 
associated with larger pre-post effect sizes (e.g. Kley et al., 2012; Oei & Boschen, 2009). 
Further, even small differences in standard deviations can result in large differences in 
pre-post effect size estimates (Lueger & Barkham, 2010). In combination, these factors 
might mean that the elevated effect size for this subset was an artefact of study design 
rather than truly reflecting the magnitude of the impact of treatment for youth with 
anxiety problems seen at the SOC CMHS agencies. That is, the effect size estimate of the 
SOCCBCL may have been larger because selection criteria meant the pre-test mean was 
higher and standard deviation was lower than the SOCdiag, rather than because treatment 
was more effective for this group. Results pertaining to the second type of benchmark   
✁clinically significant improvement✂ - can help to clarify interpretation of findings related 
to pre-post effect sizes, by allowing consideration of the consistency of outcomes across 
the two types of benchmarks. This in turns allows integration of findings and increases 
confidence in conclusions.  
Hypothesis 2: ✄☎✆✝✞✟✠✡☎☛ ☎☞ ✌✍✄ ✄✎✏✌ ✡✑✒✡✓✔✡ ✞☛✕ ✖✄✗✠☛✠✘✞✗✗✙ ✌✠✚☛✠☞✠✘✞☛✔ 
✛✆✝✟☎✜✓✆✓☛✔✢ ✣✓☛✘✤✆✞✟✥✡✦  
Inconsistent with hypothesis 2, the proportion of youth in the SOC CMHS subsets 
who ✧★✩✪✧✫✬✧✪ ✁✬✭✩✫✩✬✮✭✭✯ ✰✩✱✫✩✲✩✬✮✫✳ ✩✴✵✶✷★✧✴✧✫✳✂ ✷✫ ✳✸✧ ✹✺✹✻-Int was significantly 
lower than the proportion of youth in treatment groups of clinical trials who evidenced 
this improvement. In fact, inconsistent with hypothesis 2, the proportion of youth 
✧★✩✪✧✫✬✩✫✱ ✁✬✭✩✫✩✬✮✭✭✯ ✰✩✱✫✩✲✩✬✮✫✳ ✩✴✵✶✷★✧✴✧✫✳✂ ✩✫ ✳✸✧ SOC subsets was not significantly 
greater than those of wait list control groups. Consistent with results of pre-post effect 
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size estimates, these rates suggest that the improvement of youth in the SOCdiag subset 
were not significantly different from wait list control groups and could be considered 
clinically equivalent to rates of natural remission in youth with anxiety disorders.  While 
previous research suggests lower pre-treatment mean is associated with smaller effect 
sizes but better rates of recovery, this was not found in the SOCdiag subset, suggesting that 
results were not explained by pre-treatment CBCL profile. Results for the SOCCBCL are 
consistent with previous research that has found that higher initial symptom severity is 
associated with greater improvement (as measured by effect sizes) but less recovery 
(from pathological functioning) (e.g. Liber et al., 2010). 
There may be a number of reasons for the relatively weak results of both SOC 
CMHS subsets compared to treatment efficacy benchmarks for both effect sizes and rates 
of CSI. Firstly, it may be that treatments for anxiety being used within SOC CMHS 
agencies are not as efficacious as those ESTs tested within clinical trials. Although 
previous research found that clinicians at SOC CMHS agencies reported using evidence 
based practice (Sheehan et al., 2007), this finding was based on self-report which may 
over-estimate incorporation of evidence based components in actual practice (Hurlbert, 
Garland, Nguyen, & Brookman-Frazee, 2010).  ✁✂✄☎✆✂✝ ✄☎✆ ✞✆✟✠✡✠✄✠☛✡ ☛✟ ☞✆✌✠✞✆✡✍✆ ✎✏✑✆✞
✒✂✏✍✄✠✍✆✓ ✔✏✑ ✎✂☛✏✞ ✕✆✖✗✖ ☞✁✑✆✞ ✍☛✗✡✠✄✠✌✆ ✎✆☎✏✌✠☛✁✂✏✘ ✄☎✆✂✏✒✙✓✚ ✏✡✞ ✞✠✞ ✡☛✄ ✠✡✍✘✁✞✆ ✏
measure of adherence to particular protocols with empirical support for treatment of 
specific disorders (such as use of Coping Cat). There was no information available 
regarding the content or focus of therapy in the SOC CMHS subsets, which makes it 
more difficult to understand the sub-optimal results of the SOC CMHS with any 
confidence. There are numbers of studies showing that UC does not produce results 
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comparable with ESTs (e.g. Weisz et al., 2006), and research by Garland and colleagues 
has found that UC interventions tend to be spread over a relatively long time and are 
unlikely to include components of evidence-based practice (Hurlbert et al., 2010).  
Clinical trials evaluating ESTs for anxiety disorders were only beginning to emerge 
during the time of data collection in the SOC CMHS sample, which makes it less likely 
that the core components associated with better treatment outcomes were being used 
within SOC CMHS agencies.  This hypothesis was consistent with the observation that, 
similar to other research on  ✁✂✄☎✆ of therapy in UC (Trask & Garland, 2012) ✝ ✞✟✠✠  ✁✂✄☎✆
of therapy in the subsets did not impact outcome, suggesting that the therapy being 
delivered was not impactful.  
Alternatively, the relatively weak results might not relate to the effectiveness of 
treatment received, but rather reflect the characteristics or context of youth seen in SOC 
agencies. Consistent with previous research in community settings (Southam-Gerow et 
al., 2003), the prevalence of indices of social deprivation and complex clinical 
presentation were high in both subsets in the present research. A large proportion of the 
SOC youth lived in poverty, in sole parent homes, and their externalising symptomology 
was high, even after youth with the most severe comorbid disorders had been excluded. It 
could be argued that high externalising comorbidity and social deprivation contributed to 
weaker outcomes (c.f. Southam-Gerow et al., 2001). However, as reviewed, there have 
been inconsistent findings regarding the impact of social deprivation and externalising 
symptoms on therapy outcome.  Further, multivariate and univariate analyses (discussed 
later) found no significant associations between treatment response or reliable 
improvement on any of these potential moderators of outcome. This suggests these 
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characteristics do not explain the suboptimal outcomes of the SOC CMHS youth. 
Alternatively, although efforts were made to maximise match between SOC subsets and 
clinical trials, there may be other ways (not measured) in which populations served 
within SOC CMHS are fundamentally different from those in clinical trials and these 
differences mean that they are a more challenging population to treat. For instance, it is 
possible (and likely) that youth involved in numbers of services (including juvenile 
justice) have a history of treatment failure. They would be less likely to need to access 
further services if they experience good treatment response in one. Poor response to 
previous treatments is likely to predict poor response to future treatments and may 
account for weaker outcomes of the SOC CMHS samples.  
Another plausible explanation for the relatively poor results of SOC CMHS subsets 
is that although the youth in the subsets were experiencing substantially elevated 
symptoms of anxiety, this may not have been the focus of the treatment they received. 
There was high comorbidity in the sample, and the number of children diagnosed with 
ADHD in the SOCCBCL subset was actually higher than those diagnosed with anxiety.  
The high prevalence is not surprising, given previous research findings of high 
comorbidity between ADHD and anxiety, that having comorbid ADHD increases the 
likelihood that a child will access treatment (Hammerness et al., 2010; Kendall et al., 
2010), and that externalising disorders may be more likely to be diagnosed than 
internalising. It is possible that treatment was focused on addressing other difficulties, 
and for this reason, symptoms of anxiety did not reduce to the same degree as those of 
youth receiving ESTs for anxiety.  It is difficult to ascertain whether this was the case, 
since the SOC national evaluation data set did not contain information regarding the 
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focus of treatment. Future studies might include this information in order to aid 
interpretation of results. 
Lastly, it is possible that SOC subsets failed to achieve results comparable to the 
treatment benchmarks because they were generated using results of both  completer✁ and 
 intent to treat✁ (ITT) samples from clinical trials. Moderator analysis revealed that 
clinical trials using ITT samples had marginally lower effect sizes than those using 
 completer✁ samples. Clinical trials reporting ITT data generated an aggregate effect size 
of YITT = 0.85 which is fairly close to the observed effect size of the SOC CBCL (YSOC 
CBCL = .79), though not the SOCdiag subset (Ydiag = .52). However, this is unlikely to 
account for results. First, as mentioned, the observed effect sizes ✂✄☎ ✆✝✞  ✟✄✠✡☛✞✆✞☎✁
subsamples of both subsets were almost identical to the one generated for the full ITT 
sample for both subsets. Thus, using the  completer✁ subsample of the SOCCBCL would 
not exceed the treatment efficacy benchmark, nor would the effect size estimate of full 
subsets exceed the critical values of a treatment efficacy benchmark based exclusively on 
ITT studies. Either way, the conclusions of the present study would remain unchanged. 
Hypothesis 3, 4 and 5: Factors Associated with Treatment Response 
A logistic regression found three variables reflecting case complexity (poverty 
status; externalising comorbid diagnosis; affective comorbid diagnosis) did not predict 
reliable improvement in the SOC CMHS youth. Further, c✄✠✡☞☎✌✍✄✎ ✄✂  ✏✄✄✑✁ ☞✎✑  ✡✄✄☎✁
treatment responders failed to find significant differences on 11 variables at pre-
treatment. Previous research examining prediction of treatment response in anxious youth 
has also generated relatively few significant findings (Southam-Gerow et al., 2001; Liber 
et al., 2010). The absence of significant differences in pre-treatment variables in the 
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present research might be due to several factors. First, it may be that the variables 
available for consideration, while intuitively appealing, are not associated with treatment 
responsivity. Second, it could be that any one variable alone is not sufficient to impact 
outcome, but that their impact is cumulative (c.f. Lincoln & Rief, 2004). For instance, a 
child with ADHD and anxiety, with few emotional resiliencies, being raised by a poor, 
single parent who suffers from depressive and anxiety disorders might be more likely to 
 ✁✂✄ ☎ ✆✝✂✂✞✟ ✠✞✡☎✠☛✡☞✠ ✞✡ ✝✂☞ ✡ than a youth not challenged by any of these factors. 
Third, it could be an artefact of the operationalization of the dependent variables (i.e. 
✆reliable improvement✟ or  ✆treatment response✟). While dividing groups on either side of 
a cut off means that there are more participants in the analysis, which potentially 
improves power to detect differences, making the division in this manner reduces 
differences between the groups since participants close to the border whose scores may 
not be substantially different are included in the analysis. For instance, examination of 
differences between youth at the more extreme ends of the ✆✠✞✡☎✠☛✡☞✠ ✞✡ ✝✂☞ ✡✟ 
continuum, while excluding numbers of participants, might identify factors critical in 
predicting either extreme success or non-response. This could not be examined in the 
present research due to small sample size but could be in future research with larger 
samples. Lastly, the lack of significant findings may simply reflect an under-powered 
analysis. Using a conservative ✌✡✍✎☞✎✠✎✂☞ ✂✍ ✆✠✞✡☎✠☛✡☞✠ ✞✡ ✝✂☞ ✡✟ ✏✂☞✠✞✎✑✒✠✡✌ ✠✂ ✓✒✎✠✡ ☎☞
✒☞✡✔✡☞  ✝✕✎✠ ✎☞ ✠✁✡ ☞✒☛✑✡✞ ✂✍ ✆✖✂✂✌✟ ☎☞✌ ✆✝✂✂✞✟ ✞✡ ✝✂☞✌✡✞ ✗ ✄✎✠✁ ✆✖✂✂✌✟ ✠✞✡☎✠☛✡☞✠
responders having had a relatively small sample size (n = 21) ✏✂☛✝☎✞✡✌ ✠✂ ✆✝✂✂✞✟
treatment responders (n = 79). A larger sample size would have increased power to detect 
factors associated with treatment response.  
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Implications of Results 
The initial focus of discussion will be on the clinical implications of findings of the 
present study. Results suggest that an understanding of UC at SOC CMHS agencies is 
needed to provide context to the sub-optimal outcomes of anxious youth receiving 
services in these organisations. First, the degree to which difficulties with anxiety are 
under-diagnosed should be considered, and efforts to promote recognition of anxiety as a 
comorbid or underlying issue in the presence of other disorders should be undertaken. 
Improved recognition of anxiety disorders might be particularly important, since they can 
act as   ✁✂ ✄☎✆ ✝✞ ✄✟   ✠✟✡✄ ✟☛ ✟✄✠☎☞ problems in adolescence and adulthood (Kendall et 
al., 2012). The extent to which ESTs for the treatment of anxiety disorders are being 
utilised in SOC CMHS agencies should also be considered, particularly since results of 
the moderator analysis of published trials found there were no significant differences in 
outcomes of ESTs delivered in the community compared to research settings. If it 
emerges that ESTs are not routinely used (as previous research by Garland and 
colleagues regarding usual practice in child and youth services would predict), strategies 
to optimise dissemination and implementation of EBP could be employed. To assist in 
this process, implementation of ESTs in the community should consider both flexible 
adaptations to local conditions as well as fidelity to core components of the interventions 
(c.f. Beidas, Benjamin, Puleo, Edmunds, & Kendall, 2010; Kendall, Gorsch, Furr, & 
Sood, 2008; Mazzuchelli & Sanders, 2010). Emerging treatment and training models, 
designed to assist with incorporation of EBP in the context of the realities of community 
mental health work (including comorbidity), might also be helpful in this context 
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(Chorpita, Bernstein, & Daleiden, 2011; Chorpita & Daleiden, 2009; Chorpita, Daleiden, 
& Weisz, 2005; Kendall et al., 2012; Southam-Gerow et al., 2012; Weisz et al., 2012).  
The moderator analysis found no significant differences between the outcomes of 
treatments that make use of alternative technology (i.e. bibliotherapy, telephone 
counselling, or the internet) and those that used more traditional therapy models. This 
finding should be interpreted with caution, since it could reflect an under-powered 
analysis and includes treatments with a broad range of intensity. Nonetheless, in light of 
recent work emphasising the importance of parsimony in delivery of treatment, the 
absence of clear advantage of interventions requiring more intense therapist involvement 
suggests that future research should be invested in examining whether treatment 
protocols delivered using these alternative approaches could be considered ahead of more 
costly ones (Cougle, 2012; Kendall et al., 2012). 
Results also have methodological implications. The magnitude of data reduction 
illustrates how challenging it was to retrospectively identify youth in SOC agencies with 
anxiety problems that were commensurate with the samples of clinical trials. The 
correspondence between DSM diagnosis and profile on CBCL-DSM Anx was not 
perfectly consistent (see Table 1). That is, not all youth with an elevated CBCL-DSM 
Anx profile had a recorded DSM diagnosis, and not all youth with DSM diagnoses had 
elevated CBCL-DSM Anxiety profiles. Further, almost no youth presented with a 
diagnosis of an anxiety disorder, a presenting problem of anxiety and a CBCL-DSM Anx 
 ✁✂✄☎ ✆✝ ✞✟☎ ✠✡✂✄☛☎✄☞✆✝☎✌ ✂✄ ✠✁☞✆✝✆✁✍☞✌ ✄✍✝✎☎✏ It is likely these differences primarily relate 
to the issue of measurement in community settings. Specifically, the process of 
establishing a formal DSM diagnosis in the SOC CMHS communities was likely much 
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less systematised than that used in clinical trials. This reality necessitated the use of two 
strategies to identify youth with anxiety disorders within the broader SOC CMHS data 
set. These two strategies each have both advantages and pitfalls. The process illustrates 
that there is no single algorithm available to perfectly match youth seen at SOC agencies 
with samples from published research particularly with respect to clinical profile. The 
implications of this reality are that results of different data reduction strategies can be 
used to complement each other, with the advantages and disadvantages of each borne in 
mind when interpreting findings.  
There was substantial heterogeneity in effect sizes across treatment trials, even 
though these were established using the same measure to evaluate broadly similar 
treatment approaches (i.e. CBT). This suggests that combining results of effect sizes 
based on measures with different constructs, levels of specificity and metric are likely to 
yield findings that are increasingly difficult to interpret. Consistent with Minam  ✁✂ ✄☎✆✝✞
recommendations, results confirm the importance of generating benchmarks based on 
either identical measures, or those with similar reactivity and specificity.  Further, 
consistent with Minami et al. (2009), it is also worth considering whether specific 
benchmarks can be generated to match particular subgroups within community datasets 
(e.g. clients with comorbid conditions; ✟intent to treat✝ samples). 
Results also illustrate the importance of considering publication bias when 
generating benchmarks. The effect size estimate adjusted for possible publication bias 
generated a smaller treatment effect size benchmark than that from the original 
calculation. While using this adjusted effect size as the treatment benchmark would not 
have altered conclusions of the present research, it illustrates that it is possible and likely 
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that there is a bias for small studies to be published only if they have reasonably large 
positive findings.  The possibility of bias toward publishing small studies with large 
effect sizes (but not small studies with null findings) should be considered in any efforts 
to generate future benchmarks. 
Lastly, there were marginal (though not significant) differences in outcomes of 
 ✁✂✁✄ ☎✆  ✁✝✞ ✟✠✡☛ ☞☎✞✌✝✍✁✟✁ ✎ ✄✡✏ ☞✑✒✒✎ data, suggesting that future benchmarking 
studies should take ITT status into consideration when evaluating outcomes of 
community groups against those of published trials.  
Limitations of Study 
There was some ambiguity regarding the nature, content and focus of treatment 
received through SOC CMHS agencies which made it more challenging to interpret 
results. The length of treatment was potentially greater than was typical in clinical trials 
(up to 26 weeks), and for some youth involved far more sessions. Further, the content 
might not have reflected components of ESTs for anxiety, or the focus of treatment may 
have been on comorbid conditions. It should be noted, however, that the point of 
benchmarking comparisons is to understand whether youth seen at SOC CMHS agencies 
who presented with similar difficulties and received treatment in a similar format (i.e. 
therapy) achieved treatment gains as optimal as those seen in youth receiving empirically 
supported treatments. Further, even in the presence of comorbid conditions, the 
potentially powerful outcomes associated with treatment of anxiety disorders might make 
them the more logical choice for initial treatment focus, and the length of the treatment 
window (i.e. 26 weeks) could potentially accommodate sequential interventions for more 
than one disorder.  
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The possible confound of differences in pre-treatment mean and standard deviation 
of CBCL-Int scores also made interpretation of results more challenging. Anecdotally, 
analyses were run numbers of times with different iterations of inclusion and exclusion 
criteria. Findings were fairly consistent; changes in criteria for subsets based on 
contextual or diagnostic variables (e.g. treatment sector or DSM diagnoses) tended to 
have very modest impact on results.  Any changes in the inclusion criteria that 
systematically reduced the range and increased the mean of pre-treatment CBCL-Int 
scores were associated with increases in pre-post effect size estimates. This highlights the 
value of using more than one subset and more than one way of operationalizing outcome, 
and represents an interesting avenue for future enquiry. 
Another important difference between the SOC CMHS subsets and clinical trials 
was the stability of medication use by youth. Unstable medication use may have 
negatively impacted outcomes of the SOC CMHS subsets. Reducing the sample to 
include only those with stable medication regimes would have excluded the great 
majority of an already substantially reduced sample. For this reason, as in other 
community-based research (e.g. Oei & Boschen, 2009), unstable medication use was an 
acknowledged confound in the pres ✁✂ ✄✂☎✆✝✞✄ ✟ ✄ ✠✟✡☛ ✆ ✄☞✌✁✍  
The final analysis for examining factors associated with treatment response 
☞✁✡✎☎✆ ✆ ✏✁✎✝ ✠ ✄✑✠✎✎ ✁☎✑✒ ✟ ✏✓ ✔✌✏✏✆✞ ✂✟ ✠✂✑ ✁✂ ✟ ✄✕✏✁✆ ✟✄ ✖n = 21, 20.8%). This 
✑ ✠✁✂ ✔✟ ✎☞✠✒✎  ☞✑✕✟✏✗ ✑ ✁✂✞ ✘✠✄ ☎✄ ✆ ✠✄ ✂☛  ✆ ✕ ✁✆ ✁✂ ✗✠✟☞✠✒✎  ☞✁ ✂he logistic 
✟ ✌✟ ✄✄☞✏✁✍ ✔✙ ✎☞✠✒✎  ☞✑✕✟✏✗ ✑ ✁✂✞ is arguably a less clinically relevant 
✏✕ ✟✠✂☞✏✁✠✎☞✚✠✂☞✏✁ ✏✓ ✟ ✄✕✏✁✄  ✂✏ ✂✟ ✠✂✑ ✁✂ ✂☛✠✁ ✔✂✟ ✠✂✑ ✁✂ ✟ ✄✕✏✁✄ ✞✛ ✠✁✆ ✑✠✝ ☛✠✗  ✠
different relationship with predictor variables. Further, the relatively small number of 
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 ✁✂✂✄☎ ✆✝✞✟✆✠✞✡✆ ✝✞☛☞✂✡✄✞✝☛ limited the power of the univariate analyses and may have 
compromised the detection of important but subtle differences ✌✞✆✍✞✞✡  ✁✂✂✄☎ ✟✡✄  ☞✂✂✝☎
treatment responders. Further, the small sample may reduce generalisability of results. 
This issue can be addressed in future research using a larger number of participants.  
The psychometric properties of the CBCL and most other measures have not been 
specifically evaluated in the context of the SOC CMHS national evaluation study. The 
CBCL (and most other instruments) were self-report questionnaires, which might lessen 
the influence of a specific context on their reliability and validity. Nonetheless, ideally, 
the psychometric properties of measures should be established for the population and 
context in which they will be used. Future research should investigate the psychometric 
properties of measures in the context of use in routine clinical work in SOC CMHS 
agencies. This might be particularly important for instruments such as the CAFAS, which 
incorporate clinician judgment in scoring. 
Lastly, the present benchmarks did not incorporate results of studies treating either 
PTSD or OCD, which are both classified as DSM IV TR anxiety disorders. This is 
because there were no RCTs evaluating treatments of these disorders that met criteria for 
inclusion in the present research. Thus, the present benchmark standards may be limited 
to the anxiety disorders treated within the clinical trials ✎ mostly Generalised Anxiety 
Disorder, Separation Anxiety Disorder and phobias. It is possible that broadening 
inclusion criteria for identifying studies (e.g. by extending age range; considering studies 
with quasi experimental designs) might identify appropriate treatment studies for these 
disorders. Alternatively, separate benchmarks (e.g. for PTSD) using raw CBCL scores 
could be generated. 
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Implications for Future Research 
Future research could use common broadband outcome measures to benchmark a 
range of presenting problems and diagnoses. These might include externalising 
difficulties (such as ADHD or Oppositional Defiant Disorder), mood disorders or other 
anxiety disorders (including PTSD). Further, given many communities organise their 
outcome data in broad symptom- ✁✂✄☎ ✆✁✝✄✞✟✠✡✄✂ ☛✄☞✞☞ ✌✡✍✝✄✠✍✁✎i✂✡✍✞✏✑ ✌✄✒✝✄✠✍✁✎✡✂✡✍✞✏✑
✌✆✟✓✟✠ ✡☎✏✔✕ ✠✁✝✖✄✠ ✝✖✁✍ ✗✘✙ ☎✡✁✞✍✟✂✄✂ ☛✄☞✞☞ ✚✛✜✛✘ ✢✍✝✁✠✡✟✕ ✣✤✥✤✔✕  ✄✍✆✖✓✁✠✦✂ ✆✟✧✎☎
be generated to mirror these groupings. In addition to broadening the scope of presenting 
problems or diagnoses, future research could extend population and time frame 
parameters ★ for instance, including treatment trials for adolescents or very young 
children and examining long-term outcomes of treatment. One potential advantage of the 
present study is that it generated benchmarks based on a commonly used broadband scale 
of childhood psychopathology (the CBCL/6-18). This is useful for ongoing large-scale 
community evaluations where broadband measures are more likely to be utilised and 
future investigators should be encouraged to incorporate this common measure in their 
research designs. There are contexts, however, in which community agencies might want 
benchmarks based on symptom-specific measures of outcome (for example, when 
piloting implementation of an empirically supported treatment), and these could also be 
generated. Further, these symptom-based benchmarks could be compared to those based 
on broadband measures, to establish the relative utility of each (for example, 
consideration of the sensitivity of broad band measures to treatment effects for any given 
disorder).  
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The present study focused entirely on symptom reduction as an index of outcome. 
Other indices of outcome are important, particularly to community agencies, and can be 
benchmarked. For instance, benchmark standards can be established for child psycho -
social functioning, treatment duration and attrition (Hunsley & Lee, 2007).  Lastly, future 
research might seek to establish benchmarks for treatment within specific treatment 
contexts   for instance welfare, child protection, and juvenile justice settings - to 
establish effectiveness of empirically supported treatments in those sectors. The relatively 
small number of studies within each of these contexts might necessitate broadening 
inclusion criteria for treatment studies to contribute to the benchmark (for example, 
including non-randomised trials). Benchmarks based on ESTs in these contexts would 
lead to greater confidence in the comparability of outcomes with clinical populations 
such as those included within the SOC CMHS subsets.  
Treatment response and reliable improvement were not significantly associated 
with any of the factors examined. As mentioned, this may be because the effects of the 
variables tested are cumulative, because important moderators were not included in the 
analyses or because the analyses were underpowered. Future research could test clusters 
of possible predictors, examine as yet untested factors (e.g. history of service use), and/or 
include a greater number of participants. This would allow for multivariate analysis 
examining prediction of treatment response and maximise power to detect differences 
between groups. Process variables such as therapeutic alliance, engagement and 
homework completion could also be considered in this examination and findings could be 
used to extend to understanding of the mechanisms by which variables impact outcomes 
(Kendall et al., 2012). 
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Summary and Conclusions 
The present study applied a benchmarking strategy to evaluate the outcomes of 
youth with anxiety disorders treated at SOC CMHS agencies. Results of selected 
treatment trials were aggregated to generate two different kinds of benchmarks. First, pre-
post effect sizes from treatment trials were combined to generate pre-post effect size 
treatment efficacy (YTE) and natural history (YNH) benchmarks. These pre-post effect size 
estimates were based on a broadband measure of internalising psychopathology in youth 
(CBCL-Int; Achenbach, 1991; Achenbach & Rescorla, 2001). Second, the proportion of 
 ✁✂✄☎ ✆✝✞✁✟✠✄✡☛✄☞✟✌ ✍✎✏☞✟☞✎☛✏✏  ✠☞✌✟☞✑☞✎☛✟✄ ☞✞✒✡✁✓✝✞✝✟✄✔ ✕☛✠ ☛✌✌✡✝✌☛✄✝✆ ☛✎✡✁✠✠ ✄✡☞☛✏✠ ✄✁
generate treatment (CSITE) and natural history (CSINH✖ ✗✝✟✎☎✞☛✡✘✠ ✑✁✡ ✍✎✏☞✟☞✎☛✏✏ 
✠☞✌✟☞✑☞✎☛✟✄ ☞✞✒✡✁✓✝✞✝✟✄✔✙ ✍✚✏☞✟☞✎☛✏✏  ✠☞✌✟☞✑☞✎☛✟✄ ☞✞✒✡✁✓✝✞✝✟✄✔ ✕☛✠ ✁✒✝✡☛✄☞✁✟☛✏☞✠✝✆ ☛✠
falling ✑✡✁✞ ✍✎✏☞✟☞✎☛✏✔ ✛✚✜✚✢-✣✟✄ ✤ ✠✎✁✡✝ ✥✦ ✧★✖ ✄✁ ✍✠✂✗✎✏☞✟☞✎☛✏✔ ✡☛✟✌✝ ✁✑ ✑✂✟✎✄☞✁✟☞✟✌
(CBCL-Int T score < 65) on the CBCL-Int. Lastly, factors associated with reliable 
improvement and treatment response were examined✙ ✍✩✁✁✆✔ ✄✡✝☛✄✞✝✟✄ ✡✝✠✒✁✟✆✝✡✠ ✕✝✡✝
✆✝✑☞✟✝✆ ☛✠ ✄☎✁✠✝ ✕☎✁ ✛✪✖ ✞✁✓✝✆ ✑✡✁✞ ✍✆✝✓☞☛✟✄✔ ✄✁ ✍✟✁✡✞☛✏✔ ✡☛✟✌✝ ✁✑ ✑✂✟ctioning on the 
CBCL-DSM Anx scale (pre-treatment CBCL-DSM Anx T >= 65 to CBCL- DSM Anx T 
< 65) and (2) who demonstrated reliable improvement on the CBCL-DSM Anx scale, as 
indicated by the Jacobson and Truax (1991), Reliable Change Index (RCI)✙ ✍✫✁✁✡✔
treatment responders were those youth who were in the ✍✆✝✓☞☛✟✄✔ ✡☛✟✌✝ ✁✑ ✑✂✟✎✄☞✁✟☞✟✌ ✁✟
the CBCL-DSM Anx at baseline, but who failed to meet both these improvement criteria 
during the six months of involvement with SOC CMHS services.  Because there were too 
✑✝✕ ✍✌✁✁✆✔ ✄✡✝☛✄✞✝✟✄ ✡✝✠✒✁✟✆✝✡✠ ✄✁ ☛✏✏✁✕ ✑✁✡ multivariate analysis, a logistic regression 
examined ✒✡✝✆☞✎✄☞✁✟ ✁✑ ✍✡✝✏☞☛✗✏✝ ☞✞✒✡✁✓✝✞✝✟✄✔ ✠✄☛✄✂✠ by variables related to case 
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complexity (poverty, comorbid externalising diagnosis and comorbid affective 
diagnosis). Exploratory univariate analyses were conducted  ✁✂✄✂ ☎✆✝✝✞✟ ✠✡✞ ☎☛✝✝✄✟
treatment responders were compared on 11 variables related to demographics (gender, 
age, ethnicity), family context (family functioning, caregiver stress, poverty status, 
number of risk factors), child strengths and resiliencies, child functional impairment and 
child psychopathology (externalising comorbidity, affective comorbidity).  
Results revealed that outcomes of youth from SOC CMHS subsets were 
significantly worse than those of youth who received empirically supported treatments 
for both types of benchmarks (effect sizes and rates of ☎clinically significant 
improvement✟). The pre-post effect sizes of youth selected on the basis of elevated 
CBCL-DSM Anx scores did improve more than what might have been expected with the 
passage of time alone, whereas the pre-post effect sizes of youth selected primarily on the 
basis of DSM diagnosis did not. Neither subset achieved rates of ☎clinically significant 
improvement✟ that were significantly different than natural remission. Three indices of 
case complexity (poverty, externalising and affective comorbidity) failed to predict 
☎✄✂☞✌✠✍☞✂ ✌✎☛✄✝✏✂✎✂✡✑✟ ✌✡ ✑✁✂ ☞✝✆✌✒✑✌✓ ✄✂✆✄✂✒✒✌✝✡. Differences ✍✂✑ ✂✂✡ ☎✆✝✝✞✟ ✠✡✞ ☎☛✝✝✄✟
treatment on the 11 demographic, family context, child strength and child 
psychopathology variables that were tested were not significant. Thus, none of the 
variables examined offered an explanation for the relatively poor outcomes of youth in 
the SOC CMHS agencies. 
In conclusion, establishing benchmark standards for outcomes of evidence based 
treatment of anxiety disorders in children is potentially extremely helpful to community 
agencies to contextualise the impact of their services, including evaluating whether they 
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are commensurate with the optimal but obtainable outcomes of studies evaluating ESTs 
or with the wait list control groups of those studies.  ✁✂✄☎ ✆ ✝✞☎✟✠☎✡☛☞ ✌✆☛✡✁ ✍☎☛✎☎☎✏
clinical profile of youth in the community sample and those from research trials was not 
achieved, results were still informative. The present study showed even moderate 
improvement in symptoms may not be better than natural remission, and also that 
methodological nuance can significantly impact magnitude of effect sizes. Outcomes of 
youth in the SOC CMHS subsets were consistently worse than those of youth receiving 
ESTs in clinical trials. Outcomes for one subset were generally more comparable with the 
outcomes of wait list control groups in those trials. The reasons for suboptimal 
improvement in SOC CMHS agencies are not clear.  It may be that the content of therapy 
delivered in UC in SOC CMHS agencies was not consistent with research-supported 
interventions for anxiety. Alternatively it might be that the focus of intervention was not 
on treatment of anxiety and therefore anxiety-related symptoms were not substantially 
reduced during the course of contact with services. Results show that some differences 
between community samples and clinical trials (including baseline symptoms) can 
confound interpretation of findings. This suggests that when there is no ideal way to 
identify the target population within a broader data set, it may be pragmatic to identify 
more than one comparator group (e.g. as in the present study, using subsets identified by 
diagnosis and CBCL profile) and more than one metric of outcome (e.g. effect sizes as 
✎☎✄✄ ✆✑ ✟✆☛☎✑ ✒✠ ✝✡✄✂✏✂✡✆✄✄✓ ✑✂✔✏✂✠✂✡✆✏☛ ✂✌✞✟✒✕☎✌☎✏☛☞✖ in order to strengthen confidence in 
findings and allow cross validation of results. The present research did not identify any 
factors associated with reliable improvement or treatment response and future research 
might examine clusters of variables or alternative factors that might be associated with 
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outcome. Results of the present study emphasise the importance of understanding UC in 
SOC agencies, including whether efforts would best be directed at identifying youth with 
anxiety, disseminating, implementing, adapting and/or maintaining use of ESTs for 
treatment of anxiety within the clinical contexts of these agencies.  With appropriate 
attention to methodological and clinical issues, the process of benchmarking can be used 
as an ongoing strategy to help support these endeavours.  
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